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General Introduction
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Abstract
Cell-derived microparticles (MP) are receiving increased attention in recent 
years, and the number of publications is rapidly increasing. MP are involved 
in thrombosis, in"ammation, angiogenesis, cellular interactions and signal 
transmission. We focus on their role in thrombosis. A wide variety of 
methodologies to study MP have been employed and results can therefore 
be contradicting. Flowcytometry and solid phase capture are most commonly 
used nowadays. MP may be procoagulant by expressing phosphatidylserine and 
tissue factor, and this procoagulant potential can be measured in di#erent ways. 
Thrombin generation is often used, but more MP-speci!c measurements are 
also possible. As tissue factor is so important in thrombin generation we pay 
special attention to the role of tissue factor in MP and the impact on thrombin 
generation.
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What are microparticles
Microparticles (MP) were !rst described by Wolf in 1967 [1] and termed platelet 
dust, a sort of cellular debris, as it has been considered for many years. The past 
two decades MP research has been booming, and more and more biological 
functions of MP are being revealed. Cellular MP are small irregularly shaped 
vesicles that arise from the plasma membrane of blood – and vascular- cells 
during cell activation, or apoptosis. A precise de!nition of MP is lacking. They are 
usually de!ned as a heterogeneous population of vesicles ranging in diameter 
from 0,1 -1 µm characterized by di#erences in size, as well as phospholipid and 
protein composition. Exosomes are another kind of extracellular circulating 
vesicles. MP di#er from exosomes in size; exosomes are smaller, ranging in 
diameter from 30 to 100 nm [2] and exosomes do not derive from the plasma 
membrane but from intracellular membranes.
Process of microvesiculation
A plasma membrane consists of two lea"ets; the inner and the outer lea"et. The 
inner lea"et contains phosphatidylserine and phosphatidyl-enthanolamine, 
which are negatively charged proteins, while phosphatidylcholine and 
sphingomyelin are located on the outer lea"et. The preservation of this 
asymmetry is essential and is maintained through a complex transmembrane 
enzymatic balance [3]. Apoptosis or cell activation results in the transfer of 
phosphatidylserine to the outer lea"et, and thereby in a loss of this asymmetry 
(Figure 1). As a result, phosphatidylserine exposing MP may be released from 
the cells [4]. Several stimuli trigger microvesiculation in blood cells; chemical 
stimuli such as cytokines, thrombin and endotoxin, and physical stimuli such 
as shear stress or hypoxemia. The mechanism of microvesiculation involves 
!ve enzymes; aminophospholipid translocase, "oppase, scramblase, gelsolin 
and calpain. In quiescent cells aminophospholipid translocase is responsible 
for the transport of phosphatidylserine and phosphatidyl-enthanolamine from 
the outer lea"et to the inner lea"et, thereby maintaining the asymmetry of the 
membrane [5]. Floppase, on the other hand, moves the same phospholipids 
from the inner to the outer lea"et when the cell is activated or undergoing 
apoptosis [6]. Scramblase has a similar e#ect as it facilitates bidirectional 
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movements of phospholipids in the plasma membrane, also resulting in 
the expression of phosphatidylserine on the outer lea" et [5]. The common 
pathway for microvesiculation involves a sustained rise in intracellular calcium 
concentration, which inhibits the aminophospholipid translocase and activates 
both the " oppase and scramblase. As a result negatively charged phospholipids 
are transported to the outer lea" et, and microvesiculation will occur. An increase 
in intracellular Ca2+ also activates gelsolin and calpain, which cleave cytoskeletal 
! laments. Cytoskeleton integrity is believed to participate in the maintenance 
of membrane asymmetry and cell shape. Its cleavage could therefore facilitate 
membrane budding in stimulated cells [7].
Figure 1 Process of microvesiculation. Due to activation or apoptosis the intracellular calcium 
concentration increases and this results in translocation of phosphatidylserine from the inner lea" et to 
the outer lea" et resulting in membrane budding and microparticle formation. Figure by Bob Smit, 
printed with permission.
Clearance of microparticles
Little is known of the mechanisms by which MP are cleared from the bloodstream. 
The presence of phosphatidylserine on MP activates the macrophage scavenger 
system [8]. MP and apoptotic bodies are cleared by phagocytes [9]. Phagocytes 
recognize phosphatidylserine containing cell fragments in two ways, either 
directly or indirectly through receptors that bind proteins that have opsonized 
MP, such as protein S, lactadherin, GAS6 and complement [10]. The estimated 
half-life of MP in the blood stream varies from ! ve minutes to three hours [9,11]. 
Recently we estimated a half-life of one hour in healthy male volunteers after 
performing a bungee jump (Chapter 7). The di# erences in clearance between 
individuals as well as the factors that a# ect clearance have however not been 
identi! ed yet.
Functions of microparticles
Many di# erent functions have been attributed to MP, including a role 
in thrombosis and haemostasis, in" ammation, angiogenesis, cell-cell 
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communication [12] and signal transmission [13]. MP can interact with 
di#erent cells through proteins on their surfaces. Many proteins are described 
to be involved in binding MP to other cells. Platelet-derived MP interact with 
endothelial cells and monocytes by up-regulating cell adhesion molecules 
ICAM-1, CD 11a, CD11b [14]. Glycoprotein 1b and P-selectin are involved 
in interaction of MP with endothelial cells [15]. Moreover, MP can fuse with 
target cells or other MP, delivering proteins [15,16,17]. Mack et al. showed that 
MP containing chemokine receptor CCR5, the receptor for HIV-1 virus, could 
transfer this receptor to CCR5 negative cells and thus exacerbate infection 
[18]. MP contain micro-RNA and this can also be transferred to other cells 
[16,19]. Because MP have so many di#erent functions they have been studied 
in many di#erent diseases. In this chapter we further focus on the role of MP 
in thrombotic disease.
Microparticles and thrombosis
Several lines of evidence indicate that MP are indeed procoagulant. Firstly, 
increased numbers of MP are present in diseases associated with higher risk of 
thromboembolic diseases. Secondly, when these MP are isolated they support 
coagulation in vitro and thirdly, when platelets have a decreased capacity to 
generate MP such as in Scott syndrome, this results in a bleeding tendency. 
It is however unknown whether variations in MP production contribute to 
variations in bleeding diathesis in patients with congenital or acquired 
disorder [20].
We give an overview of the literature on MP in diseases that are known to have 
an increased risk of thrombosis, such as cardiovascular disease, cancer and 
haematological disorders. Thrombosis can be divided in arterial and venous 
thrombosis, which both have a di#erent pathogenesis. Arterial thrombosis 
is related to atherosclerosis and endothelial dysfunction, whereas venous 
thrombosis is related to hypercoagulability (congenital or acquired such as in 
cancer), in"ammation, immobilisation and/or endothelial dysfunction. Both in 
arterial and venous thrombosis MP are thought to play a role.
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Cardiovascular and metabolic diseases
Elevated levels of platelet and endothelial derived MP are described in 
cardiovascular and metabolic diseases such as acute coronary syndrome [21-
24], hypertension [25], renal disease [26-30], diabetes [31-33] and stroke [34]. 
In acute coronary syndromes higher levels of procoagulant MP were detected 
[23,24,35] and their levels at day 1 of myocardial infarction were indicative of 
a poor outcome [23], suggesting a prognostic potential for MP. Endothelial-
derived MP (EMP) in acute coronary syndromes appear suitable for assessing 
endothelial cell injury as these MP were higher in myocardial infarction 
compared with stable and unstable angina [22]. With regard to platelet-derived 
MP (PMP), these are increased in acute coronary syndromes [22,24,35]. PMP 
subpopulations re"ecting platelet activation by exposing CD63 and P-selectin 
were increased in peripheral arterial disease and myocardial infarction [21]. 
PMP could discriminate myocardial infarction from unstable angina [22]. In 
hypertensive patients EMP and PMP correlate with blood pressure, EMP and PMP 
may therefore be mediators of, as well as markers for, endothelial and platelet 
activation and hypertensive target organ injury [36]. In diabetes the level of EMP 
is closely associated with vascular dysfunction, as CD31+/CD42b- and CD51+ 
levels correlated with brachial ankle pulse wave velocity and endothelium 
dependent "ow mediated dilatation of the brachial artery [31]. In well regulated 
type 2 diabetes, tissue factor-positive MP were increased and correlated with 
fasting glucose and insulin. However, no correlation was observed between 
tissue factor-positive MP and markers of coagulation, which suggests that 
tissue factor-positive MP in diabetes may be involved in other processes than 
coagulation, including transcellular signalling or angiogenesis. Di#erences in MP 
pro!le between type 1 and 2 diabetes are described, both in MP subsets (diabetes 
type 1 more PMP and EMP) and MP-associated procoagulant activity (higher 
in diabetes type 1) measured with a prothrombinase assay [33]. An increase in 
CD105+ EMP was observed in patients with acute ischemic stroke [34].
Solid tumors
Bouillaud was the !rst to recognize the association between cancer and 
thrombosis in the 19th century [37]. Indeed, an increased rate of venous 
thrombosis is observed in cancer, and cancer associated thrombosis is an 
important cause of mortality in a#ected patients [38]. In cancer patients venous 
thrombosis is associated with tissue factor-positive MP levels [39]. Although MP 
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levels of patients without metastasis do not always di#er from controls [17,40], 
patients with disseminated adenocarcinoma have higher MP levels, as observed 
for breast [17,40,41], colorectal [42], gastric [43], and pancreatic [17] cancer. In 
colorectal cancer TF- bearing MP correlated with d-dimer levels, an indicator of 
hemostatic system activation [42]. In cancer patients MP contribute to higher 
thrombin generation [40]. Thrombin can result in tumor growth and angiogenesis 
[44]. Hence, a vicious circle can be formed in which thrombin generation can 
result in tumor progression with an increase in both tumor- and endothelial-
derived MP, and tumor progression and MP can result in increased thrombin 
generation. Cancer cells can shed MP, which can be measured in "owcytometry 
as they express epithelial mucins. Tesselaar et al. [17] showed that patients with 
both high MP-associated tissue factor activity and MP-associated epithelial 
mucin had a lower survival rate at 3-9 months follow up. Highly interesting 
is the role of MP in tumor progression, including angiogenesis, tumor growth 
and metastasis. MP can activate tumor environment [45], what might result in 
survival of cancer cells and resistance to chemotherapy. In angiogenesis MP 
can promote proliferation, stimulate the forming of a capillary network and 
stimulate the expression of pro-angiogenic factors by tumor cells [46]. There 
is evidence that MP may enhance metastasis. Janowska et al. [47] observed 
that MP derived from activated platelets interacted with lung cancer cells and 
enhanced their metastatic potential.
 
Haematological disorders
In 1985 Carr described membrane vesicles that shared antigens with leukemic 
cells, and related these membrane vesicles to coagulation disorders [48]. 
However, these vesicles were observed only in leukemic patients with clinical 
coagulopathies, of which the severity did not show a direct correlation with 
vesicle numbers. Since then MP have been studied in many haematological 
disorders, both in malignant and non-malignant diseases. In lymphoma, B-cell 
chronic lymphocytic leukemia and acute myeloid leukemia MP derived from 
tumor cells are described [45,49]. In the latter these MP were shown to be more 
procoagulant at the onset of the disease compared to time at remission. MP 
numbers declined during chemotherapy. In a recent study by Ghosh et al. in CLL 
patients a phenotypic shift was observed from predominantly platelet-derived 
MP in early stage of disease to leukemic B-cell-derived MP in the advanced stage 
[45]. Furthermore these leukemic B-cell-derived MP were capable of activating 
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human bone marrow stromal cells by activating and modulating signalling 
pathways. Interaction between CLL MP and bone marrow stromal cells induced 
increased VEGF production, which may modulate the CLL microenvironment in 
favor of CLL survival and resistance to chemotherapy. 
In myeloproliferative neoplasms such as Essential Thrombocythemia and 
Polycythemia Vera elevated numbers of both platelet- and endothelial-derived 
MP are found [50]. MP in myeloproliferative neoplasms were shown to be more 
procoagulant [51], although correlations with thrombosis were not observed. 
In sickle cell disease higher numbers of erythrocyte-MP were found during a 
sickle crisis [52,53]. In patients in steady state these MP were still increased. In 
addition, Shet et al. [53] described elevated numbers of endothelial-derived MP 
that did not bind to phosphatidylserine, but co-expressed tissue factor, resulting 
in a shortened plasma clotting time compared with control MP. In paroxysmal 
noctural haemoglobinuria [54] and thrombotic thrombocytopenic purpura 
[55] increased levels of endothelial-derived MP are described. In conclusion, 
in hematological disorders MP have been shown to be involved in the risk of 
thrombosis and might be involved in disease progression.
How to measure MP
MP analysis is widely applied to investigate the potential involvement of MP 
in various diseases. Although still considered investigational, it may be poised 
to enter the mainstream of clinical testing [56]. However, a wide variation in 
methodologies is responsible for the problem that results from di#erent studies 
cannot be always directly compared and that results can even be inconsistent 
or con"icting. Furthermore, variation in pre-analytical methods also account 
for di#erences in results. Pre-analytical variables such as blood collection, 
sample processing, transportation and centrifugation conditions may have a 
major impact on MP measurements, and have not been adequately addressed 
in literature [57]. Also the process of freezing as storage method may in"uence 
endothelial-derived MP numbers depending on the phenotype studied, for 
example increase in CD31+CD42b- and CD62E+ MP and a decrease in CD144+ 
MP [58]. Many di#erent technique principles are in use, of which "owcytometry 
and solid phase capture are the most common ones. All techniques have their 
own speci!c advantages and limitations.
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Flowcytometry
Flowcytometry is well known for counting and separating MP in "uids at a rate of 
thousands per second. MP are labelled using antibodies with "uorophores and/
or phosphatidylserine binding protein. Flowcytometry is the most commonly 
applied optical method to detect MP, approximately 75% of laboratories use 
"ow cytometry to enumerate MP in clinical samples  [59]. An advantage of 
"owcytometry is that thousands of MP can be analysed in one sample, and that 
multiple markers can be simultaneously determined. Even small subpopulations 
can be identi!ed and analysed. All MP can be measured, and not only those 
positive for the surface binding marker as is the case in capture assays. A 
limitation is that in "owcytometry the smallest MP may escape detection due 
to the detection limit of most commercial "owcytometers [56]. 
Solid phase capture
In solid phase capture assays Annexin V or biotinylated antibodies are 
insolubilized onto streptavidin coated microtiter plates to which platelet-free 
plasma is added, incubated and washed. A prothrombinase assay is used for the 
determination of the amount of captured MP. The phosphatidylserine content of 
MP is measured through its ability to promote the activation of prothrombin to 
thrombin. In this prothrombinase assay the blood clotting factor concentrations 
have been determined to ensure that the phosphatidylserine content is the rate-
limiting parameter of the reaction. With this assay most of the MP can be captured 
also allowing functional characterization of the procoagulant potential of MP. 
However, possible interference of soluble antigens may lead to underestimation 
of MP levels by antigenic capture [60]. Moreover, due to the washing steps prior 
to analysis this technique can fail to immobilize platelet-derived MP > 100nm of 
diameter, which result in an underestimation of this group of MP [61]. 
Other (impedance based !owcytometry, atomic force microscopy)
Both impedance based "owcytometry and atomic force microscopy are new 
and promising techniques for the measurement of MP. The Coulter principle is 
employed in an impedance- based "owcytometer to count and measure the size 
of MP in a "uid [62]. In atomic force microscopy MP must bind to an extremely 
"at surface such as mica. The surface binding might a#ect the morphology of 
MP, and the e$ciency of MP binding to a surface is unknown [63,64]. In atomic 
force microscopy smaller MP can be detected than with "owcytometry [63]. 
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In both techniques the observed concentrations of MP were 1000-fold higher 
than those counted by standard light scatter "owcytometry.
Functional tests for microparticles
The procoagulant activity of MP may result from their phospholipid content 
and/or the bearing of tissue factor. Therefore functional MP testing is aimed 
at phospholipid content, tissue factor activity, or both. Three types of tests to 
assess the procoagulant activity of MP are available. Procoagulant phospholipid 
activity assays re"ect the ability of the phospholipid content of MP to generate 
thrombin. MP-associated TF activity tests are used to investigate the functional 
capacity of TF on the membrane of MP. In thrombin generation tests results are 
in"uenced by both the phospholid content of MP as well as the presence of TF 
on MP. 
 
Procoagulant phospholipid activity assays 
Anionic phospholipids present in MP membranes act as catalytic sites for 
factor Xa and thrombin formation, giving MP a procoagulant activity in vivo 
[65]. In this procoagulant phospholipid activity (PPA) assays phosphatidylserine 
is measured through its ability to promote activation of prothrombin to 
thrombin [60]. Two di#erent methods are used; chromogenic and clot-based. 
In the chromogenic method, plasma is added to a microplate well coated with 
Annexin V, which binds MP with exposed phosphatidylserine on their surface. 
The plate is washed with bu#er, followed by addition of factors Va and Xa 
and calcium to generate thrombin, which is measured using a chromogenic 
substrate [60]. Thrombin generation is proportional to the anionic phospholipid 
content. In the clot-based method patient plasma is added to human 
phospholipid-depleted plasma, which provides human factor V, prothrombin, 
and !brinogen, followed by addition of bovine factor Xa and calcium. This 
complex reaction involves multiple steps ending with clotting. The clotting 
time is dependent on the amount of anionic phospholipid present. A shorter 
clotting time represents higher amounts of anionic phospholipids. This method 
can detect procoagulant phospholipid activity arising from phosphatidylserine 
on the MP surface, however, other factors bound to the surface of MP may also 
contribute to enhanced thrombin generation detected by this assays. Connor 
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et al. observed that MP were capable of higher degrees of thrombin generation 
than equivalent concentrations of phosphatidylserine. This was not due to the 
presence of TF on MP as this test was insensitive to TF, but may be due to the 
presence of other coagulation factors [66].
Functionality of TF on MP
Tissue factor (TF) is a small 47 kd transmembrane glycoprotein, which initiates 
blood coagulation by binding coagulation factor VII in its activated form (factor 
VIIa) [67]. The factor VIIa/TF complex activates factor IX and X, triggering the 
coagulation pathway [67]. The ultimate results of this cascade are thrombin 
generation and thrombin-catalyzed events, as well as activation of factors V 
and VIII, formation of !brin and activation of factor XIII, which lead to thrombus 
formation and stabilization. Tissue factor can exist in a latent (or “encrypted”) 
form that lacks coagulant activity or in an active form that initiates blood 
coagulation [68]. The activity of TF is regulated by its physiological inhibitor; 
tissue factor pathway inhibitor (TFPI), which not only inhibits the factor VIIa/
TF complex but also exerts a direct inhibition of factor Xa [67]. Giesen et al. 
were the !rst to describe that normal blood contains circulating tissue factor 
in the form of MP [69], detectable with "owcytometry. Subsequently, Zwicker 
et al. used imdepance based "owcytometry to detect TF-bearing MP [39]. 
Next it was demonstrated that blood-borne TF, in the form of MP, is indeed 
required for thrombus extension in a laser-induced microvascular injury model 
in mice [70]. MP-associated TF activity is measured by determining factor VII-
dependent factor Xa generation in the presence of excess negatively charged 
phospholipids under conditions that the TF concentration is rate limiting [17].
MP-linked TF activity was increased in ST elevation myocardial infarction, and 
correlated with failure of !brinolysis [71]. MP-linked TF activity in myocardial 
infarction correlated with survival [72]. Circulating MP were identi!ed as the 
prevailing reservoir of plasma TF activity. Increased TF activity was observed 
by Tesselaar et al. [17] in patients with disseminated adenocarcinoma, and 
correlated with mortality.
Thrombin generation; de"nition
Thrombin is one of the central enzymes in blood coagulation and both the 
rate of thrombin formation and the total amount of thrombin formed can be 
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considered a re"ection of the potential coagulation activity in plasma [73]. This 
thrombin potential in plasma can be assessed by several commercial methods, 
of which the Calibrated Automated Thrombogram (CAT; Thrombinoscope 
BV, Maastricht, The Netherlands) is the most commonly used application. In 
this method a calibration factor is measured in a plasma sample identical to 
that in which thrombin generation is being determined and the course of the 
calibration factor is assessed during the entire experiment [73].
The initial concept of a thrombin generation test was described in 1953 by two 
British groups. However, this method was manual, time-consuming and the 
requirement for clot removal during the procedure was a source of error [74]. 
In the 1980s a new computer-assisted method to obtain a thrombin generation 
curve using a chromogenic substrate of thrombin was developed by Hemker 
and Beguin [74]. In 2000 automated measurement of thrombin generation 
was possible in plasma. This made the method more practical and suitable for 
performance in clinical laboratories and signi!cantly improved the accuracy. In 
the CAT, coagulation is initiated by adding phospholipids and TF to platelet poor 
plasma or platelet rich plasma, and then one or more of the following variables 
of thrombin generation are measured: lag time, peak height, time to peak, time 
to tail, velocity and endogenous thrombin potential (area under the curve).
Thrombin generation assay for MP
A thrombin generation assay can be used to test the procoagulant ability of MP. 
MP can be a source for phospholipids and TF in thrombin generation. Berckmans 
et al. [75] discovered that MP in blood from healthy individuals supported 
thrombin generation. In the thrombin generation assay a correlation between 
phospholipid content and peak height as well as a correlation between MP 
number and peak height are described, which indicates that phospholipids on 
the membrane of MP account for thrombin generation [76,77]. Changes in lag 
time on the other hand are dependent of TF activity [77]. A higher TF activity 
results in a shorter lag time. Hellum et al. described that changes in the lag time 
in the CAT assay re"ect levels of MP-associated TF activity in a more sensitive 
manner than TF activity measured by the Zymuphen MP-TF kit [77]. Thrombin 
generation is not only performed in MP rich plasma. Isolated MP can be added 
to human MP-free pooled plasma to make the assay more sensitive for MP, and 
to exclude any e#ects of plasma. A higher MP dependent thrombin generation 
was found in plasma of patients with recurrent thrombosis [78].  
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With regard to the procoagulant potential of MP many questions remain, which 
will be partly addressed in this thesis. Firstly, it is of importance to elucidate 
whether the ancestry of MP results in di#erences in procoagulant ability. For 
example, are monocyte-derived MP more procoagulant than platelet-derived MP. 
Monocyte-derived MP expres TF, and shorten lag time and increase peak height in 
a TF-dependent manner [79,80]. Aleman et al. described that platelet-derived MP 
did not support plasma thrombin generation in the absence of a procoagulant 
trigger (contact or TF). However, after initiation, platelet-derived MP signi!cantly 
increased thrombin generation [79]. Van der Meijden et al. observed that platelet-
derived MP, as well as erythrocyte-derived MP, initiated thrombin generation 
indepedently of TF in a Factor XII-dependent manner [80]. Platelet-derived MP 
and monocyte-derived MP di#erentially modulate thrombosis, the physiological 
relevance of this !nding, especially in various disease states, requires further 
investigation. Secondly, it is of interest whether (tromboembolic) diseases 
in"uences the procoagulant potential of MP or mainly result in an increase of MP. 
Patients with recurrent venous thromboembolism and with myeloproliferative 
disease have been shown to have increased MP-associated thrombin generation 
[51,78]. Lastly, it is of great interest whether therapy can result in a change in 
the procoagulant ability of MP. The relation between therapy and procoagulant 
ability of MP have not yet been !rmly established.
Outline of the thesis
The aim of this thesis is to investigate the phenotypic pro!le and procoagulant 
potential of MP in pre-thrombotic states. In this pre-thrombotic state patients 
have an increased risk of developing thrombosis due to their disease and/
or medication used. We report a number of studies on the characterization 
of MP in association with di#erent pathophysiological conditions. Chapter 1 
is the General Introduction to the work described in this thesis. We describe 
the de!nition of MP, their formation and the technical di$culties involving 
their analysis. In addition, we provide an overview of the literature on MP in 
thromboembolic disease. In Chapter 2 and 3 MP in myeloproliferative diseases 
are described. Myeloproliferative diseases are clonal disorders: Essential 
Thrombocythemia (ET) patients demonstrate a large increase in platelet 
numbers and Polycytemia Vera (PV) patients show an increased erythrocyte 
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and leukocyte count. Patients with either disorder have an increased risk of 
thrombosis, and patients with the JAK2V167 mutation and high leukocyte 
numbers are at an even higher risk. In Chapter 2 we focus on MP in Essential 
Thrombocythemia and investigate whether there is an association between MP 
and established risk factors for thrombosis. The study described in Chapter 3 
compares the phenotypic pro!les of MP and their procoagulant potential in 
Essential Thrombocythemia and Polycythemia Vera. In Chapter 4 we determined 
MP levels and their procoagulant potential in patients with chronic renal failure. 
The ratio between mature von Willebrand factor antigen and its propeptide 
was used as a measure for acute or chronic endothelial activation to study 
endothelial activation in these patients. In Chapter 5 and 6 we look further into 
the e#ect of anti-cancer therapy on MP numbers and MP-dependent thrombin 
generation. In Chapter 5 we describe a cross-sectional study in 40 breast 
cancer patients using endocrine therapy. Half of the patients had had curative 
therapy and were considered disease free, and the other half of the patients 
had metastatic disease. All patients used either an aromatose inhibitor or an 
anti-estrogen. The e#ect of endocrine therapy on MP levels and MP-assosciated 
thrombin generation is investigated in this study. We used the same approach 
to assess MP numbers in acute myeloid leukemia (AML) patients in Chapter 
6. In three patients we measured MP levels and their procoagulant potential 
in subsequent samples obtained before and during chemotherapy and in 
remission. Changes in MP levels due to chemotherapy were determined, as 
well as changes in procoagulant potential of MP during this therapy. Finally, we 
determined MP levels in a bungee jump study that was designed to investigate 
the e#ect of stress on the immune system. Twenty healthy volunteers performed 
a bungee jump from a 60 meter high crane, half of them were pre-treated with 
propranolol three days prior to the jump. With this design, described in Chapter 
7, we were able to gain more insight into biological parameters of MP such 
as their formation and clearance. Moreover we could investigate the e#ect of 
stress on the numbers and phenotypic pro!les of MP. Finally, in Chapter 8 the 
principal !ndings of this thesis and relevance into understanding the role of 
microparticles in pre-thrombotic states are discussed in relation to literature.
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Abstract
Background: Most cell types, including blood - and vascular cells, produce 
microparticles (MP) upon activation. Since cellular MP are known to be elevated 
in thromboembolic diseases, we hypothesized a role for MP in the pathogenesis 
of thrombosis in essential thrombocythemia.
Design and methods: In plasma samples from 21 essential thrombocythemia 
patients and ten healthy subjects, the levels and the cellular origin of MP were 
determined by "owcytometric analysis, while the MP-associated procoagulant 
activity was measured using a thrombin generation assay.
Results: Patients with essential thrombocythemia had signi!cantly higher 
numbers of circulating AnnexinV-positive MP than controls (median 4500 
vs. 2500x106 events/L; p=0.039), including signi!cantly higher number of MP 
positive for the platelet marker CD61 (p=0.043), the endothelial markers CD62E 
(p=0.009) and CD144 (p=0.021), and for tissue factor (p=0.036). CD62E was co-
expressed with the platelet marker CD41 on MP, suggesting a bilineal origin of 
such MP, which were observed only in patients with risk factors for thrombosis. 
Patients with essential thrombocythemia had higher plasma levels of mature 
von Willebrand factor (p=0.045) but similar propeptide levels compared to 
controls. In thrombin generation analyses, MP-rich plasma from patients with 
essential thrombocythemia had a shorter lag time (p=0.001) and higher peak 
height (p=0.038) than plasma from controls. Peak height correlated signi!cantly 
with the total number of MP (R=0.634, p<0.001). 
Conclusions: Patients with essential thrombocythemia had higher number 
of circulating MP with platelet and endothelial markers, suggesting ongoing 
platelet and endothelial activation. This was con!rmed by an increased level 
of mature von Willebrand factor, an abnormal mature von Willebrand factor/
propeptide ratio, and a hypercoagulable state re"ected in thrombin generation. 
These !ndings suggest a role for microparticles in thrombosis in essential 
thrombocythemia.
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Introduction
Cellular microparticles (MP) are plasma membrane vesicles of <1,5 μm in 
diameter, mainly composed of lipids and proteins, which are released into the 
circulation by blood cells and vascular cells during cellular activation or apoptosis 
[1]. MP are heterogeneous, di#ering in size, as well as in phospholipid and 
protein composition. In addition, MP display some speci!c cell surface proteins 
that indicate their cellular origin. Depending on the cellular process and the 
cellular origin triggering their formation, the outer surfaces of cellular MP may 
contain phosphatidylserine, which provides a suitable anionic phospholipid 
surface for assembly of the tenase and prothrombinase complexes, and they 
may express tissue factor (TF), the primary initiator of coagulation [2]. Such 
phosphatidylserine- and/or TF-bearing MP may contribute to the pathogenesis 
of thrombosis in di#erent diseases, including cancer–associated thrombosis 
and sepsis [3].
Indeed, the numbers and characteristics of circulating MP have been found to 
be altered in many vascular diseases associated with an increased risk of both 
arterial and venous thrombosis. In particular, elevated numbers of platelet-
derived MP have been described in diabetes mellitus [4], acute coronary 
syndrome [5], myocardial infarction [6] and disseminated intravascular 
coagulation [7]. Elevated levels of endothelial-derived MP have been found 
in venous thromboembolism [8] and in the antiphosholipid syndrome [9]. 
The majority (more than 90%) of MP in healthy controls are of platelet origin, 
whereas less than 10% originate from granulocytes and less than 5% from 
endothelial cells, red blood cells and monocytes [10]. 
Essential thrombocythemia (ET) is a chronic myeloproliferative disease 
characterized by an increased risk of both arterial and venous thrombosis. At 
the time of diagnosis approximately 20% of the patients with ET have had a 
major thrombotic event and approximately another 20% will subsequently 
have an event [11]. This makes venous and (more often) arterial thrombosis 
the leading causes of morbidity and mortality in ET. Established risk factors 
for thrombosis in ET are older age (over 60 years) and previous thrombotic 
events [12]. Recently, leukocytosis has been identi!ed as an additional risk 
factor [11,13,14]. Numerous mechanisms, including blood hyperviscosity and 
quantitative/qualitative abnormalities of blood cells, have been advocated to 
be at the origin of the hypercoagulable state in these patients [15]. An increased 
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number of platelets [16], abnormal function of platelets [12], activation of 
platelets and leukocytes [17,18], their interaction to form platelet-leukocyte 
aggregates [17], and endothelial activation may all contribute to the increased 
thrombotic state in ET, which is still not completely understood. 
In the present study, we investigated the numbers and the procoagulant 
potential of circulating MP in a group of patients with ET, using "owcytometry 
and a thrombin generation assay, respectively. In addition, levels of mature von 
Willebrand factor (vWF) and propeptide, and soluble E-selectin were determined 
in the same plasma samples as a measure of ongoing endothelial activation. 
Design and methods
Study subjects
Twenty-one consecutive ET patients (8 males and 13 females, median age: 58, 
range: 34-83 years) were enrolled at the Haematology Department of Bergamo 
Hospital (Italy), after giving informed consent. Patients were diagnosed as 
having ET according to the Polycythemia Vera Study Group (PVSG) criteria [19]. 
All investigations were approved by the local ethical committee (Comitato di 
Bioetica, Ospedali Riuniti, Bergamo, Italy). The patients’ characteristics are shown 
in Table 1. Nine patients were heterozygous carriers for the JAK2V617F mutation. 
At the time of the sample collection 18 patients were receiving treatment with 
aspirin, eight with hydroxyurea and three patients were not receiving any 
treatment. The sample size was chosen on a power calculation using data of a 
preceding unpublished pilot study in which the mean number of microparticles 
in control subjects was 3400 x106/L and that in ET patients was 7500 x106/L. 
With an α of 0.05 this calculation showed that nine controls and 18 ET patients 
would provide the analysis with su$cient power. In addition, we investigated 
ten healthy controls (6 males and 4 females, median age 46, range 19-59). None 
of the healthy controls was on antiplatelet medication at the time of blood 
collection. Controls were signi!cantly younger than ET patients, p=0.015.
Blood collection and isolation of microparticles
Blood samples were drawn early in the morning, before any therapy, with a 
21-gauge needle after applying a light tourniquet. After discarding the !rst 3 
mL, blood was collected into a 5 mL tube containing 3.2 % citrate (BD, Plymouth, 
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UK). Plasma was prepared within 30 min after blood collection by centrifugation 
for 20 minutes at 1,550 x g at room temperature, without brake. Aliquots of 
plasma were snap-frozen in liquid nitrogen, and then stored at –750C until use. 
In order to isolate the MP, 250 µL of plasma was thawed on ice for 60 min and 
then centrifuged for 30 min at 17,570 x g at 20 °C. Subsequently, 225 µL of 
supernatant (i.e. microparticle-free plasma) were removed. The remaining 25 µL 
containing the MP pellet was resuspended in 225 µL of phosphate-bu#ered 
saline (PBS; 154 mM NaCl, 1.4 mM phosphate, pH 7.4), containing 10.9 mM 
trisodium citrate to prevent coagulation activation. Samples were centrifuged 
for 30 min at 17,570 x g at 20 °C; thereafter, 225 µL of supernatant were removed 
and the MP pellet was resuspended in 125 µL of PBS.
Table 1. Characteristics of study subjects at enrollment into the study. Data are presented as median 
(range) or number (%)
Controls ET patients 
(n=21)
Male/Female 6 /4 13/8
Age (years) 46 (19-59) 58 (34-83)
Platelets (x109/L)  ND* 510 (315-1340)
White blood cells (x109/L) ND 7.2 (3.13-14.7)
Polymorphonuclear cells ND 4.46 (1.71-10.2)
Hematocrit (%) ND 40.5 (31.5-47.6)
Patients’ therapy - 18 (85% )
 Aspirin - 18 (85% )
 Hydroxyurea - 7 (38%)
History of thrombosis - 6 (28%)
*Not determined
Phenotypic analysis of plasma-derived microparticles
Flowcytometric analysis was used to quantify and characterize plasma-derived 
MP, as previously described [20]. Brie"y, 5 µL of MP sample were diluted in 35 µL 
PBS containing 2.5 mM CaCl2 (pH 7.4). The samples were then incubated for 
30 min at room temperature in the dark with 5 µL Annexin V-allophycocyanin 
(Caltag Laboratories, Burlingame, CA, USA) and/or 5 µl "uoresceinisotyocianate 
(FITC)-, phycoerythrin (PE)-, peridinin-chlorophyll-protein complex (PerCP)- 
labelled anti-human monoclonal antibodies, or 5 µL isotype-matched control 
monoclonal antibodies.
For the phenotypic characterization of microparticles the following cell speci!c 
monoclonal antibodies were used: anti-CD8-PE (SK1, IgG1), anti-CD14-PE (MΦP9, 
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IgG2b), anti-CD15-PE (HI98, IgM), anti-CD20-PE (L27, IgG1), anti-CD45-PerCP 
(H130, IgG1, k), anti-CD61-FITC (VI-PL2, IgG1), anti-CD63-FITC (H5C6, IgG1), anti-
CD146-PE (P1H12, IgG1), labeled isotype controls IgG1 (X40) and IgG2a (X39), 
all from Becton Dickinson (San Jose, USA); IgG2b-PE, anti-glycophorin A-FITC 
(JC159, IgG1) and anti-CD41-FITC (5B12, IgG1) from DAKO (Glostrup, Denmark); 
anti-CD144-FITC (BMS158FI, IgG1) from Bender MedSystems (Vienna, Austria); 
anti-CD106-FITC (1.G11B1, IgG1) from Calbiochem (Darmstadt, Germany); anti-
CD54-PE (K562, IgG1), anti-CD66b-FITC (80H3, IgG1N) and anti-CD62P-PE (CLB-
Thromb/6, IgG1) from Immunotech (Marseille, France); anti-CD62E-PE (HAE-1f, 
IgG1) from Kordia (Leiden, the Netherlands); anti-CD4-PE (CLB-T4/2, IgG1) and 
anti-CD66acde-PE (CLB-gran/10, IH4Fc, IgG1) from Sanquin (Amsterdam, the 
Netherlands). 
For TF measurement on MP, anti-TF-FITC from American Diagnostics (VD8, IgG1, 
Stamford, CT, USA) was used in the same experimental conditions.
After incubation, 760 µL PBS/calcium bu#er was added and the samples were 
analysed on a FACS Calibur using Worklist Manager (BD) for 1 min during 
which the "owcytometer analyzed approximately 55 µL of the suspension. 
Forward scatter (FSC) and sideward scatter (SSC) were set at logarithmic 
gain. To distinguish MP from events due to noise, MP were identi!ed on the 
basis of their speci!c FSC and SSC characteristics, with gates set using in vitro 
platelet activation and microparticle generation data (results not shown), and 
by annexin V positivity (Figure 1A and 1B) [21]. To identify annexin V-positive 
events, a threshold was set in a MP sample prepared without calcium. The 
number of MP per liter of plasma was calculated as previously described # MPper 
minute *(Volume(V) tube/Vminute) *(Vend/ Vstart) * (1000/ Vlabeled)= # events/mL [7]. Data 
were analyzed with CellQuest-pro software (Becton Dickinson).
Thrombin generation measurements
Thrombin generation in platelet-poor but MP-rich plasma as prepared for 
MP isolation (described above) was measured with the calibrated automated 
thrombogram method (Thrombinoscope BV, Maastricht, the Netherlands) [22,23]. 
Thrombin generation was triggered in 80 PL plasma by di#erent conditions; 1 
pM of TF and 4 PM of phospholipids, 4 PM of phospholipids alone, and bu#er 
(no exogenous TF or phospholipids added), using reagents obtained from 
Thrombinoscope BV. Thrombin generation was measured as "uorescence, read in 
a Fluoroskan Ascent reader (Thermo Labsystems OY, Helsinki, Finland) equipped 
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with a 390/460 !lter set and thrombin generation curves were calculated with the 
Thrombinoscope software (Thrombinoscope BV). Three parameters were derived 
from the thrombin generation curves: lag time (initiation phase of coagulation), 
endogenous thrombin potential, and peak height. Lag time was de!ned as the 
time to reach 1/6 of the peak height. Validation of the calibrated automated 
thrombogram method showed normalization of non-time-dependent parameters 
to be mandatory to obtain acceptable inter-assay variations [23]. Intra-assay 
variations for normalized parameters are typically below 6%, and inter-assay 
variations below 8% [23]. Therefore, each thrombin generation measurement 
includes normal pooled plasma and both the endogenous thrombin potential 
and peak height values are expressed as the ratio of patients’ value to the value 
in normal pooled plasma, expressed in percentages. 
Plasma markers of endothelial activation
Plasma concentrations of soluble E-selectin were determined by a commercially 
available enzyme-linked immunosorbent assay (ELISA), according to 
manufacturer’s instructions (Diaclone, Cedex, France). Mature vWF and 
propeptide plasma levels were measured by ELISA as described previously [24]. 
The half-life of mature vWF is four times that of the propeptide half-life, and due 
to this di#erence in half-life their relative concentration is a distinctive indicator 
for ongoing chronic as opposed to acute endothelial activation [25].
 
Statistical analysis
We established the statistical signi!cance of di#erences in MP numbers between 
groups with the non-parametric Mann Whitney U test and Kruskal-Wallis tests, 
where appropriate. Bivariate correlations were estimated by Spearman’s rank 
correlation (R). All tests for statistical signi!cance were two-tailed and P values 
of <0.05 were considered statistically signi!cant. Analyses were performed 
using SPSS 15.0 for windows (SPSS Inc., Chicago, USA).
Results
Number and phenotypic characterization of microparticles
The total number of MP is signi!cantly higher in ET patients (median: 4500 x 
106/L) than in controls (2500x106/L, p=0.039). For most study subjects, more 
than 90% of circulating MP bound to annexin-V, indicating the presence of 
phosphatidylserine on their membrane (Figure 1A and 1B).
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Figure 1: Flowcytometric analysis of MP. A representative set of scattergrams from "owcytometric MP 
analysis in a sample from an ET patient is shown to illustrate MP and subpopulation de!nition. Panel A: 
Forward and side scatter were used to de!ne the MP and platelet (Plts) gates as shown. Panel B: Events 
de!ned as MP were then selected for their annexin V binding, determined by positivity for AnnexinV-
allophycocyanin "uorescence (on the x-axis). Panel C: annexin V-positive MP were further examined for 
expression of other antigens by co-labelling with PE - and FITC- labelled antibodies as is shown here for 
CD62E-PE and TF-FITC binding.
The phenotypic characterization of MP depicted in Figure 2 showed that 
the subset composition of the MP population (i.e. of platelet -, leukocyte -, 
endothelial cell or erythrocyte origin) is similar in ET patients and controls. 
The large majority of MP is of platelet origin in both groups of subjects, as 
determined by positivity for the platelet markers CD41 and/or CD61 (CD41 ET 
vs. controls: median±SD 95±0,34% vs. 95,7±0,7%; p=0,15). Accordingly, the 
number of platelet-derived MP was greater in ET patients than in controls (CD61 
median 4000 vs. 2400x106/L; p=0.043). The levels of the two platelet activation 
markers CD62P and CD63 were lower on MP from ET patients than on those 
from controls, and this di#erence was statistically signi!cant for CD63 (median 
5,5 vs. 40x106/L, p<0.001). 
26739 Trappenburg, Marijke.indd   36 08-10-13   14:31
2Microparticles in ET 37
Figure 2 Size of circulating MP subpopulations in ET patients and controls. Bar graph: Number of MP 
from speci!c cellular origin as de!ned by marker positivity in plasma from ET patients (ET) and controls 
(CTR). Data are presented as medians. Numbers of MP positive for CD15, CD20, CD45, CD106 and CD144 
were too low to adequately show in this graph. Inset: dotplot of the same data presented individually 
for the platelet marker CD61 and the endothelial marker CD62E.
With regard to endothelial-derived MP, the number of MP expressing the 
endothelial marker CD62E was signi!cantly higher in ET patients than in controls 
(median 875 vs. 14x106/L; p=0.007) (Figure 1C) as was the number expressing 
CD144 (p=0.021). 
MP of granulocyte (CD66b and CD66acde) and of monocyte (CD14) origin were 
present in low but signi!cantly higher numbers in ET patients. MP derived from 
T-cells (CD4 or CD8), B-cells (CD20), intracellular adhesion molecule (ICAM)-
positive cells (CD54) and vascular cell adhesion molecule (VCAM)-positive cells 
(CD106) account for less than 1% of all MP and their numbers were not di#erent 
between ET patients and controls (data not shown).
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Relation of MP with the presence of JAK2V617F mutation or pharmaceutical treatment
Neither JAK2V617F mutation status nor the treatment given (hydroxyurea or 
aspirin) a#ected the number or the cellular origin of MP in ET patients, including 
TF-positive MP in ET patients (data not shown). 
CD41- and CD62E- positive MP 
Since more than 95% of MP were positive for CD41 and CD61, we suspected 
that the CD62E-positive MP, constituting 27% of all MP in ET patients, but 1% in 
controls, could also co-express a platelet marker. We, therefore, analysed the MP 
with a combination of CD41-FITC/CD62E-PE monoclonal antibodies. Indeed, in 
both groups 90% of the CD62E-positive MP also expressed CD41. The CD62E-
positive MP constituted 24% of the CD41-positive MP in ET patients and 1% 
in controls. When patients with ET were classi!ed according to a risk score, 
allocating one point for a history of thrombosis, age over 60 years, platelet count 
over 1000x109/L, and the presence of a cardiovascular risk factor (for example 
hypertension or diabetes) [26], MP with combined expression of CD41/CD62E 
were  increased only in patients with one or more risk factors (Figure 3, p=0.045). 
This correlation was not observed for MP originating from other cells. 
Plasma markers of endothelial cell activation
Since ET patients had higher levels of CD41/CD62E-positive MP, which suggests 
endothelial activation, we investigated the activation status of endothelium 
by measuring plasma levels of soluble E-Selectin, mature vWF and propeptide.
No signi!cant di#erences in the plasma levels of E-selectin were observed 
between ET patients (20 ng/mL, range, 5-40) and controls (14 ng/mL, range, 
5-41, p=0.52). The removal of MP from plasma by centrifugation did not a#ect 
the levels of E-Selectin (data not shown), indicating that most of the soluble 
E-Selectin was not bound to these MP. Furthermore, no correlation was found 
between soluble E-selectin levels and the number of CD41/CD62E-positive MP 
(data not shown). 
26739 Trappenburg, Marijke.indd   38 08-10-13   14:31
2Microparticles in ET 39
Figure 3: CD41/CD62E-positive MP and risk factors for thrombosis. Dotplot of the number and the 
median of CD41/CD62E-positive MP in controls and in ET patients categorized for number of risk factors 
(age older than 60, previous thrombotic event, platelets > 1000x109/l, presence of a cardiovascular risk 
factor [26]: 0=no risk factor, 1=one risk factor, 2= two risk factors etc.) * ET patients have signi! cantly 
more CD41/CD62E-positive MP than controls (p=0.01), and ** ET patients with one or more risk factors 
have higher number of CD41/ CD62E-positive MP compared to ET patients without risk factors 
(p=0.034).
ET patients had signi! cantly higher concentrations of mature vWF in plasma 
than did controls (median 50 vs. 35 nM, p=0.045) but similar concentrations of 
propeptide (7 vs. 5 nM, p=0,07). The mature vWF and propeptide pattern was, 
therefore, signi! cantly di# erent in patients and controls, resulting in a higher 
mature vWF: propeptide ratio, a pattern previously shown to indicate a state of 
chronic endothelial activation [25] (Figure 4). No correlation was found between 
mature vWF, propeptide and CD41/CD62E-positive MP.
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Figure 4: Relation between mature vWF and propeptide levels in patients with ET and controls. Dotted 
lines represent the upper limit of the 95% con! dence interval of mature vWF and propeptide levels of 
the control group. ET patients have higher levels of mature vWF (p=0.045), and similar levels of 
propeptide as compared to levels in controls.
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Tissue factor- positive MP 
TF-positive MP accounted for less than 1% of all MP in both patients and 
controls. TF was expressed on MP also expressing platelet markers and CD62E. 
The number of MP carrying TF was signi!cantly higher (p=0.036) in ET patients 
(median 1.8x106/L) than in controls (median 0.9x106 /L). No correlation was 
found between a history of thromboembolic events or positive risk score for 
thrombosis and TF-positive MP. 
Thrombin generation
Thrombin generation triggered with 1 pM of TF and 4 PM of phospholipids was 
increased in MP -rich plasma from ET patients as indicated by increased peak 
height [ET vs. controls: 411 nM (95%CI: 358-465) and 279 nM (95%CI: 196-361), 
respectively, p=0.01]. No di#erences were found in lag time and endogenous 
thrombin potential, suggesting attenuated inhibition rather then altered 
activation or stimulation under these conditions. Since plasma-, possibly MP-, 
derived TF may contribute to the initiation of coagulation, thrombin generation 
was repeated in the absence of additional TF and only 4 PM of phospholipids 
were added. Again, the peak height was higher for ET patients (325 nM 95%CI: 
289-360) than for controls (171 nM 95%CI: 94-249, p=0.001). Furthermore, 
the lag times were on average 4 min shorter for ET patients (12.0 min 95%CI: 
10.7-13.4) than for controls (15.8 min 95%CI: 12.0-19.7, p=0.04). This latter 
observation is suggestive of the presence of more TF in plasma, and indeed 
maybe on MP, from ET patients than from controls. To further characterize the 
procoagulant potential of plasma and MP from patients with ET, the thrombin 
generation assay was performed in the absence of both TF and phospholipids 
(Figure 5). Using these conditions, ET patients had a shorter lag time (9.7 min; 
95%CI: 8.7-10.7 vs. 15.9 min; 95%CI: 10.9-20.9, p=0.001), and an increased peak 
height (215 nM; 95%CI: 189-241 vs. 142 nM; 95%CI: 87-189, p=0.038), indicating 
endogenous presence of procoagulant phospholipids and TF, possibly provided 
by MP. Indeed, a negative correlation was found between the total number 
of MP and lag time (R= -0.379, p=0.039) and a positive correlation between 
the total number of MP and peak height (R=0.634, p<0.001) (Figure 6). Finally, 
after the removal of MP by centrifugation there was no activation of thrombin 
generation (data not shown), which is compatible with the absence of MP-
derived TF and phospholipids. 
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 A B C
Figure 5: Thrombin generation in the absence of exogenous TF and phospholipids in platelet-poor, 
MP -rich plasma 
The results of the parameters lag time (A), endogenous thrombin potential (ETP) (B) and peak height (C) 
are shown for ET patients (•) and controls (CTR) (°). Lines represent the median value. ET patients have a 
signi!cantly shorter lag time and a higher peak height compared to controls. *p<0.05.
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Figure 6: Correlation between the peak height of thrombin generation in the absence of exogenous TF 
and phospholipids, and the total number of MP.
Data are shown from MP-rich plasma of ET patients (•) and controls (°). R=0.634, p<0.001. 
Discussion
This is the !rst extensive analysis of MP and their cellular origin in patients 
with ET. Like patients with other thromboembolic diseases, ET patients show 
higher levels of platelet-derived MP than healthy subjects [4,5,27]. This is not 
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necessarily attributable to higher numbers of platelets because neither in ET 
patients nor in controls did platelet-derived MP numbers correlate with the 
platelet numbers. This lack of correlation was also observed in an earlier study 
[28], suggesting that MP formation may be a regulated rather than a constitutive 
process. In spite of the large proportion of platelet-derived microparticles in 
ET patients, the actual number of these MP with markers of platelet activation 
(CD62P and CD63) was not increased. This could be because most ET patients 
were on anti-thrombotic drugs at the time of blood sampling, which may have 
a#ected markers of platelet activation; aspirin inhibits the expression of CD62P 
and CD63 on platelets [29].
Remarkably, half of the ET patients showed a large increase in CD62E-positive MP. 
These CD62E-positive MP are not normal endothelial MP since they co-expressed 
CD41, a platelet marker, a !nding that we did not observe in other conditions 
characterized by endothelial perturbation, including diabetes mellitus [20] and 
renal failure (data not shown). Chirinos et al. [8] described marked elevations 
of CD62E-positive MP in patients with venous thromboembolism, but co-
expression with platelet markers was not investigated. CD62E, or E-selectin, 
is an adhesion molecule that mediates contact between endothelial cells and 
other cells, including platelets. Normal resting endothelial cells do not express 
E-selectin, but a soluble form of this molecule is released from activated cells 
[30]. The presence of CD62E-positive MP suggests endothelial activation, a 
!nding substantiated by the higher levels of mature vWF in ET. The observation 
that this was not accompanied by a rise in propeptide levels suggests that the 
endothelial activation is chronic rather than acute in nature [25]. 
However, these CD62E-positive MP co-express CD41, a platelet marker. CD62E 
was not observed on platelets from controls or ET patients (data not shown). 
An explanation for this double positivity could be interaction between platelets 
(or platelet fragments) and endothelial cells resulting in cellular activation and 
generation of MP of bilineal origin. Circulating MP with characteristics of two 
distinct cell populations have been described, and substantiated by confocal 
immuno"uorescence microscopy [10]. Membrane transfer from MP to cells 
resulting in expression of cell lineage-unrelated receptors is also a recognized 
phenomenon [31,32]. In these cases MP express antibodies of both original cell 
types, thereby showing that they are the result of direct or indirect cell-cell 
contact, in this case endothelial cell/platelet activation. It is also conceivable that 
MP acquire CD62E during their formation via expression by the MP source, the 
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activated platelet. Passive adherence of CD62E was considered as an alternative 
explanation. However, we consider this unlikely since there was no relation 
between MP CD62E expression and soluble E-selectin levels and removal of 
the MP from plasma by centrifugation did not a#ect soluble E-selectin levels, 
indicating a very low quantity of CD62E on MP compared to soluble E-selectin 
in the plasma of patients as well as controls. A low quantity of CD62E on MP 
compared to soluble E-selectin in the plasma was shown previously for septic 
patients [33]. 
Increased numbers of CD41/CD62E-positive MP may be of pathophysiological 
signi!cance since they appear to be related to risk factors for thrombosis in ET. 
A relation between these MP and actual thrombosis was not apparent in our 
present study that was not designed to detect such a relation, and had a limited 
sample size and short follow-up. 
Higher numbers of CD66acde and CD66b-positive MP in ET are likely to be 
related to granulocyte activation in this condition [34]. The level of TF- positive 
MP was increased for ET patients, but such MP accounted for less than 1% of all 
MP in this study, and it is unclear whether this di#erence is clinically relevant. In 
this respect, the absence of a correlation between TF-positive MP and clinical 
parameters, such as a history of thromboembolic events or a positive risk 
score for thrombosis, may be primarily due to a lack of power. TF expression 
on platelets is related with the presence of a JAK2V617F mutation [34], but a 
correlation was not observed in our study between TF-positive MP and the 
presence of a JAK2V617F mutation.
A limitation of this study is that the ages of the control subjects and patients 
di#ered signi!cantly. However, we did not !nd a correlation between older age 
and MP in our study, and such a correlation has not been described in other 
studies [35].
The thrombin generation measurements showed an increased peak height for 
assays with 1 pM of TF and 4 PM of phospholipids, which is compatible with a 
hypercoagulable state in ET patients [36]. The shorter lag times observed for ET 
patients whose assays were conducted without additional TF and phospholipids 
provide evidence for the presence of a procoagulant factor, possibly on the 
membrane of MP, in the plasmas of these patients. We suggest that the di#erences 
found in thrombin generation are due to MP, since removal of phospholipids 
abolished thrombin generation. This result is compatible with the observation 
from Pereira et al. [37] that thrombin generation is largely dependent on the 
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number of MP in plasma, the only available phospholipid source in such a system. 
We found a correlation between peak height and the total number of MP, as well 
as for lag time and MP under these conditions, suggesting that phospholipids 
from MP and intrinsic or extrinsic (TF) coagulation activators in plasma and/
or on the membrane of MP do indeed account for the observed di#erences 
that were abolished after removal of MP by centrifugation. In the light of the 
previously described evidence of the presence of non- MP bound functional TF 
in human plasma [38], future studies should address the question of whether a 
particular form of plasma TF contributes to the observed di#erences between 
MP-rich ET plasma and normal plasma.
In conclusion, ET patients have higher numbers of MP expressing platelet 
and endothelial markers, suggesting ongoing endothelial activation. This is 
con!rmed by a signature of chronic endothelial activation given by an elevated 
level of mature vWF in the presence of a relatively low propeptide. MP from 
patients with ET are associated with increased thrombin generation, shortened 
lag time and increased peak height. CD41/CD62E-positive MP are elevated only 
in ET patients with risk factors for thrombosis. These !ndings suggest a role for 
MP in thrombosis in ET and this deserves further prospective studies.
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Abstract
Background: Essential thrombocythemia (ET) and polycythemia vera (PV) are 
complicated by thrombotic events. In this study we compare microparticle 
(MP) numbers, phenotypic pro!les and MP-dependent thrombin generation 
between ET and PV patients, and with healthy controls.
Materials and methods: In plasma samples from 18 ET patients, 24 PV patients 
and 20 controls, the levels and cellular origin of MP were determined by 
"owcytometry and MP-dependent thrombin generation by an adapted ETP 
assay. 
Results: ET patients, but not PV patients, had higher numbers of platelet-
derived MP (CD41+) than controls (median: ET 9000, PV 5970, controls 4100 
x106/L; p<0.001), not clearly related to the thrombocyte count. Numbers of 
leukocyte-derived MP (CD45, CD11b, PSGL-1+) were higher in PV patients than 
in ET patients and controls, and correlated with the leukocyte count (p<0.001) 
and JAK2V617Fstatus. MP expressing the endothelial marker CD62E were highly 
abundant in ET and moderately increased in PV compared with controls (median: 
ET 2975, PV 324, controls 80x106/L; p<0.001 and p=0.02 respectively). Related 
to their MP numbers, ET patients had a higher MP-dependent endogenous 
thrombin potential (ETP) than controls (median: ET 377, PV 340, controls 282 
milliAbsorbance; p<0.01). 
Conclusions: ET and PV patients had elevated numbers of MP with phenotypic 
pro!les re"ecting di#erent degrees of platelet, endothelium and leukocyte 
ancestry. MP attributed to hypercoagulability in patients as the MP-dependent 
thrombin generation was highest for ET patients. The MP-speci!c endogenous 
thrombin potential, however, was equally proportional to ET, PV and controls 
suggesting similar procoagulant properties. 
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Introduction
Essential thrombocythemia (ET) and polycythemia vera (PV) are both 
myeloproliferative neoplasms (MPN). MPN are associated with a high risk 
of thromboembolic events, 20 % of patients had a major arterial or venous 
thrombosis at time of diagnosis, and another 20 % will have an event during 
follow-up [1]. The pathogenesis of thrombosis in MPN is ill understood. Currently 
accepted risk factors for thrombosis are age >60 years and previous thrombotic 
events [2,3]. Other suggested risk factors are leukocytosis and JAK2V617F 
mutational status [4,5]. Leukocytosis has been related to thrombosis in several 
retrospective analyses [1,6], although its value in predicting future thrombosis 
remains under debate [7]. In addition, a positive JAK2V617F mutation status 
correlated with an increased risk of thrombosis [8]. Patients with the JAK2V617F 
mutation [9] have elevated levels of activated polymorphonuclear cells [10] and 
neutrophil-platelet aggregates. Such aggregates form through interaction of 
membrane adhesion molecules such as CD11b and PSGL-1 on neutrophils and 
GP1b (CD42b) and P-selectin (CD62P) on platelets and have been related to 
the risk of thrombosis [11-13].  Furthermore, several alterations in expression of 
platelet adhesive molecules such as CD42b, GpIIb/IIIa (CD41/CD61) and CD62P 
have been described in these diseases, also possibly contributing to altered 
haemostasis [14,15].
These activation markers involved in coagulation in MPN can be expressed 
by blood cells, but by microparticles (MP) as well. MP are small (0.1-1.0 µm) 
membrane vesicles shed by cells upon activation or apoptosis. They mainly 
mirror their parent cell’s membrane and cytoplasmic composition. Most MP are 
platelet-derived, de!ned by CD41-positivity. Especially interesting in patients 
with ET is the observation made by Flaumenhaft et al. that these CD41-positive 
MP could be derived from megakaryocytes as well [16]. MP are active in 
coagulation through several mechanisms and are not just a passive by-product. 
MP expressing phosphatidylserine, tissue factor (TF), P-selectin and PSGL-1 
were shown to be involved in several mechanisms resulting in coagulation [17].
MP are increased in thrombotic diseases and involved in thrombosis [18,19]. In 
addition, MP induce thrombin generation and in previous studies, MPN patients 
had increased thrombin generation [20]. Earlier we observed elevated numbers 
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of MP in patients with ET and MP-dependent thrombin generation was shown 
to closely correlate to the numbers of MP [19]. In PV however, MP have not yet 
been assessed. 
ET is characterized by an overproduction of mature cells, predominantly of the 
megakaryocytic lineage and PV by cells of the erythroid lineage. Therefore we 
determined whether the spectrum of origin of MP (red blood cells, platelets, 
leukocytes and polymorphonuclear or endothelial cells) di#ered between 
patients with ET and patients with PV and to compare with the spectrum in 
healthy controls. In this study we used "owcytometry to assess the number and 
phenotypic characteristics of MP in patients with ET and PV. In addition, levels 
of mature von Willebrand factor (vWF) and propeptide were determined as a 
measure of ongoing endothelial activation. To gain insight into the interplay 
between MP phenotypic characteristics and direct MP procoagulant properties, 
we measured the endogenous thrombin generation potential of MP in these 
groups, using an adapted MP-dependent thrombin generation assay. 
Materials and Methods
Study subjects
After giving written informed consent, 18 consecutive patients with ET (8 males 
and 10 females, median age: 63, range 36-85 years) and 24 consecutive patients 
with PV (14 males and 10 females, median age: 60, range 39-92 years) were 
enrolled at the haematology department of the Onze Lieve Vrouwe Gasthuis 
in Amsterdam (The Netherlands). Patients were diagnosed as having ET or PV 
according to the revisited WHO criteria [21,22]. All investigations were approved 
by the local medical ethical committee (Medisch Ethische Commissie, Onze 
Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands).  Patients’ characteristics 
are shown in Table 1. Eight patients with ET (44%) and 21 patients with PV (88%) 
were diagnosed with the JAK2V617F mutation. Seven patients with ET (39%) and 
6 patients with PV (25%) had a history of vascular thrombotic events. At the 
time of the sample collection, all patients with ET and 22 patients with PV 
were treated with aspirin, nine ET and seven PV patients were treated with 
hydroxyurea, and one patient with PV did not receive any medical treatment. 
All patients with PV were treated with phlebotomy. In addition we investigated 
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20 healthy controls (13 males and 7 females, median age: 51, range 22-69 years). 
None of the healthy controls were on antiplatelet medication shortly before or 
at the time of blood collection. Controls were signi!cantly younger than ET and 
PV patients (p<0.05 for both). Di#erences in the male to female ratios were not 
signi!cant between patients and controls. 
Isolation and phenotypic analysis of MP
Blood sampling and MP isolation were performed as previously described 
[19]. Flowcytometric analysis was used to quantify and characterize plasma-
derived MP. Brie"y, 5 µL of MP sample was diluted in 30 µL phosphate-bu#ered 
saline (PBS; 154 mM NaCl, 1.4 mM phosphate, pH 7.4). The samples were then 
incubated at room temperature in the dark for 30 min with 5 µL of diluted 
Annexin-V-allophycocyanin (Caltag Laboratories, Burlingame, CA, USA), 5 
µL of diluted Mouse IgG1 Pure (BD Biosciences, San Jose, CA, USA) and 5 µL 
"uoresceinisothiocyanate (FITC)- and phycoerythrin (PE)-labeled anti-human 
monoclonal antibodies.
Table 1:  Characteristics of study subjects. Data are presented as median (range) or number(%)
Controls 
(n=20)
PV patients 
(n=24)
ET patients 
(n=18)
Male/Female ratio 13/7 14/10 8/10
Age 51 (22-69) 60 (39-92) 63 (36-85)
Presence of JAK2V617F mutation nd 21 (88%) 8 (44%)
Platelets (x109/L) 237 (147-377) 369 (119-1495)* 519 (198-1945)*#
Leukocytes (x109/L) 5.3 (4.3-9.4) 11.8 (2.4-26.9)*§ 6.5 (1.8-23.8)
Hematocrit (%) 0.43 (0.34-0.49) 0.44 (0.32-0.53) § 0.38 (0.19-0.47)
F1F2 (pmol/L) 128 (71-300) 180 (32-304) 255 (119-746)*
TAT (μg/L) 4.4 (1.5-14.6) 4.7 (2-15) 5.5 (2.4-43.5)
Mature vWF antigen (nM) 46 (27-102) 49 (32-65) 52 (33-198)
Propeptide (nM) 4.5 (2.7-8.9) 4.8 (3.1-7.7) 4.4 (3.0-12.4)
Aspirin - 22 (92%) 18 (100%)
Hydroxyurea - 7 (29%) 9 (50%)
Phlebotomy - 24 (100%) -
History of thrombosis - 7 (29%) 6 (33%)
Nd= not determined *p<0.05 vs. controls, §p<0.05 vs. ET patients, #p<0.05 vs. PV patients
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For the phenotypic characterization of MP the following cell speci!c monoclonal 
antibodies were used: anti-glycophorin-A-PE (JC159, IgG1) and anti-CD41-FITC 
(5B12, IgG1) from Dako (Glostrup, Denmark); mouse IgG1-PE (X40); mouse IgG1-
FITC (X40), anti-CD11b-PE (ICRF44, IgG1 κ), anti-CD31-PE (WM-59, IgG1), anti-
CD36-PE (CB38, IgM κ), anti-CD41-FITC (MWReg30, IgG1 κ), anti-CD42b-PE (HIP1, 
IgG1), anti-CD45-FITC (HI30, IgG1), anti-CD71-FITC (M-A712, IgG2a) and anti-
CD162-PE (KPL-1, Mouse IgG1) from BD (San Jose, USA); anti-VEGF R2-PE (89106, 
IgG1) from R&D systems (Abingdon, UK); anti-CD54-PE (84H10, IgG1), anti-CD62P-
PE (CLB-Thromb/6, IgG1) and anti-CD66b-PE (80H3, IgG1) from Immunotech 
(Marseille, France); anti-CD62E-PE (HAE-1f, IgG1) from Ancell (Bayport, USA); 
anti-CD144-FITC (BMS158FI, IgG1) from Bender MedSystems (Vienna, Austria); 
anti-CD142-FITC (VD8, IgG1) from American Diagnostics (Stamford, USA); anti-
CD105-FITC (MEM-226, IgG2a) from antibodies-online.com (Aachen, Germany); 
anti-CD239-FITC (BRIC221, IgG2b) from Santa Cruz Biotechnologies (Heidelberg, 
Germany); anti-CD66a,c,d and e-PE (CD66e, CLB-gran/10, IH4Fc, IgG1) from 
Sanquin reagents (Amsterdam, The Netherlands). 
After incubation, 360 µL PBS/calcium bu#er was added and the samples were 
analysed on a FACS Calibur using Worklist Manager (BD) for 30 seconds during 
which the "owcytometer analysed approximately 30 µL of the suspension. 
Forward scatter (FSC) and sideward scatter (SSC) were set at logarithmic gain. 
To distinguish MP from events due to noise, MP were identi!ed on the basis of 
their speci!c FSC and SSC characteristics, with gates set using in vitro platelet 
activation and MP generation data (results not shown), and Annexin V-positivity. 
Variations in FACS Calibur sensitivity due to maintenance and altered settings 
of the FACS may explain the di#erences in numbers of MP in patients with ET 
and controls in this study and in the previous study [19]. To identify Annexin 
V-positive events, a threshold was placed in a MP sample prepared without 
calcium. The number of MP/L plasma was calculated as previously described 
[23]. Data were analysed with CellQuest-pro software (BD).
Markers of coagulation and endothelial activation 
Mature von Willebrand Factor and propeptide plasma levels were measured 
by ELISA as described previously [24]. Coagulation activation was assayed 
by measuring the concentration of prothrombin fragments 1+2 (F1+2) and 
thrombin antithrombin complex (TAT). F1+2 levels were determined using 
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the Enzygnost F1+2 (monoclonal) ELISA kit (Siemens Healthcare Diagnostics 
Deer!eld, USA). TAT was determined using the Enzygnost TAT micro testkit.
Analysis of MP-dependent thrombin generation
To assess MP-dependent thrombin generation we adapted the Siemens 
endogenous thrombin potential (ETP) assay on a BCS-XP analyser (Siemens 
Healthcare Diagnostics, Marburg, Germany). Measurements lasted 30 min and 
the read interval was 0,5 seconds. The reaction was initiated using 30 times 
diluted Actin FS (Siemens) instead of Innovin (Siemens), thus reducing the 
added amount of phospholipids and not providing reagent-derived TF in the 
ETP reaction mixture. To exclude the role of soluble plasma-derived factors, 
thrombin generation was determined after addition of washed MP to MP-poor 
normal human pooled plasma. MP were isolated as described for FACS analysis 
[19]. To obtain MP-poor pooled plasma, fresh MP-plasma from healthy controls 
was submitted to a second centrifugation step at 1,550 x g for 20 min at 20˚C 
and the top layer of the plasma was centrifuged through a 0,2 µm !lter at 3,000 
x g for 5 min in a Vivaspin 20 tube (Sartorius Stedim, Goettingen, Germany) after 
which the plasma was stored at -80˚C until use. The thrombin generation curves 
were calculated with Curves (v 1.0 spec. 3.2, Dade Behring). Three parameters 
from the thrombin generation curves were analysed: ETP (Endogenous 
Thrombin Potential, or area under the curve, that represents the total amount 
of thrombin generation), lag time (time from onset of the reaction to start of 
thrombin generation) and peak height (represents the maximum speed of 
thrombin generation). Linear dose-response relations between MP numbers 
derived from normal pooled plasma and the ETP-parameters were observed 
within certain limits of numbers of MP added (data not shown). Therefore, ETP 
was determined in three di#erent MP dilutions (2x, 5x and 20x diluted) in MP-
poor pooled plasma for each subject. 
Analysis of MP-speci"c endogenous thrombin potential
In order to determine the procoagulant properties of the MP population, we 
calculated ETP per MP (MP-speci!c ETP). Since the ETP assay depends on a 
minimum number of MP for thrombin generation to occur, and ETP values 
reached a maximum (plateau phase) when large amounts of MP were added 
to the reaction, we determined test limits for these calculations. Within these 
limits ETP values showed a linear correlation with the number of MPs of normal 
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pooled plasma added. The linear phase of the ETP values for this particular 
normal MP-poor pooled plasma was 170-350 milliAbsorbance (mA) (data not 
shown). MP-speci!c ETP was calculated by calculating (ETP of dilution/number 
of MP in dilution) x 1000 = ETP per 1000/MP. During each analytical session ETP 
values were corrected for the background ETP of the MP-poor pooled plasma, 
which in general was negligible. 
Results 
Number and phenotypic characterization of MP
The total number of MP was highest in patients with ET (median: ET 9050, PV 6125 
and controls 4240x106/L), and di#ered signi!cantly from controls, p<0.001. The 
mean "uorescence intensity of Annexin V did not di#er between the groups. 
The phenotypic characterization of MP is shown in Table 2. The large majority 
(>95%) of MP was platelet-derived in all groups, as determined by positivity for 
platelet marker CD41 (GpIIb). Patients with ET, but not patients with PV, had 
signi!cantly higher numbers of CD41-positive MP than controls (median: ET 
9000, PV 5970 and controls 4100x106/L, p<0.001).
With regard to the platelet activation marker CD62P, patients with ET showed 
the highest absolute numbers of MP expressing CD62P (median ET 291, PV 
252 and controls 146x106MP/L) without reaching signi!cance. When looking at 
the relative numbers, patients with PV had the highest percentage of CD62P-
positive MP compared with both ET patients and controls (median ET 3.4, PV 
4.8 and controls 3.7%).
Patients with ET had the highest number of CD42b-positive MP (ET 1700, PV 
1100 and controls 1000x106/L) without reaching signi!cant di#erences. 
Numbers of leukocyte-derived MP (CD45-positive) were higher in both ET 
and PV patients compared with controls, being highest in patients with PV 
(median: ET 77, PV 112 and controls 21x106/L; p<0.001; p<0.001). MP expressing 
the granulocyte-marker CD66e were observed in higher numbers in ET and 
PV patients (median ET 65, PV 145 and controls 5x106/l; p<0.001; p<0.001) 
compared with controls. 
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Table 2: Number of MP from speci!c cellular origin as de!ned by marker positivity in plasma from ET 
and PV patients and controls. Data are presented as median (interquartile range) x 106/L and median 
percentage.
  Controls PV patients ET
AnnexinV+ MP 4240 (2630-6480) 6125 (3050-11030) 9050 (5420-11760)*
CD41+ MP 4100 (2470-6340) 5970 (2920-10940) 9000 (5370-11690)*
97.8 98.2 99.2
CD62P+ MP 146 (60-249) 252 (109-436) 291 (140-466)
3.7 4.8 3.4
CD42b + MP 1000 (620-2500) 1100 (540-1900) 1700 (1100-3000)
23.3 16.9 20.8
CD45+ MP 21 (14-54) 112 (64-174)* 77 (40-174)*
0.7 2.2 1.0
CD11b + MP 30 (16-48) 77 (77-187)* # 32 (25-72)
0.8 1.9 0.4
CD66a,c,de, + MP 8 (5-16) 145 (26-478)* 65 (26-211)*
<1 3.6 <1
PSGL-1+ MP 131 (98-176) 235 (163-361)* # 167 (76-220)
3.1 4.6 2.0
CD62E 80 (34-211) 324 (64-2680)* 2970 (146-7300)*
2.8 21 51
glycoA 96 (66-145)
2.1
273 (87-972)*
6.6
508 (50-1150)
                  8.4
CD71 0 (0-1) 21 (10-57)* # 5 (0-29)*
<1 <1 <1
tissue factor 2 (0-10) 6 (2-9) 6 (4-21)
<1 <1 <1
*p<0.05 compared with controls, #p<0.05 compared with ET patients
MP expressing the myeloid adhesion molecule CD11b were found in higher 
numbers in PV patients than in ET patients and controls (median: ET 30, PV 77 
and controls 32x106/L, p=0.02 and p<0.001, Figure 1, Figure 2C). In addition, the 
number of MP expressing PSGL-1 was increased in PV patients as well (median: 
ET 167, PV 235 and controls 131x106/L; p=0.01; p=0.002)(Figure 1). 
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Figure 1: Number of MP expressing leukocyte markers CD45, CD11b and PSGL-1 in ET and PV patients 
and controls (CTR). Data are expressed individually, lines represents the medians. Both patients with ET 
and PV have more CD45-positive MP than controls. With regard to leukocyte-activation markers PSGL-1 
and CD11b, these markers were expressed in higher numbers in PV patients compared with ET patients 
and controls.*p<0.05 compared with controls. #p<0.05 compared with ET patients.
Overall the expression of TF on MP was low. In each group the percentage of 
TF- positive MP was less than 1%. Despite the low numbers, ET patients had 
signi!cantly more TF-positive MP than controls, p<0.05. TF was co-expressed 
with PSGL-1, with PSGL-1 positive MP co-expressing TF in up to 32% (Figure 2D).
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Figure 2: Scattergrams of MP expressing di#erent antibodies. CD62E-positivity was often present in 
patients as is shown on the y-axis (A) however, in some patients completely absent(B), as it was in 
controls, expression of CD11b (C) and PSGL-1 (D) was clearly visible, however, TF-positivity was weak (D, 
x-axis).
With regard to endothelial-derived MP, a signi!cant increase of MP expressing 
the endothelial marker CD62E (median: ET 2975, PV 324, controls 80x106/L) was 
observed in ET and PV patients compared with controls (p<0.001 and p=0.02 
respectively, expression shown in !gure 2A and 2B). Other endothelial cell 
markers CD144, CD105 and CD54 were expressed on <1% of MP and did not 
di#er between the groups.
With regard to the erythrocyte-derived MP, these were higher in patients with 
PV than in controls (median: ET 508, PV 273, controls 96x106/L, p=0.01). ET 
patients had the highest median, however probably due to the wide range 
of values, this did not result in a signi!cant increase compared with controls. 
Expression of erythrocyte transferring receptor CD71, which could be used as 
a marker for reticulocytes [25], was higher in PV patients compared with ET 
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patients and controls (median ET 5, PV 21 and controls 0x106/L, p=0.02 and 
p<0.001, respectively) 
There was a weak correlation between leukocyte count and leukocyte-derived 
MP (CD45+) in patients with PV and ET (R= 0.45, p=0.03 and R=0.49, p=0.04 
respectively). This correlation was absent in controls (R=-0.21, p=0.37). In 
addition, platelet count correlated strongly with platelet-derived MP in PV 
patients (R= 0.59, p=0.005), this correlation was weaker for ET patients (R=0.51, 
p=0.03) and again was absent in controls (R= 0.26, p=0.26).
Relation of MP with presence of JAK2V617F mutation or pharmaceutical treatment
Compared with patients with a negative JAK2V617Fmutational status (n=13), 
patients with a positive JAK2V617F mutation status (n=29) not only had a 
higher number of leukocytes (median: 11.8 vs. 6.5x109/L, p<0.001) but also 
an increased number of MP expressing leukocyte makers CD45 (median: 116 
vs. 43x106/L, p=0.001, Figure 3) and CD11b (median 78 vs. 26x106/l, p=0.002). 
The mutational status did not correlate with number of CD62E-positive MP 
or thrombin generation results. Treatment with hydroxyurea did not result in 
di#erences in number of leukocytes at the time of blood sampling, numbers 
of MP, or in thrombin generation results. The impact of aspirin on the above 
mentioned parameters is unknown as all but two patients used aspirin.
Figure 3: Dotplots of leukocyte-derived MP (CD45 and CD11b) and JAK2 mutational status. Lines 
represent the median value. JAK2 positive patients have more leukocyte-derived MP than those with a 
JAK2 negative status. *p<0.05 
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Markers of coagulation and endothelial activation 
No di#erences were observed in levels of mature von Willebrand Factor and its 
propeptide between groups (Table 1). The ratio in all groups was compatible 
with chronic as opposed to acute endothelial activation [19,26]. With regard to 
markers of coagulation activation, results of thrombin-antithrombin complexes 
(TAT) did not di#er between patients and controls. F1F2 was higher in ET 
patients compared with controls (median: ET 255, PV 180 and controls 128 
pmol/L; p<0.001, Table1). 
MP- dependent thrombin generation
One PV patient was excluded from ETP analysis because the ETP values of MP-
dilutions showed that the MP pellet could not be properly resuspended. As 
observed before [19], MP-dependent thrombin generation of ET patients was 
higher than controls since higher ETP and peak height and lower lag times were 
observed (p=0,001, p=0,001 and p=0,12 (NS) respectively, Table 3). In contrast, 
ETP of MP-dependent thrombin generation of PV patients was slightly increased 
and therefore values were intermediate between ET patients and control values, 
without signi!cant di#erences (Figure 4A). Median (IQR) ETP values were: ET 377 
(312-392), PV 340 (250-376) and controls 282 (213-347) mA, Table 3). 
Table 3: Thrombin generation (TG) results in 2x dilution. Data presented in median (IQR)
controls PV patients ET patients
MP-dependent TG
Lag time (sec) 693 (660-768) 680 (635-760) 665 (608-710)
Peak Height (mA/min) 37 (29-48) 46 (35-57) 52 (43-58)*
ETP (mA) 282 (213-347) 340 (250-376) 377 (312-392)*
MP-speci!c TG
ETP/1000MP 1.54 1.80 1.41
*p<0.05 versus controls
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Figure 4  A: endogenous thrombin potential (ETP) results of isolated MP (2 times diluted) of patients and 
controls (CTR) added to human pooled plasma. Lines represent the median value. ETP was higher in 
patients, especially ET patients had a higher ETP than controls, *p<0.05.  B: Correlation between total 
numbers of MP and ETP in di#erent dilutions (2x, 5x and 20x diluted).
MP-speci"c thrombin generation
In general, ETP values (!gure 4B), as well as peak height, correlated with the 
total number of MP (R2=0.6, p<0.001 and R2=0.6, p<0.001, respectively). 
To further investigate qualitative functional di#erences in MP, MP-speci!c 
thrombin generation (i.e. thrombin generation per MP) was determined. In 
MP-speci!c thrombin generation the ETP has been corrected for MP numbers. 
No di#erences were observed between the groups concerning MP-speci!c 
thrombin generation (median: ET 1.41, PV 1.80 and controls 1.54 ETP per 1000 
MP), indicating that no overall qualitative functional MP di#erences were 
present in patients compared with controls. However only in patients, mostly 
PV patients, an ETP/MP ratio above 2.5 was detected.
MP and thrombin generation in high risk patients for thrombosis
No correlations were observed between ETP values and established thrombosis 
risk factors (age >60 and previous thrombosis), MP numbers or MP phenotypic 
characteristics. 
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Discussion 
Patients with ET and PV had elevated numbers of MP with phenotypic pro!les 
re"ecting di#erent proportions of platelet, endothelium or leukocyte ancestry. 
PV patients di#ered from ET patients only regarding numbers of leukocyte-
derived MP, being higher in PV. Furthermore thrombin generation was increased 
in ET patients, which was dependent on the increased number of MP in these 
patients and could not be related to a functional di#erence in MP properties. A 
high clinical risk of thrombosis by established risk factors did not correlate with 
the afore mentioned parameters. 
ET patients had more platelet-derived MP than controls. In concordance with 
our previous results the vast majority of MP was derived from platelets [19]. 
Indeed, CD41-positive MP could in part be megakaryocyte-derived as well 
[16,27] which would especially be important in ET, and might explain why the 
correlation between platelets and platelet-derived MP in ET was weaker than 
in PV. However, this correlation was absent in controls.
Similar to our previous results [19], abundant CD62E expression was again found 
on MP in patients with ET, and moderately increased on MP in patients with PV. 
Again, CD62E was co-expressed with CD41. These MP of bilineal origin were 
described in our previous study and their origin can only be speculated upon, but 
most probably resulted of membrane transfer when platelets and endothelial cells 
interact. As patients with PV had less platelets than patients with ET this might 
contribute to their di#erence in expressing CD62E. In our previous study we 
showed that patients with ET with high numbers of CD62E-positive MP had more 
risk factors for thrombosis [19]. This was not observed in the current study, probably 
because the included patients had less risk factors for thrombosis. CD62E-positive 
MP suggest endothelial activation, however, in contrast to our former study, no 
higher levels of mature vWF were observed in these patients compared with 
controls, due to higher values of mature vWF antigen in the control group. This is 
not well understood, but could be related to increased age of the control group, 
as vWF antigen is known to increase with age [28]. As described before the ratio 
between mature vWF and its propeptide in the patients groups was compatible 
with chronic endothelial activation. The increased F1+2 fragment, values in the 
patient group provided evidence for ongoing coagulation activation.
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With regard to leukocyte-derived MP, especially in patients with PV higher 
numbers were observed, and their numbers correlated with the leukocyte 
counts. Moreover, patients with PV had higher numbers of MP carrying markers 
of neutrophil activation CD66b, CD11b and PSGL-1. Neutrophil activation 
is important in the formation of leukocyte-platelet aggregates in PV and ET 
patients [11], which have been related to thrombosis [13]. These aggregates are 
formed through the interaction of platelet and leukocyte adhesive molecules, 
such as between platelet CD62P and leukocyte PSGL-1, inducing the formation 
of leukocyte-derived MP, which can express TF and so enhance clot formation 
[17] but also between platelet CD42b and leukocyte CD11b [11]. MP expressing 
these activation markers might contribute to the forming of leukocyte-platelets 
aggregates as well, or in"uence adhesion to the vessel wall. Patients with ET 
showed a trend to increased numbers of CD42b-positive MP, and patients with 
PV had the highest numbers of MP expressing CD11b and PSGL-1.
We observed a correlation between the presence of the JAK2V617F mutation 
and both leukocyte count and numbers of leukocyte-derived MP. A correlation 
between JAK2V617F mutational status and leukocytosis has been described 
previously [9].
The procoagulant potential of MP was con!rmed in MP-dependent thrombin 
generation experiments. Patients with ET had higher ETP compared with 
controls. The higher phospholipid load as provided by the higher number of 
MP in ET patients is most likely responsible for this result. Moreover, both ET 
and PV patients had a shorter lag time than controls, which suggest that they 
had more tissue factor. Tissue factor could be carried by leukocyte-derived MP. 
Di#erences in lag time are mostly in"uenced by the amount of tissue factor 
in the reaction [29], and no exogenous tissue factor was added. Numbers of 
tissue factor-bearing MP did not di#er between groups, and were relatively low 
(<1%). As observed before using the CAT assay, the ETP assays are probably 
more sensitive for the presence of tissue factor than the FACS analysis [19]. 
Qualitative di#erences of MP in thrombin generation experiments were 
investigated by calculating MP-speci!c thrombin generation, which is the 
amount of thrombin that is generated per MP. This MP-speci!c thrombin 
generation did not di#er between the groups. This suggests that the increased 
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total MP-dependent ETP is a re"ection of the increased numbers of MP, 
and probably of the increased surface of negatively charged membrane 
phospholipids, rather than a result of di#ering phenotypic characteristics. A 
recently published study by Duchemin et al. [20] on circulating procoagulant 
activity in ET and PV patients, also reported on increased procoagulance in 
patients due to increased circulating phospholipid content. Our MP-speci!c 
ETP did not involve the isolation of MP from one speci!c lineage and therefore 
represents the average ETP taken over a group of MP derived from several cell 
lines. As previously described higher percentages of leukocyte-derived MP 
could in"uence ETP [30]. However, as leukocyte-derived MP were present at 
very low numbers, it is possible that minor e#ects escaped detection, or that 
their main e#ects are mediated through interaction with the vessel wall. 
In conclusion, MP in patients with ET and PV showed di#erences with regard to 
both phenotypic characteristics and thrombin generation potential compared 
with controls. Patients had higher numbers of MP and patient groups di#ered in 
the !nding that PV patients showed higher numbers of MP expressing markers 
of leukocyte activation. Interestingly, leukocytosis as well as the number of 
leukocyte-derived MP correlated to the presence of the JAK2V617F mutation. ET 
patients showed an impressive, and PV patients a moderate, increase of MP 
expressing CD62E, a selectin involved in leukocyte-endothelium interactions. 
This was entirely absent in controls and may re"ect a novel mechanism involved 
in the increased risk on thrombosis in MPN patients.
With regard to the direct procoagulant properties of MP in these patients, 
MP in patients with ET showed a particularly high ETP. As no di#erences were 
found in thrombin generation per MP, this e#ect seems to rely on numbers 
of MP, and more speci!cally on their phospholipid content. Therefore MP in 
myeloproliferative disease could partake in the thrombotic diathesis through 
both indirect mechanisms (mediation of intercellular adhesion), and direct 
mechanisms (MP-induced thrombin generation).
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Abstract:
Background: In patients with chronic renal failure (CRF), cardiovascular disease 
is the leading cause of increased morbidity and mortality. We hypothesized a role 
for endothelial activation and microparticle (MP) numbers and procoagulant 
activity in the pre-thrombotic state of these patients. 
Methods: We analysed blood samples of 27 patients with CRF (8 chronic 
kidney disease Stage 4 (CKD4), 9 peritoneal dialysis (PD) and 10 haemodialysis 
(HD), samples taken before and after haemodialysis, and 10 controls. Degree 
and nature of endothelial activation were assessed by measuring mature 
von Willebrand factor (vWF) and vWF propeptide levels. Cellular MP were 
characterized by "owcytometry and MP-speci!c thrombin generation (TG) 
measurements.
Results: CRF was accompanied by chronic (CKD4 and PD) or acute (HD) 
endothelial activation. Patients with CRF had substantially higher MP numbers 
than controls (median 9400 vs. 4350*106/L, p=0.001), without signi!cant 
di#erences between the treatment subgroups, or between pre- and post-
HD. The vast majority of MP was platelet derived. Of the minor populations, 
endothelial MP and tissue factor-bearing MP were more abundant in CRF. 
MP were procoagulant, but the increase in numbers was not re"ected in a 
proportional increase in MP-speci!c TG. 
Conclusions: Renal failure is accompanied by endothelial activation of a 
di#erent nature in CKD4 and PD patients compared to HD patients, and results 
in all subgroups in an increase of mainly platelet derived MP that appear to be 
less procoagulant than in other disease states, possibly because of the uraemic 
functional defect of their cellular source.
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Introduction
Cardiovascular disease is the leading cause of mortality in patients with chronic 
renal failure (CRF), regardless of progression to end stage renal disease [1,2]. 
In fact, patients with chronic kidney disease Stage 3 or 4 (glomerular !ltration 
rate between 30 and 60 ml/min/1.73 m2) more often die of cardiovascular 
causes rather than progress to end-stage renal disease [3]. The development of 
cardiovascular disease in uraemic patients involves atherosclerosis, a complex 
process accompanied by endothelial dysfunction and in"ammation. Moreover 
patients with CRF have an increased risk of venous thromboembolism [4].
Circulating microparticles (MP) are shed membrane vesicles of <1.0 μm in 
diameter and are generated as result of cellular apoptosis or activation in 
response to various stimuli [5]. MP display speci!c cell surface proteins that 
indicate their cellular origin, e.g. platelets, leukocytes, endothelial cells or red 
blood cells. MP expose phosphatidylserine on their outer membrane lea"et, 
which provides a suitable anionic phospholipid surface for assembly of the 
tenase and prothrombinase complexes [5,6]. They may express tissue factor (TF) 
[7], the primary physiological initiator of coagulation. Such phosphatidylserine- 
and/or TF-bearing MP contribute to thrombosis in di#erent diseases. Moreover, 
MP contribute to endothelial cell activation and dysfunction leading to vascular 
in"ammation and development of atherosclerosis [8]. Indeed, in patients with 
cardiovascular disease increased numbers of circulating MP are observed [9,10] 
and are associated with dysregulation of vascular tone [11,12] and correlate 
with disease severity and clinical outcome [10].
In uraemic patients, elevated levels of circulating MP have been detected as 
well [11,13], and two possible mechanisms are described by which chronic renal 
disease may lead to elevated MP levels. Firstly, in vitro high concentrations of 
uraemic toxins cause a rise in endothelial-derived MP [11], although it is not yet 
clear whether in vivo there is a correlation between the urea level and number of 
circulating MP. Secondly, patients with uraemia are at a high risk of cardiovascular 
disease, which may further propagate the production of MP that are also 
implicated in its cause. When uraemic patients are subjected to haemodialysis 
(HD), shear stress and the contact between blood and non-human materials 
could add to the previous two mechanisms in generating MP [14,15]. 
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Because of their established contribution to cardiovascular risk factors, platelet- 
and endothelium-derived MP are of interest, and an increase in their numbers 
indicates a poor clinical outcome [16]. Both types of MP have previously been 
described to be increased in renal disease [11,15,17,18]. Daniel et al. [15] described 
elevated numbers of granulocyte-derived MP as a marker of in"ammation in 
HD. MP carrying membrane-bound markers of coagulation, such as P-selectin 
and TF, are not described in renal disease yet. P-selectin-positive MP re"ect the 
source platelet activation status and have been observed in increased numbers 
in myocardial infarction [19]. TF-bearing MP are involved in arterial thrombosis 
[20] and TF is thought to play a major role in plaque thrombogenicity [21]. In 
the present study, we have made a !rst extensive inventory of the cellular and 
molecular spectrum of MP in renal disease. 
To gain more insight into the interplay between endothelial dysfunction and 
MP numbers and properties in CRF, we have assessed the activation status 
of the endothelium as re"ected by levels of plasma mature von Willebrand 
Factor (vWF) and propeptide. The half-life of mature vWF measures four times 
the propeptide half-life, and due to this di#erence in half-life, their relative 
concentration is a distinctive indicator for ongoing chronic as opposed to acute 
endothelial activation [22]. Also, MP procoagulant capacity was assessed in an 
MP- dependent thrombin generation (TG) assay. Uniquely, this allowed us to 
eliminate pro- or anticoagulant e#ects of other patients’ plasma components 
since TG was performed by addition of isolated MP to a normal human pooled 
plasma background. 
Materials and Methods
Patients
A cross-sectional study was performed in 27 patients with CRF (median age 
54, range 22-80), including 10 patients with end-stage renal disease on HD, 9 
patients with end-stage renal disease on peritoneal dialysis (PD), and 8 patients 
with CKD stage 4 (CKD4, glomerular !ltration rate between 15-30 ml/min/1.73 
m2). Patients’ characteristics are listed in Table 1. Patients with diabetes or on 
coumarin derivatives were excluded. The groups did not di#er in age and sex 
ratio. The average time of HD in the HD group was 2.6 ± 3.1 years. The patients 
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were dialysed three times a week with a low "ux polysulfone membrane 
(Fresenius Medical Care, Bad Homburg, Germany), and the duration of dialysis 
was individually adjusted to maintain an eKt/V above 1.3 per dialysis. All patients 
were dialysed in the same dialysis unit using the same dialysate system (Onze 
Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands). Heparinization during 
dialysis session was performed in all patients with infusion of 2500 or 5000 IU 
of low-molecular weight heparin (LMWH) at the beginning of each HD session. 
All patients were dialysed through an arteriovenous !stula, and blood samples 
were obtained from the arterial end of the !stula after two days o# dialysis, 
before and after HD. The PD group consisted of nine patients (three patients 
on continuous ambulatory PD and six on automated PD) and had an average 
time on dialysis of 2.2 ± 1.8 years. Blood samples of CKD4 and PD patients were 
obtained during the routine outpatient visits. 
In addition, at the start of the study, we collected blood samples from ten 
healthy control subjects (median age 46, range 19-59), 6 men and 4 women who 
were not using oral contraceptives or hormonal therapy. In their blood samples 
we analysed all parameters discussed here, except TG of isolated MP added 
to human pooled plasma. As a healthy control group for this MP-speci!c TG 
experiment, designed and performed later in time during the course of a study 
on MP in breast cancer patients (manuscript submitted), we included twenty 
healthy control subjects (women, median age: 54 ± 12 years), not using oral 
contraceptives or hormonal therapy. We feel this is valid because the number 
of Annexin V-positive MP in this control group did not di#er signi!cantly from 
the !rst control group (median 6400*106/l, p=0.15), with a narrow distribution 
range. The mean "uorescence intensity (MFI) of MP-bound-labelled Annexin 
V was very similar in both control groups (MFI 416 in CTR (n=20) and 438 in 
CTR (n=10), indicating similar MP procoagulant phospholipid exposure. Finally, 
in thrombin generation, no male/female di#erences have been found [23]. All 
patients and controls agreed to participate in the study following informed 
consent and this study was approved by the local medical ethical committee 
(Medisch Ethische Commissie, OLVG, Amsterdam, The Netherlands).
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Table 1 Patients’ characteristics
controls CKD4 PD HD
Number 10 8 9 10
Median age 46 60 50 50 
Sex ratio (male/female) 6/4 4/4 8/1 5/5
Mean years on dialysis N.A. 2.2 2.6
Causes of kidney disease 
Vascular disease 6/8 5/9 4/10
Glomerular disease 1/8 0 2/10
Nephrolithiasis 0 1/9 1/10
IgA nephropathy 0 1/9 1/10
Polycystic Kidney Disease 1/8 1/9 0
Unknown 0 1/9 2/10
Hypertension 8/8 7/9 8/10
Biological parameters (mean)
Haemoglobin (mmol/L) 7.7 7.7 7.5
Albumin (g/L) 43 37 42
Kreatinin (μmol/L) 284 947 874
Urea (mmol/L) 17 19 27
Ferritin (µg/L) 127 152 573
Treatments
ARB* or ACE# inhibitor 6/8 4/9 4/10
ß blocker 4/8 8/9 5/10
calcium antagonist 6/8 7/9 5/10
central agents 2/8 3/9 4/10
diuretics 3/8 6/9 7/10
aspirin 0 2/9 4/10
statins 5/8 6/9 3/10
erythropoietin 2/8 6/9 10/10
Ferri oxide saccharate 0 0 9/10
(VenoferR)intravenous
*Angiotensin II receptor blockers
#Angiotensin converting enzyme
Plasma markers of endothelial activation
Mature von Willebrand Factor and propeptide plasma levels were measured by 
ELISA as described previously [24]. 
Blood collection, isolation and !owcytometric analysis of MPs
Blood samples were drawn with a 21-gauge needle after applying a light 
tourniquet. After discarding the !rst 4 mL, blood was collected into a 4.5 mL 
tube containing 3.2 % trisodium citrate [Becton Dickinson (BD), Plymouth, UK]. 
Plasma was prepared within 20 min after blood collection by centrifugation for 
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20 min at room temperature at 1,550 x g, without brake. Aliquots of plasma were 
snap frozen in liquid nitrogen, and then stored at –800C until use. MP isolation 
was performed as previously described [25]. For "owcytometric analysis MP 
(5 µL) were diluted in 35 µL PBS containing 2.5 mmol/L CaCl2 (pH 7.4). Then 
5 µL Annexin V-allophycocyanin (APC) from Caltag Laboratories (Burlingame, 
CA, USA) and 5 µL "uoresceinisotyocianate (FITC)-, phycoerythrin (PE)- and/or 
peridinin chlorophyll protein complex (PerCP)-labeled cell-speci!c monoclonal 
antibodies or isotype-matched control antibody were added. We used anti-TF-
FITC (VD8, IgG1) from American Diagnostics (Stamford, CT, USA); anti-CD8-PE 
(SK1, IgG1), anti-CD14-PE (MΦP9, IgG2b), anti-CD15-PE (HI98, IgM), anti-CD20-
PE (L27, IgG1), anti-CD45-PerCP (H130, IgG1, k), anti-CD61-PE (VI-PL2, IgG1), anti-
CD63-FITC (H5C6, IgG1), anti-CD146-PE (P1H12, IgG1) from BD (San Jose, USA); 
anti-glycophorin A-FITC (JC159, IgG1) and anti-CD41-FITC (5B12, IgG1) from 
DAKO  (Glostrup, Denmark), anti-CD144-FITC (BMS158FI, IgG1) from Bender 
MedSystems (Vienna, Austria), anti-CD106-FITC (1.G11B1, IgG1) from Calbiochem 
(Darmstadt, Germany); anti-CD54-PE (K562, IgG1), anti-CD66b-FITC (80H3, 
IgG1N) and anti-CD62P-PE (CLB-Thromb/6, IgG1) from Immunotech (Marseille, 
France); anti-CD62E-FITC (HAE-1f, IgG1) from Kordia (Leiden, The Netherlands); 
anti-CD4-PE (CLB-T4/2, IgG1) and anti-CD66acde-PE (CLB-gran/10, IH4Fc, IgG1) 
from Sanquin (Amsterdam, The Netherlands). Labelled isotype controls IgG1 
(X40) and IgG2a (X39) were used from BD (San Jose, USA), and IgG2b-PE (MCGb) 
from IQProducts (Groningen, The Netherlands).
The mixtures were incubated in the dark for 30 min at room temperature. 
Subsequently, 760 µL PBS/calcium bu#er were added. All samples were analysed 
for 1 min during which the "owcytometer analysed approximately 55 µL of 
the suspension. The samples were analysed in a FACS Calibur "owcytometer 
with CellQuest-pro software (BD, San Jose, CA, USA). Forward scatter (FSC) 
and sideward scatter (SSC) were set at logarithmic gain. To distinguish MP 
from events due to noise, MP were identi!ed on FSC, SSC, and AnnexinV-
positivity. To identify Annexin V-positive events, a threshold was placed in a MP 
sample prepared without calcium. They were further categorised by binding 
of a monoclonal antibody directed against a cell-speci!c antigen. To identify 
MP that bound cell-speci!c monoclonal antibodies, MP were incubated with 
identical concentrations of isotype-matched control antibodies to set the 
threshold. Some antibodies had higher background "uorescence than the 
isotype matched control and with these antibodies the threshold was set on 
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the population MP negative for the antibody. The number of MP per litre plasma 
was calculated as previously described [25].
Thrombin generation measurements
Thrombin generation (TG) was measured by means of the Calibrated Automated 
Thrombogram (CAT) method (Thrombinoscope BV, Maastricht, The Netherlands) 
[23]. TG was determined in the MP rich plasma samples or in the supernatant 
or pellet after centrifugation for MP isolation (as described above), TG (in 80 PL 
plasma or after addition of 10 µL MP pellet to 70 µL of normal pooled platelet-
poor plasma, obtained from 80 to 90 healthy volunteers) was triggered without 
the addition of exogenous TF and phospholipids added. All reagents used were 
obtained from Thrombinoscope BV. TG was measured as "uorescence, read in a 
Fluoroskan Ascent reader (Thermo Labsystems OY, Helsinki, Finland) equipped 
with a 390/460 !lter set and TG curves were calculated with the Thrombinoscope 
software (Thrombinoscope BV). 
Four parameters may be derived from the TG curves: lag time, endogenous 
thrombin potential (ETP), time to peak and peak height. For this MP study only 
the ETP was used. Validation of the CAT method showed normalization of non-
time-dependent parameters to be mandatory to obtain acceptable inter-assay 
variations [23]. Intra-assay variations for normalized parameters are typically 
below 6%, inter-assay variations below 8% [23]. 
Statistical analysis
The majority of variables were not normally distributed and therefore, all 
variables are reported as medians and range, unless otherwise stated. We 
compared the di#erence of MP numbers and results of thrombin generation 
between groups with non-parametric Mann Whitney U test or Kruskal Wallis 
test, where appropriate. Results before and after haemodialysis were compared 
using a paired student’s t-test. Bivariate correlations were estimated by 
Spearman’s rank correlation (R). All tests were two-tailed and p values of <0.05 
were considered statistically signi!cant. Analyses were performed using SPSS 
16.0 for windows (SPSS Inc., Chicago, USA).
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Table 2 Levels of vWF antigen and propeptide, presented as medians and IQR
  Controls CKD4 PD HD before HD after
vWF antigen (nM) 34.8 63.6* 71.8* 39.5 46.0*
28.1-37.0 42.8-78.0 62.3-106.4 30.6-54.8 41.4-61.7
Propeptide (nM) 5.2 8.5* 8.0 4.7 8.0#
4.4-6.4 5.7-12.9 5.4-11.0 2.9-6.1 5.0-12.8
* p<0.05 compared to controls  #p<0.05 compared to before dialysis session
Results
Endothelial activation: mature von Willebrand Factor and propeptide 
We investigated the activation of endothelium by measuring mature vWF and 
its propeptide [22]. Table 2 shows that patients with CKD4 and PD had increased 
levels of mature vWF  [median: CKD4 63.6nM, PD 71.8nM and controls 34.8 nM 
(ref range 26-49nM); p<0.01 and p<0.01], with similar (PD patients) or slightly 
elevated (CKD4 patients) propeptide concentrations compared with controls 
[median: CKD4 8.5nM, PD 8.0nM and controls 5.2 nM (ref range 4.2-9.3nM)], 
indicating chronic endothelial activation (Figure 1). Mature vWF levels in HD 
patients were not elevated (median 39.5nM). However, there was a moderate 
vWF increase during the dialysis process (median HD before 39.5 nM, HD after 
46.0 nM, p=0.48) with a disproportional rise in the propeptide levels, indicating 
acute endothelial activation (median HD before 4.7nM, HD after 8.0 nM, p=0.04). 
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Figure 1: Levels of vWF antigen (x-axis) and propeptide (y-axis) of controls (A), CKD4 (B), PD (C) and HD 
patients before (D) and after (E) haemodialysis session. The box represents values within the normal 
range. CKD4 and PD patients have higher levels of vWF antigen compared to controls (p<0.05) in a 
pattern compatible with chronic endothelial activation and HD patients have higher levels of propeptide 
after haemodialysis compared to before (p<0.05) compatible with acute endothelial activation [22].
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Table 3 Number, cellular origin and composition of MP in plasma (x106/L) in di#erent patient groups and 
controls. Data presented as medians (range) or % of total (=Annexin V-positive) MP. 
  Controls
n=10
All CRF patients
n=27
CKD4
n=8
PD
n=9
HD before
n=10
HD after
n=10
AnnexinV+ MP 4350 9400** 9150 * 8500 * 10350 * 13350 *
(3800-9400) (4000-25500) (4000-13100) (5000-25500) (4200-22000) (4000-22200)
CD41+ MP 4100 9200** 9000 * 7700 * 10230 * 11900 *
(3500-9200) (3600-21000) (3600-12000) (4700-21000) (3800-19000) (3250-22200)
94 95 93 95 95 94
CD62P+ MP 140 320** 340 ** 250 410 * 285 * 
(50-270) (70-720) (220-720) (70-650) (105-710) (100-690)
2.0 3.6 4.8 3.0 2.5 2.3
CD63+ MP 8 46** 65 * 50 * 30 * 40 *
(0-35) (8-190) (17-130) (8-190) (10-145) (30-150)
<1 <1 <1 <1 <1 <1
GlycoA+ MP 62 63 40 65 111 110
(26-199) (13-197) (13-160) (13-192) (41-197) (32-307)
1.4 0.9 0.4 0.9 1.2 1.0
CD144+ MP 4 8* 8 * 4 9 * 5 *
(0-13) (0-150) (0-30) (1-70) (0-150) (0-175)
<1 <1 <1 <1 <1 <1
CD66e+ MP 8 14* 12 20* 18* 20* 
(1-19) (0-44) (0-16) (6-44) (4-39) (3-49)
<1 <1 <1 <1 <1 <1
CD14+ MP 7 12 11 10 18 * 26 *
(0-17) (1-225) (1-39) (4-17) (7-225) (6-180)
<1 <1 <1 <1 <1 <1
TF+ MP 2.5 4.4* 4.6 * 4.1 6.7 * 5.0
(2-7) (1-215) (3-8) (1-10) (2-215) (2-220)
<1 <1 <1 <1 <1 <1
* p<0.05 compared with controls, **p<0.001 compared with controls.
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Number and phenotypic characterization of MP
The total number of MP was substantially increased in CRF patients compared 
with controls, (9400 vs. 4350 x106/L p<0.001, Table 3). No signi!cant di#erences 
were observed between patient subgroups, or between pre- and post dialysis 
samples. The lowest median value was found in PD. 
In most study subjects more than 90% of circulating MP bound Annexin-V, 
indicating the presence of phosphatidylserine on their membrane. The 
phenotypic characterization of MP depicted in Figure 2 showed that the cellular 
subset composition of the MP population (i.e. of platelet -, leukocyte -, endothelial 
cell or erythrocyte origin) is similar between CRF and controls. The large majority 
of MP in all groups was of platelet origin, as determined by positivity for the 
platelet marker CD41 (CRF vs. controls: 95 vs. 94%). Re"ecting the higher total 
number of MP, the absolute number of platelet-derived MP (CD41 positive) was 
signi!cantly higher in CRF than in controls (9200 vs. 4100x106/l; p<0.001, Figure 
2), again without di#erences between patient subgroups. Notably, the numbers 
of platelet derived-MP did not correlate with urea levels. 
Co-expression of platelet (CD41) and activated platelet markers (CD62P 
and CD63) was increased in CRF (CD41, CD62P double positive median 320 
vs. 140x106/L; p=0.001, CD41, CD63 double positive median 46 vs. 8*106/L; 
p<0.001). For CD62P- positive MP a relative increase was observed as well; in 
renal failure they accounted for 3.6% of all MP vs. 2.0% in controls (Table 3, 
Figure 2). Although in PD patients the lowest numbers of MP were observed, 
di#erences were not statistically signi!cant in subgroups. 
With regard to minor MP fractions, numbers of red blood cell-derived MP 
(glycophorinA-positive) were a priori hypothesized to be in"uenced by the HD 
process. However, similar numbers in all patient subgroups were shown and 
no signi!cant increase upon HD was observed (Table 3). Endothelium-derived 
MP however, though relatively low, di#ered between groups with a higher 
number of MP expressing CD144 in CKD4 and HD compared to controls, but 
not in PD. Whereas total numbers of leukocyte-derived MP (CD45-positive) did 
not di#er between CRF and controls, MP positive for the granulocyte marker 
CD66e indeed were increased in CRF compared with controls (median: 14 vs. 8* 
106/L; p=0.02), and monocyte-derived MP were observed in higher numbers in 
HD patients compared with controls (p=0.005). All numbers of MP observed in 
other subsets did not di#er signi!cantly from controls (Figure 2).
26739 Trappenburg, Marijke.indd   80 08-10-13   14:32
Chapter
4
Microparticles in chronic renal failure 81
Fi
gu
re
 2
: S
iz
e 
of
 c
irc
ul
at
in
g 
M
P 
su
bp
op
ul
at
io
ns
 in
 C
RF
 p
at
ie
nt
s a
nd
 c
on
tr
ol
s.
Ba
r g
ra
ph
: n
um
be
r o
f M
P 
fro
m
 sp
ec
i!
c 
ce
llu
la
r o
rig
in
 a
s d
e!
ne
d 
by
 m
ar
ke
r p
os
iti
vi
ty
 in
 p
la
sm
a 
fro
m
 p
at
ie
nt
 su
bg
ro
up
s: 
CK
D
4,
 P
D
, H
D
 a
nd
 c
on
tr
ol
s (
CT
R)
. S
ho
w
n 
ar
e 
th
e 
nu
m
be
r o
f M
P 
po
sit
iv
e 
fo
r m
ar
ke
rs
 o
f p
la
te
le
ts
 (C
D
41
, C
D
61
), 
ac
tiv
at
ed
 p
la
te
le
ts
 (C
D
62
P, 
CD
63
), 
le
uk
oc
yt
es
 (C
D
66
e,
 C
D
14
, C
D
20
, C
D
66
b,
 C
D
8,
 C
D
45
, C
D
4,
 C
D
15
), 
en
do
th
el
ia
l c
el
ls 
(C
D
62
E,
 C
D
14
4,
 C
D
54
, C
D
10
6)
, e
ry
th
ro
cy
te
s (
G
ly
co
A)
 a
nd
 T
F. 
D
at
a 
pr
es
en
te
d 
as
 m
ed
ia
ns
. 
In
se
t: 
do
tp
lo
t o
f t
he
 sa
m
e 
da
ta
 p
re
se
nt
ed
 in
di
vi
du
al
ly
 fo
r t
he
 p
la
te
le
t m
ar
ke
r C
D
41
 a
nd
 th
e 
m
ar
ke
r f
or
 p
la
te
le
t a
ct
iv
at
io
n 
CD
62
P. 
*p
<0
.0
5 
co
m
pa
re
d 
w
ith
 c
on
tr
ol
s.
26739 Trappenburg, Marijke.indd   81 08-10-13   14:32
Chapter 482
Finally, the number of TF-positive MP, accounting for < 1% of total MP, was 
signi!cantly higher in CRF compared with controls. There were no di#erences 
between patient groups (Table 3) but relatively low values were observed in 
PD without any high outliers. TF was predominantly co-expressed with platelet 
marker CD41. 
Thrombin generation experiments
As a !rst experiment, TG was performed in MP-rich plasma. The reaction was 
initiated without exogenous TF and phospholipids added, thus rendering the 
assay MP sensitive. HD patient samples could not generate thrombin in this 
manner, probably due to the presence of trace amounts of LMWH before an HD 
session. Samples of CKD4 and PD patients did not di#er from control samples 
in endogenous thrombin potential (ETP), (median: 1103nM.min (524-1653) vs. 
1300 (596-1559) nM.min; p=0.78) (Table 4). 
Table 4 TG results for patient subgroups and controls. Results are presented as medians (range). P-value 
describes di#erences between the groups by Kruskal Wallis test. Due to heparin remnants in plasma no 
ETP results in plasma are available for HD patients. 
Controls CKD4 PD HD p-value
ETP plasma (nM.min)
(bu#er)
1300
 (596-1559)
1170 
(857-1653)
1031 
(524-1624)
N.D. 0.78
ETP microparticles (nM.min)
(bu#er)
1029 
(822-1234)
1263 
(1017-1364)
1042 
(852-1385)
1115 
(932-1163)
0.03
N.D. not determined
In a following experiment, performed to verify the role of MP in TG by excluding 
the role of the patients’ plasma components, MP were isolated and MP and 
supernatant were added separately to normal pooled plasma and again tested 
for TG as described above. After removal of MP, the supernatant plasma did not 
show TG under these conditions (data not shown), indicating that TG is MP-
dependent. Indeed, when isolated MP were added to normal human pooled 
plasma, thrombin was generated and the ETP was higher in patient MP than 
in control MP (Table 4). Among the various patient subgroups, ETP values were 
the lowest in PD, without the di#erences between groups being statistically 
signi!cant. The total number of Annexin V-positive MP (weakly) correlated with 
ETP (R=0.43, p=0.03, Figure 3). 
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When ETP values were expressed relative to MP numbers, MP from CRF patients 
generated substantially less ETP than those from controls, or in other words, MP 
in CRF possessed impaired thrombogenicity. MP phospholipid exposure is an 
important contributor to this property [26]. Interestingly, the mean "uorescence 
intensity (MFI) of MP-bound-labelled Annexin V was signi!cantly higher in the 
control group than in patients, which implies that MP in CRF patients expose 
less procoagulant phospholipids (MFI 416 in CTR (n=20) vs. 305 in CRF; p<0.001).
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Figure 3: Correlation between number of Annexin V-binding MP and ETP (R= 0.43, p=0.03) performed 
in human pooled plasma to which MP of CRF patients were added. TG was initiated without exogenous 
tissue factor and phospholipids.
Discussion
This is the !rst study that in parallel assesses endothelial activation and 
characterizes MP with an extensive panel of antibodies in di#erent treatment 
groups of patients with CRF, and studies MP-speci!c TG in these patients. 
We observed that patients with CRF and an activated endothelial status had 
elevated levels of platelet, activated platelet and endothelium-derived MP, 
irrespective of their dialysis modality. Other groups have described an absolute 
increase of platelet-derived MP in CRF as well [11,17]. This increase in MP, which 
were procoagulant since they supported TG, did not result in a proportional 
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increase in MP-dependent TG compared with controls. Apparently, the CRF MP 
are not as potent thrombin generators as control MP. 
The endothelial activation parameters mature vWF and propeptide provided 
evidence of an important di#erence between the CKD4 and PD groups, which 
showed a pattern compatible with chronic activation [22], and the HD group, 
which showed a pattern compatible with acute activation. This was inferred 
from the rise in levels of propeptide with an, apparently only moderate, mature 
vWF increase, observed during the HD session only. Previously, Tomura et al. 
[27] showed that patients on HD su#ered from progressive endothelial cell 
damage, and that the capacity of their endothelial cells for the release of vWF 
antigen gradually decreases in the months following initiation of HD. This may 
re"ect the duration and intensity of endothelial challenge during HD, putatively 
leading to a relative vWF secretional exhaustion. However, it is shown here not 
to coincide with a signi!cantly di#erent MP pro!le or MP procoagulant capacity. 
With further regard to endothelial activation in renal failure, not only plasma vWF 
levels but also endothelium-derived MP, are considered markers for endothelial 
dysfunction [11,28] being predominantly produced by endothelial cells. In our 
study, endothelium-derived MP (CD144+) accounted for approximately 1% of all 
MP, and as described before were thus a minor fraction [29]. Still, endothelium-
derived MP expressing CD144 were increased in CRF patients supporting the 
concept of ongoing endothelial activation, PD patients formed an exception 
in this regard: their CD144+ MP numbers did not di#er from those in controls. 
This is in line with a recent study by Merino et al. [30] in which an increase 
was observed in endothelial damage-related CD14+/CD16+ cells in CKD-non 
dialysis and HD patients but not in PD patients, suggesting a di#erent pathway 
promoting the endothelial damage in PD.
As stated above, the observed increase in platelet- and endothelium-derived 
MP in renal failure may be due to either uraemia, or to the chronic vascular 
dysfunction and atherosclerosis that often accompanies CRF. The actual 
increase in MP numbers in the present study is substantial, with levels of MP 
approximately two times higher in patients than in controls. (Pre) analytical 
conditions being similar, this indicates that metabolic dysregulation indeed 
plays a major role in the generation of high MP counts in renal failure. In 
agreement with this conclusion, MP levels have been shown to rapidly decline 
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after renal transplantation [31], when the renal function improves while the 
cardiovascular risk factors remain the same. In addition, renal clearance of MP 
may be speculated to in"uence MP half-life in blood as urine is known to contain 
MP [32]. If indeed MP are removed from the circulation by renal clearance, the 
defective clearance in patients may also cause a rise in MP numbers. 
Superimposed on uraemia, the HD process itself was a priori hypothesized to 
increase MP numbers as described previously [11,15]. Perhaps surprisingly, we 
did not observe such an increase but counted similar levels of platelet derived 
MP before and after dialysis. This is in concordance with the results of Ando et 
al. [17] and Boulanger et al. [29]. A possible explanation for these !ndings is 
the use of di#erent dialysis membranes. We used synthetic membranes, just as 
Boulanger et al. [29], while in the apparently con"icting studies [11,15] cellulose 
membranes were used. The use of synthetic membranes might result in less 
platelet activation although attachment of MP to the membrane during dialysis 
cannot be excluded. 
We show an absolute increase of MP carrying markers of platelet activation 
(CD62P and CD63) [19] in CRF, that may contribute to an increased risk of 
vascular disease. CD62P, or P-selectin, is an important player in one of the cellular 
pathways for the initiation of blood coagulation. P-selectin-positive platelets 
are known to induce leukocyte-derived MP to express TF, which can induce 
clot formation [33,34]. P-selectin expression by MP is likely to have the same 
e#ect. In support of this, we did !nd higher numbers of leukocyte-derived MP 
and TF-bearing MP in patients with CRF, although the account of both subsets 
was low (<1%). 
The procoagulant potential of the CRF MP was con!rmed in TG experiments. 
MP-rich plasma samples from CKD4 and PD patients could generate thrombin 
under MP-dependent (without exogenous TF and phospholipid) conditions. 
Despite the higher MP numbers in these samples, the resulting ETPs were not 
di#erent from those in controls. This suggested either less potent procoagulant 
properties of the CRF MP, and/ or a negative in"uence of patients’ plasma 
components (inhibition, coagulation factor depletion). TG experiments with 
isolated control- and CRF MP added to normal pooled MP-free plasma provided 
evidence for the former mechanism. The higher number of MP in the isolates 
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of CRF patients resulted in a higher, but not proportionally higher with respect 
to MP numbers, TG in the normal plasma background. This was not due to an 
overload of MP since in this MP number range for CRF samples a dose-response 
relationship with ETP values was apparent (no plateau was reached yet). These 
data suggest that MP in CRF patients indeed are procoagulant but at the same 
time points to a qualitative di#erence in MP properties between CRF patients 
and controls.  Herewith, we provide another example of disease-related MP 
populations with disease-speci!c procoagulant potential. In CRF it refers to a 
decreased potential, whereas in a previous study, we identi!ed myeloblast-
derived MP in patients with Acute Myeloid Leukemia (AML) that were more 
intrinsically procoagulant than control MP [35]. With regard to the relatively 
poor TG capacity of the CRF MP, it is of interest to note that their main cellular 
source (platelets) is functionally challenged by the kidney failure (uraemic 
thrombopathy). For example, uraemic platelets have been reported to show 
diminished adhesion and aggregation [36]. It may therefore be speculated 
that thrombopathic platelets in uraemia generate ‘thrombopathic’ MP being 
only moderately procoagulant. Indeed, we found that MP in CRF showed a 
diminished exposure of phosphatidylserine which is expected to result in a 
lower ETP [37]. 
It will be of interest to further study the role of plasma components in the 
net similar MP-driven TG in the control - and patient MP-rich plasma samples. 
Since apparently the role of MP in cardiovascular complications in CRF does 
not so much derive from an increase in MP-driven plasmatic coagulability, we 
speculate that their function is altered regarding the cellular processes leading 
to endothelial damage and / or the recruitment of procoagulant factors in vivo. 
This is in line with a recent study by Terrisse et al. [38] showing that endothelial 
cells internalised MP, which resulted in enhanced platelet /endothelium 
interactions, involving vWF and P-selectin. Indeed, in CRF, atherosclerosis is the 
main vascular problem, not venous thrombosis in which hypercoagulability 
would be expected.
In conclusion, CRF is accompanied by endothelial activation of a di#erent 
nature in CKD4 and PD patients versus HD patients but results in all subgroups 
in an increase (without increment during HD) of mainly platelet-derived MP 
with minor endothelial marker - and TF-positive fractions. Although presence 
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of these MP in higher numbers may explain an increased prothrombotic state, 
these MP appear to be less procoagulant than in other disease states, possibly 
because of a functional defect of their cellular source due to chronic uraemia. In 
spite of that, these MP may still be important messengers at the cellular level in 
the development of atherosclerosis. Further studies are required to investigate 
these functional properties of MP in CRF.
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Abstract
Introduction: Microparticles (MP) can be elevated in cancer and 
thromboembolic disease. We hypothesized a role for MP in the hypercoagulable 
state in breast cancer patients using endocrine therapy, in whom both 
cancer and the use of endocrine therapy are independent risk factors for the 
development of thrombosis.
Design and methods: Plasma samples were collected from 40 breast cancer 
patients using endocrine therapy (20 patients without metastases receiving 
adjuvant therapy and 20 patients with metastatic disease treated in a palliative 
setting) and from 20 female healthy controls. The endocrine therapy used was 
either an anti-estrogen or an aromatase inhibitor. Numbers and cellular origin 
of MP subsets were analysed by "owcytometry. MP-associated procoagulant 
activity was measured using a thrombin generation assay using conditions that 
allow analysis of MP induced thrombin generation.
Results: Breast cancer patients using endocrine therapy had higher levels of 
MP positive for Annexin V (median 10000 vs. 6500 x106/L), P-selectin (330 vs. 200 
x106/L), tissue factor (33 vs. 15 x106/L), and of MP derived from platelets (CD41+) 
and leukocytes (CD45+). Thrombin generation in plasma was dependent on the 
presence of MP and thrombin generation performed after addition of isolated 
MP to normal plasma showed a higher endogenous thrombin potential (1105 
vs. 1029 nM.min) in breast cancer patients. No di#erences were observed in 
MP levels and thrombin generation parameters between the metastatic and 
adjuvant group. 
Conclusion: Breast cancer patients using endocrine therapy have an increased 
MP number and a higher MP-dependent thrombin generation, irrespective of 
the presence of metastatic disease. Altered MP subset characteristics in these 
patients, especially the higher number of (activated) platelet derived MP and 
leukocyte derived MP, may in part explain a heightened procoagulant state in 
breast cancer patients using endocrine therapy.
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Introduction
Circulating microparticles (MP) are shed membrane vesicles of <1.0 μm in 
diameter, resulting from apoptosis or activation of cells in response to various 
stimuli [1]. MP comprise a heterogeneous population characterized by 
di#erences in size, phospholipid- and protein composition [2].
Breast cancer patients and cancer patients in general, are at risk of venous 
thromboembolic events (VTE) and this risk further increases in advanced 
stages of cancer and during adjuvant chemotherapy. Traditionally, the 
hypercoagulability that occurs with cancer and especially in patients with 
metastatic cancer, has been associated with increased levels of coagulation 
proteins, e.g. tissue factor (TF) and factor VIIa [3,4]. More speci!c, tumour 
associated risk factors include mucinous glycoproteins [5] and selectin-mucin 
interactions [6]. 
These hypercoagulable mechanisms may involve the increased shedding of 
MP, known to play a role in thrombogenic conditions including atherosclerosis, 
VTE, essential thrombocythemia [7] and other malignant diseases. TF-bearing 
MP have been associated with thrombosis in cancer [8,9]. Indeed, elevated 
numbers of platelet-derived MP were demonstrated in metastatic gastric- [10], 
breast- [8,11] and pancreatic [8] cancer. 
In patients with breast cancer Toth et al. observed increased numbers of 
leukocyte-derived MP. The number of leukocyte-derived MP correlated with 
tumour load [11] and expression of selectins such as P-selectin, which appears 
to play a role in coagulation by enabling interaction between platelets and 
leukocytes, mediating the formation of procoagulant TF-bearing MP [12]. 
Patients with breast cancer are often treated with adjuvant endocrine therapy 
in the form of either anti-estrogens or aromatase inhibitors. In patients without 
metastatic disease the intent is to prevent metastases, in patients with known 
metastatic disease the intent is to reduce tumour load and tumour activity. 
This treatment and particularly its anti-estrogen component, comprises an 
independent risk factor for VTE [13]. However, the mechanism by which 
endocrine therapy contributes to VTE is not clearly understood. Several 
plasmatic e#ects have been observed such as tamoxifen-associated reductions 
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in antithrombin, protein C [14], protein S [15] and tissue factor pathway inhibitor, 
as well as an increase in activated protein C resistance [16]. The use of aromatase 
inhibitors also seems to be associated with an increased risk of thromboembolic 
events, although less so than with tamoxifen [17,18].
The e#ect of endocrine therapy at a cellular level, speci!cally platelet and 
endothelial activation, is largely unknown. It has been demonstrated that 
tamoxifen increases reactive-oxygen species and raises intraplatelet calcium 
levels, thus enhancing platelet-mediated thrombosis and platelet activation, 
respectively [19,20]. The latter may theoretically result in elevated numbers 
of platelet-derived MP. Similarly, endothelial activation in the course of 
coagulation, angiogenesis and metastasis may yield endothelial derived MP. In 
concert with tumour cell derived MP, the shedding of such MP may contribute 
to the observed cancer and therapy related risk of VTE [21,22].
The main aim of our study was to establish whether MP of breast cancer patients 
with or without metastatic disease using endocrine therapy have a more 
prothrombotic pro!le than those of healthy controls. This prothrombotic pro!le 
was de!ned by the numbers, cellular origin and procoagulant potential of MP. 
Design and methods
Study subjects
Forty patients with breast cancer who were treated with endocrine therapy 
were enrolled (Table 1) at the Oncology department of the Onze Lieve Vrouwe 
Gasthuis (The Netherlands). Of these, 20 patients received adjuvant endocrine 
therapy (mean age: 56 +/- 13 years) whereas the other 20 patients had been 
diagnosed with metastasized breast cancer and received palliative endocrine 
therapy (mean age: 59 +/- 17 years). Exclusion criteria were: previous thrombosis, 
the use of anticoagulant therapy, any form of oncologic breast surgery in the 
previous six months and/or treatment with chemotherapy or radiation therapy 
in the previous 6 months. All 40 breast cancer patients were using endocrine 
therapy. 15 patients (37.5%) were using anti-estrogens (tamoxifen, fulvestrant) 
and 25 patients (62,5%) were using aromatase inhibitors (anastrozole, lezetrole, 
exemestane). At the time of blood collection both patient groups had been 
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using endocrine therapy for a median of 20 months (IQR 6,3-34,3). The period 
since the last chemotherapeutic treatment in the adjuvant group was a median 
26 months (IQR 10,8-32,5).
Table 1 Patient characteristics
Controls
  Breast cancer patients
Adjuvant    Metastatic All
Number 20 20  20 40
Age (mean ± SD) 52±8 56±13  59±17 57±15
Hematological parameters (mean ± SD)
   Haemoglobin (mmol/L) 8.2±0.6 8.4±0.7  8.2±1.0 8.3±0.8
   Leukocytes(109/L) 5.9±1.7 5.1±1.3  7.0±3.2 6.1±2.6
   Thrombocytes (109/L) 235±49 220±41  234±80 227±63
   D-dimer (μg/mL) 0.25±0.1* 0.39±0.2 0.71±0.7 0.56±0.55
   Antithrombin (%) 97±10 94±10     102±23 98±18
   Fibrinogen (g/L) 3.1±0.6 3.1±0.8  3.3±0.7 3.2±0.7
    Thrombin-antithrombin complex (μg/L) 7.5±17.3 12.4±25.7   9.5±13.5 10.9±20.3
    Prothrombin fragment 1 + 2 (pmol/L) 173±137.5* 229±190 272±264 250±228
Tumour size cm (Mean ± SD)**  2.7±1.2
Metastases
   Skeletal  12 (60%)
   Liver  5 (25%)
   Pulmonary  8 (40%)
   Brain  0 (0%)
Months to surgery (Median (IQR)) 30.5(16-38)
Months to chemotherapy (Median (IQR)) 26.0(10.7-
32.5)***
Treatments (number (%))
   Anti-estrogens 7 (35)  8 (40) 15 (37.5)
   Aromatase Inhibitors 13 (65)  12 (60) 25 (62.5)
Cardiovascular risk factors (number (%))
   Hypertension 4 (20) 1 (5)  6 (30) 7 (17.5)
   Hyperlipidemia 2 (10) 2 (10)  5 (25) 7 (17.5)
   Smoking 1 (5) 5 (25)  4 (20) 9 (22.5)
* p<0.05 between all breast cancer patients and controls
** In some patients, multiple tumours were excised. 
***  n=14  
Patient characteristics are shown in Table 1. The adjuvant group comprised 
of 20 patients in whom the primary tumour had been surgically removed. 
At diagnosis tumour stage had varied from T1 to T3. Of these patients, 65% 
had undergone lumpectomy with additional radiation therapy while 35% had 
undergone a modi!ed radical mastectomy. All surgical and invasive procedures 
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as well as chemotherapy and radiation therapy were completed at least six 
months before enrolment. We consider the majority of the adjuvant group to 
be without active malignant disease. In the ATAC study [23] in breast cancer 
patients treated with endocrine therapy in the form of tamoxifen or anastrozole 
or a combination of these two therapies, the cancer recurred in either a localized 
or metastasized form in 7.2%, 8.5% and 9.1% of the patients respectively after 
three years. In the current study 1 patient (5%) in the adjuvant group was 
diagnosed with recurrence of the primary tumour, two years after admission 
and blood sampling.
In the metastasized group, which consisted of 20 breast cancer patients, at 
admission and blood sampling liver metastases had been found in 25%, skeletal 
metastases in 60% and pulmonary metastases in 40% of patients. Therefore, we 
consider this group as bearing a large tumour load. None of the breast cancer 
patients, neither in the adjuvant group nor in the group with metastasized 
disease, developed actual venous thrombosis during the course of disease or 
during the course of endocrine treatment. 
In addition, we investigated 20 healthy female controls matched for age (mean 
age: 52 +/- 8 years), recruited from the hospital sta#, who were not diagnosed 
with breast cancer and who were not treated with endocrine therapy in any 
form, including oral anticontraceptives.  None of the healthy controls were 
on anti-platelet medication at the time of blood collection. All patients and 
controls agreed to participate in the study following informed consent. This 
study was approved by the local medical ethical committee (Medisch Ethische 
Commissie, OLVG, Amsterdam).
Blood collection and MP isolation
Blood samples were drawn with a 21-gauge needle without tourniquet. After 
discarding the !rst 4 mL, blood was collected into a 4 mL tube containing 3.2% 
citrate (BD, Plymouth, UK). MP rich plasma was prepared within 30 minutes after 
blood collection by centrifugation for 20 min at 1,550 x g at room temperature, 
without brake. Aliquots of plasma were snap frozen in liquid nitrogen, and then 
stored at -75ºC until use. For MP isolation, 250 µL of plasma was thawed on ice 
for 60 min and then centrifuged for 30 min at 17,570 x g at 20°C. Subsequently, 
225 µL of supernatant (i.e. MP-free plasma) was removed. The remaining 25 µL 
containing the MP pellet was resuspended in 225 µL of phosphate-bu#ered 
saline (154 mM NaCl, 1.4 mM phosphate, pH 7.4, PBS), containing 10.9 mM 
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trisodium citrate to prevent coagulation activation. Samples were centrifuged 
for 30 minutes at 17,570 x g at 20°C, thereafter, 225 µL of supernatant was 
removed and the MP pellet was resuspended in 125 µL of PBS.
Phenotypic analysis of plasma derived MP
Flowcytometric analysis was used to quantify and characterize plasma derived 
MP, as previously described [24]. Brie"y, 5 µL of MP sample was diluted in 35 µl 
PBS containing 2.5 mM CaCl2 (pH 7.4). Then, the samples were incubated for 
30 minutes at room temperature in the dark with 5 µL Annexin V-APC (Caltag 
Laboratories, Burlingame, CA, USA) and/or 5 µL "uoresceinisotyocianate (FITC)-, 
and phycoerythrin (PE)- labelled anti-human monoclonal antibodies (mAb), or 
5 µL isotype-matched control mAb. 
For the phenotypic characterization of MP the following cell speci!c mAb 
were used: anti-CD14-PE (MΦP9, IgG2b), anti-CD20-PE (L27, IgG1), anti-CD31-
PE (WM-59, IgG1), anti-CD34-PE (8G12, IgG1), anti-CD45-FITC (HI30, IgG1,κ), 
anti-CD61-PE (VI-PL2, IgG1), anti-CD142-PE (HTF-1, IgG1, κ), anti-CD227-FITC 
(HMPV, IgG1, κ) from BD (San Jose, USA); anti-CD54-PE (84H10, IgG1), anti-
CD62P-PE (CLB-Thromb/6, IgG1) and anti-CD66b-FITC (80H3, IgG1N) from 
Immunotech (Marseille, France); anti-CD62E-PE(HAE-1f, IgG1) from Kordia 
(Leiden, the Netherlands); anti-CD66acde-PE (CLB-gran/10, IH4Fc, IgG1) from 
Sanquin (Amsterdam, the Netherlands); anti-CD106-FITC (1.G11B1, IgG1) from 
Calbiochem (Darmstadt, Germany); anti-CD142-FITC (VD8, IgG1) by American 
Diagnostics (Stanford, CT, USA); anti-CD144-FITC (BMS158FI, IgG1) from Bender 
MedSystems (Vienna, Austria);  anti-CD41-FITC (5B12, IgG1, κ), anti-Glycophorin 
A -FITC (JC159, IgG1  κ) from DAKO (Glostrup, Denmark); anti-CD227-FITC 
(B24.1, IgG1) from Genetex (Irvine, USA); anti-VEGF R2-PE (89106, IgG1) from 
R&Dsystems (Minneapolis, USA). Labelled isotype controls IgG1 (X40) and IgG2a 
(X39) were used from BD (San Jose, USA), and IgG2b-PE (MCGb) from IQProducts 
(Groningen, the Netherlands). 
After incubation, 360 µL PBS/calcium bu#er was added and the samples were 
analysed on a FACS Calibur using Worklist Manager (BD) for 30 seconds during 
which the "owcytometer analysed approximately 30 µL of the suspension. 
Forward scatter and sideward scatter were set at logarithmic gain. To distinguish 
MP from events due to noise, MP were identi!ed on the basis of their speci!c 
26739 Trappenburg, Marijke.indd   97 08-10-13   14:32
Chapter 598
forward scatter and sideward scatter characteristics, with gates set using in vitro 
platelet activation and MP generation data (results not shown), and by Annexin 
V positivity [25]. To identify Annexin V-positive events, a threshold was placed 
in a MP sample prepared without calcium. The number of MP/L plasma was 
calculated as previously described # MPper minute *(Volume(V) tube/Vminute) *(Vend/ 
Vstart) * (1000/ Vlabeled)= # events/mL [26]. Data were analysed with CellQuest-pro 
software (BD). The numbers of MP measured may vary up to 4 fold depending 
on FACS laser settings, which may alter due to the half yearly maintenance 
performed by the manufacturer. Therefore, MP measurements were always 
performed in series and patient and control plasma’s were measured on the 
same days. In addition, standard pool plasma was measured daily to secure 
similarity in FACS "ow sensitivity throughout the study. During measurements 
for this study, the numbers per mL were higher than previously observed [7] 
indicating the FACS was more sensitive for MP. However, the distribution of MP 
markers in the pool plasma was comparable.
Thrombin generation measurements
Thrombin generation (TG) was measured by means of the Calibrated 
Automated Thrombogram (CAT) method (Thrombinoscope BV, Maastricht, the 
Netherlands) [27,28]. TG was determined in the MP rich plasma samples or in 
the supernatant or pellet after centrifugation for MP isolation (as described 
above), TG (in 80 PL plasma or after addition of 10 µL MP pellet to 70 µL of 
normal pooled platelet-poor plasma, obtained from 80-90 healthy volunteers) 
was triggered by 1 pM TF and 4 PM phospholipids, 4 PM phospholipids alone, 
or bu#er (no exogenous TF and phospholipids added). All reagents used were 
obtained from Thrombinoscope BV. TG was measured as "uorescence, read in a 
Fluoroskan Ascent reader (Thermo Labsystems OY, Helsinki, Finland) equipped 
with a 390/460 !lter set and thrombin generation curves were calculated with 
the Thrombinoscope software (Thrombinoscope BV). 
Six parameters were derived from the thrombin generation curves: lag time 
(initiation phase of coagulation, de!ned as the time to reach 1/6 of the peak 
height), endogenous thrombin potential (ETP), time to peak, time to tail, peak 
height and velocity. Validation of the CAT method showed normalization of non-
time-dependent parameters to be mandatory to obtain acceptable inter-assay 
variations [28]. Intra-assay variations for normalized parameters are typically 
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below 6%, inter assay variations below 8% [28]. Therefore, each thrombin 
generation measurement includes normal pooled plasma and both the ETP 
and peak height values are expressed as the ratio of value patient/value normal 
pooled plasma, expressed in percentages. 
Markers of endothelial activation and plasmatic coagulation activation.
Mature von Willebrand factor (vWF) and vWF propeptide plasma levels were 
measured by ELISA as described previously [29]. Coagulation activation was 
assayed by measuring the concentration of prothrombin fragments 1+2 
(F1+2), thrombin antithrombin (TAT) complexes and D-dimer. F1+2 levels 
were determined using the Enzygnost F1+2 (monoclonal) ELISA kit (Siemens 
Healthcare Diagnostics, Deer!eld, USA). Normal F1+2 values are reported 
to range from 69-229 pmol/l (kit insert information as provided by the 
manufacturer). TAT was determined using the Enzygnost TAT micro testkit. 
Normal values are reported to range from 1-4.1 µg/l (kit insert information). 
D-dimer concentrations were determined on a Roche/Hitachi Modular P800 
system using the Tina-quant assay (Roche Diagnostics, Indianapolis, USA). 
Decision limit in VTE exclusion protocols is 0.5 µg/ml (kit insert information). 
Antithrombin activity levels and !brinogen concentrations (Claus method) 
were measured on a Sysmex CA-1500 System using the Berichrom Antithrombin 
III assay and Dade Thrombin Reagent with Dade Owrens Veronal Bu#er, 
respectively (all Siemens Healthcare Diagnostics, Deer!eld, USA).
Statistical analysis
We compared the di#erence of MP numbers, mature vWF and propeptide levels 
and results of thrombin generation between groups with non-parametric Mann 
Whitney U test or Kruskal Wallis test where appropriate. Bivariate correlations 
were estimated by Spearman’s rank method (R). All tests for statistical signi!cance 
were two-tailed and P values of <0.05 were considered signi!cant. Analyses 
were performed using SPSS 16.0 for windows (SPSS Inc., Chicago, USA).
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Results
Biological parameters
Most hematological parameters were similar between controls and breast 
cancer patients including haemoglobin, number of thrombocytes, antithrombin 
and !brinogen values (Table 1). Breast cancer patients had signi!cantly higher 
D-dimer and prothrombin fragments 1+2 levels than controls, indicating 
coagulation activation. Although not statistically signi!cant, both parameters 
were highest in the group with metastatic disease. With regard to endothelial 
activation markers, breast cancer patients had higher levels of mature vWF and 
vWF propeptide compared with controls. Median (range) levels of mature vWF 
were 48 (26-100) nM for controls and 81 (35-245) nM for patients (p<0.001). 
For propeptide the median levels were 5.7 (4.1-10.3) nM for controls and 7.9 
(3.6-29.2) nM for patients (p=0.002). This pattern of mature vWF levels being 
relatively more elevated than propeptide levels (Fig. 1) is compatible with 
chronic (as opposed to acute) endothelial activation [30].
Number and phenotypic characterization of MP
As is shown in Table 2 and Fig.2 the total numbers of Annexin V-positive MP were 
higher in breast cancer patients compared to controls (p=0.03) (median: adjuvant 
10600x106/L, metastasis 8875x106/L, all patients 10000x106/L, controls 6500x106/L). 
MP of controls, as well as patients, were mainly platelet-derived (>98%). Accordingly, 
platelet-derived MP were also higher in breast cancer patients (CD41, p=0.03). With 
regard to MP derived from activated platelets, patients had higher numbers of MP 
expressing P-selectin (CD62P, p=0.01, median: adjuvant 325x106/L, metastasis 
400x106/L, all patients 330x106/L, controls 200x106/L)  (4.1 vs. 3.1% of total MP). 
The number of TF-positive MP (p=0.001 median: adjuvant 31x106/L, metastasis 
34x106/L, all patients 33x106/L, controls 15x106/L) was higher in patients compared 
with controls, although the percentage of MP expressing TF is very low for both 
groups, namely <1%. The number of leukocyte-derived MP (CD45 positive) was 
higher in patients compared with controls (p=0.005, median: adjuvant 61x106/L, 
metastasis 65x106/L, all patients 61x106/L,  controls 42x106/L). There was a correlation 
of leukocyte-derived MP with P-selectin positive MP (R=0.35, p=0.005) and with TF-
positive MP (R=0.53, p<0.001). Endothelium-derived MP expressing CD144 were 
slightly increased in patients. Notably, MP expressing other endothelial markers (CD 
62E, CD106 and CD54) did not di#er signi!cantly.
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Figure 1: Relation between mature vWF and propeptide levels in patients with breast cancer and 
controls. Dotted lines represent the upper limit of the 95% con!dence interval of, respectively, mature 
vWF and propeptide levels of the control group. Breast cancer patients have higher mature vWF 
(p<0.001) and propeptide levels (p=0.002) compared with controls.
For granulocyte-derived MP (CD66b, CD66e), B-cell-derived MP (CD20), 
monocyte-derived MP (CD14) and erythrocyte-derived MP (glycophorinA) no 
signi!cant di#erences were found and all accounted for <1% of total MP count.
To detect tumor cell-derived MP, CD227 (MUC1) expression was assessed. Only 
in breast cancer patients (four patients) very small numbers of CD227 positive 
MP were detected, accounting for <1% of total MP.
We found a positive correlation between CD227-positive MP and TF-positive 
MP, (R= 0.68, p=0.001), indicating that cancer-derived MP may carry TF.
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Table 2. Numbers of MP with di#erent phenotypic characteristics as determined by FACS analysis. MP 
were de!ned based on FSC/SSC pattern as well as Annexin V-positivity. Numbers are 106/L.
Controls
(n=20)
Breast cancer patients 
on endocrine therapy 
(n=40)
P-value
(Mann Whitney U)
Total MP
Range
%
6500
1100-13600
100
10000
3450-37150
100
0.03
CD41+ MP
Range
%
6400
1100-13200
98.7
9850
2900-37000
98.1
0.03
CD62P+ MP
Range
%
200
18-450
3.1
330
10-900
4.1
0.01
CD45+ MP
Range
%
42
12-80
<1
61
20-185
<1
0.005
CD144+ MP
Range
%
4
0-180
<1
8
0-125
<1
0.002
Tissue Factor+MP
Range
%
15
0-25
<1
33
8-200
<1
0.001
Figure 2:  Numbers and subsets of MP in patients and controls. 
Numbers of MP from speci!c cellular origin as de!ned by marker positivity in plasma from controls 
(CTR) and breast cancer patients using endocrine therapy divided in those without (ADJ) and with me-
tastasizing (MET) disease. Lines represent median. Dotplots of total numbers of MP (Annexin V positive), 
activated platelet derived (CD62P+), leukocyte derived (CD45+) and TF positive MP are shown.
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Relation of MP numbers and subsets with endocrine treatment and tumour load
No correlations were found between the numbers of MP from any cellular subset 
and the di#erent types of endocrine therapy that patients used. In addition, no 
correlation was found between these parameters and the absence or presence 
of metastases.
Thrombin generation
The thrombin generation (TG) assay as performed with the CAT method allows 
variation in experimental conditions by variation of externally added TF and/
or phospholipids. 
As a !rst experiment, the TG was performed using the MP rich plasma as used 
for the FACS analysis. Using standard assay conditions i.e. initiation of the 
reaction with 1 pM TF and 4 PM phospholipids, a trend for higher endogenous 
thrombin potential (ETP) was observed in the patient groups compared with 
controls (p=0.09, Table 3). Since TF is a strong initiator of TG, it may render the 
test insensitive for small di#erences in endogenous TF. Therefore, the TG of MP 
rich plasma was tested after initiation with 4 PM phospholipids in the absence 
of exogenous TF, and again a higher endogenous thrombin potential (ETP) was 
observed for breast cancer patients compared with controls (p=0.05). Finally, 
in the absence of both exogenous TF and phospholipids, still slightly higher 
ETP was observed in plasmas from breast cancer patients compared with 
controls (p=0.13). Also, a higher peak height (p= 0.03) was observed in breast 
cancer patients compared with controls, indicating a role for the phospholipids 
content of the patient’s plasma in hypercoagulability, probably consisting of 
MP, as is shown by a correlation (R=0.45, p=0.001) between peak height and 
the total number of MP (Figure 3).
As a control experiment in order to determine the role of the MP in the observed 
di#erences in TG, TG was performed in the supernatant plasma after removal of 
MP by centrifugation. In this supernatant, in the absence of both exogenous TF 
and phospholipids, TG was very low. ETP was 8%, peak height 6% and lagtime 
162% of what was observed in MP rich plasma, indicating that MP contributed 
most to TG in MP rich plasma and may account for the di#erences found between 
patients compared with controls. 
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Table 3: Results of thrombin generation experiments
Results are shown as median (range) for MP-rich plasma (row 1-3, 5) and standard plasma to which 
isolated MP were added (row 4). Di#erent conditions were used, adding 1 pM TF and 4 μM PL (row 1), 
4 μM PL only (row 2) or without exogenous PL and TF added (bu#er, row 3-5). P-values representing 
di#erences between all patients and controls.
Controls All patients Adjuvant 
group
Metastasis 
group
P-value
ETP plasma (nM.min)
(1 pM TF and 4 µM PL)
954 
(669-1664)
1018  
(536-1295)
1057 
(799-1295)
980 
(536-1250)
0.09
ETP plasma (nM.min)
(4 µM PL)
888
(219-1538)
947 
(325-1231)
967 
(670-1231)
915 
(325-1188)
0.046
ETP plasma (nM.min)
bu#er
899 
(604-1663)
1014  
(297-1347
1076 
(743-1347)
958 
(297-1174)
0.13
ETP microparticles (nM.min)
(bu#er)
1029 
(822-1234)
1105 
(893-1336)
1117 
(893-1336)
1100 
(990-1212)
0.03
Peak Height plasma (nM)
(bu#er)
72 
(32-171)
115 
(13-257)
119 
(37-181)
106 
(13-257)
0.03
Figure 3: Correlation between peak height and the total number of MP in plasma in the absence of 
exogenous tissue factor and phospholipids. 
Data are shown from plasma of breast cancer patients using endocrine therapy, with ( n=15) and with-
out (y n=17) metastases and of controls (0 n=19). R=0.45, p=0.001. 
Lastly, to verify the role of MP in TG and to exclude the role of the plasma, the 
isolated MP were added to normal pooled plasma and tested for TG. In these 
conditions a higher ETP was observed for breast cancer patients compared to 
controls (p=0.03) (Figure 4), suggesting that the di#erences observed were 
MP and not plasma related. Both disease progression and type of endocrine 
therapy used did not cause signi!cant di#erences in thrombin generation. 
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Figure 4: Thrombin generation of isolated MP added to standard plasma in the absence of exogenous 
TF and phospholipids. The result of the endogenous thrombin potential (ETP) is shown for controls (CTR 
0) and for breast cancer patients without (ADJ y) and with metastatic disease (MET ). Lines represent 
median. Breast cancer patients (ADJ and MET together) have a signi!cantly higher ETP (p=0.03) 
compared with controls. 
Discussion
Our study assessed whether MP of patients with breast cancer treated with 
endocrine therapy would have a more prothrombotic pro!le as compared to 
those of healthy controls. In addition, we established whether the presence 
of metastasized disease would augment such a prothrombotic e#ect. Indeed, 
increased F1+2 fragment, TAT complex and D-dimer values in the patient group 
together with increased mature vWF levels accompanied by only a modest 
increase in vWF propeptide levels provided evidence for ongoing coagulation- 
and endothelial activation. 
As parameters of MP procoagulant properties we used numbers and origin 
of MP by "owcytometry and MP-related procoagulant potential by thrombin 
generation analysis. Our data show that compared to non diseased individuals 
breast cancer patients (both the adjuvant- and the metastasized group) on 
endocrine therapy have higher absolute numbers of MP that are predominantly 
platelet derived (>98%), indicating normal proportion of platelet derived MP. 
In addition, patients have signi!cantly more CD62P-positive MP than controls 
indicating platelet activation as has been described for breast cancer patients 
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before [8,11,31]. CD62P or P-selectin is stored in secretory granules of resting 
platelet and endothelium and is rapidly translocated to the cell surface upon 
activation. The CD62P-positive MP may interact with leukocytes, inducing the 
formation of leukocyte-derived MP, which can express TF and so enhance clot 
formation [12,32,33]. Indeed a correlation between leukocyte-derived MP and 
P-selectin- as well as TF-positive MP was observed. 
The patient MP were procoagulant since the ETP was increased in breast 
cancer patients on endocrine therapy, and this was related to the MP rather 
than to a plasma component since the increase of the ETP was retained when 
thrombin generation was performed with isolated MP. The increased MP-
induced thrombin generation in patients may have several causes. Firstly, 
the larger quantity of MP in breast cancer patients provides more negatively 
charged phospholipid procoagulant surface. Secondly, MP of patients may 
be qualitatively di#erent, speci!cally the increased numbers of leukocyte 
derived MP may have procoagulant properties, i.e. an increased amount of 
TF expression. In both scenarios, the increase in MP procoagulant surface or 
properties, the end result is a procoagulant state as re"ected by the elevated 
thrombin generation parameters. 
As most adjuvant patients remain disease free after 3 years (93% in ATAC study) 
[23], the lack of di#erence between patients with and without metastases was 
unexpected. The surprising element was the relative lack of abnormalities in 
the metastatic group. We observed markedly lower numbers of MUC1-positive 
MP than previously described by Tesselaar and colleagues [8]. One explanation 
for the low numbers could be that patients with metastasized breast cancer on 
endocrine treatment generally have a suppressed form of disease and therefore 
di#er signi!cantly from the patients included in the Tesselaar study at the time of 
diagnosis of metastasized cancer and not (yet) treated with endocrine - or other 
therapy. The same patient characteristic may also account for our observation 
that breast cancer patients with disseminated disease do not express higher 
numbers of MP compared to those without active malignant disease (the 
adjuvant group), which is in discordance with previous observations [8,11,31] 
all of which included patients before any therapy, including endocrine therapy, 
was started. Preanalytical and analytical methods, being similar, or a putative 
lack of statistical power are both unlikely to underlie this intriguing di#erence. 
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Numbers of patients with disseminated disease were higher in our study, which 
was designed to hold su$cient statistical power to detect di#erences between 
patients and controls of similar magnitude as described in these previous studies 
[8,11,31]. Apparently, by including stable metastatic breast cancer patients on 
endocrine therapy, we have selected a group more similar to patients with local 
disease, illustrated by the overall modest e#ects on MP pro!le that have also 
been demonstrated by others. The similarity between the two patients groups is 
also re"ected in the !nding that concurrent with total MP numbers, the relative 
size of MP subsets from various sources and thrombin generation did not di#er 
between the metastasized and adjuvant group. It may be speculated that 
di#erences in MP and thrombin generation parameters between breast cancer 
patients on endocrine therapy and controls are linked to the use of endocrine 
therapy rather than to the malignant disease. However, the type of endocrine 
therapy used (anti-estrogens or aromatase inhibitors) was not related to any of 
the parameters studied.
Several limitations should be taken into consideration. Since we did not include 
a control group of healthy women treated with endocrine therapy or an 
untreated group of breast cancer patients, the exact contribution of endocrine 
therapy to the presence of (subsets of ) MP remains to be elucidated. Also, we 
cannot rule out an e#ect of prior tumour presence, chemotherapy, lumpectomy 
or radiation therapy in the adjuvant group on MP numbers and subsets. Clearly, 
the small di#erences and the large scale of distribution of values imply that 
larger patient groups need to be included in future studies on MP pro!les in 
breast cancer patients. 
In conclusion, breast cancer patients receiving endocrine therapy have increased 
numbers of mainly platelet derived MP and a higher MP-dependent thrombin 
generation, irrespective of the presence of metastatic disease or the kind of 
endocrine therapy used. Altered MP subset characteristics in these patients, 
especially the higher number of activated- platelet derived MP and leukocyte 
derived MP, may in part explain a heightened procoagulant state in breast 
cancer patients treated with endocrine therapy.
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Several lines of evidence indicate that cell-derived microparticles (MP) are 
functional entities involved in thrombotic disease [1]. Negatively charged 
phosphatidylserine in the MP membrane may provide a surface for catalytic 
complexes such as the tissue factor (TF)/VIIa complex. In addition, MP may 
express TF and PSGL-1, the latter being able to bind platelet- and MP-bound 
P-selectin (CD62P), promoting thrombus development [2, 3].
Patients with cancer are at increased risk of thrombosis [4, 5]. This may involve 
MP [6,7], possibly via increased MP numbers and/or altered MP origin and 
functional properties in malignant disease. In a proof of concept study we 
addressed the changes in MP phenotypical and procoagulant (sub) population 
characteristics in three consecutive patients with acute myeloid leukaemia 
(AML), providing highly dynamic conditions of malignant cell proliferation 
and chemotherapy-induced cell death in the circulation.  Blood samples were 
collected during routine blood sampling before, during and late after the !rst 
cycle of chemotherapy. All patients had been included in the HOVON 42 AML 
treatment trial (http://www.hovon.nl/trials) (approved by the local medical 
ethical committee [Medisch Ethische Commissie, OLVG, Amsterdam]), agreed 
to participate in the study following informed consent.
Preanalytical conditions and "owcytometric analysis of MP and the antibodies 
used, were as described [8]. Antibodies used speci!cally to de!ne myeloblast 
origin were: anti-CD117-PE (104D2, IgG1) (Dako, Glostrup, Denmark); anti-HLA-
DR-PE (L243, IgG2a), anti-CD13-PE (WM15, IgG1), and anti-CD34-PE (8G12, IgG1) 
(BD, San Jose, California, USA). In addition, anti-CD162 (PSGL-1)-PE (KPL-1, IgG1) 
and Mouse Pure (X40, IgG1) (BD) were used. Because MP are small and labelling is 
often less e$cient than with whole cells, expression of markers was determined 
as positive events (% of MP) and as mean "uorescent intensity (MFI) of MP. FACS 
data were analyzed using CellQuest software (BD). Statistical signi!cance of MFI 
changes was analysed with Student’s t-test. 
To assess MP procoagulant properties as MP-speci!c thrombin generation, we 
adapted the Siemens Endogenous Thrombin Potential (ETP) assay on a BCS-XP 
analyser (Siemens Healthcare Diagnostics, Marburg, Germany). The MP-speci!c 
ETP reaction was initiated using 30 times diluted Actin FS (Siemens) instead of 
Innovin (Siemens), thus reducing the phospholipid content and not providing 
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reagent-derived TF in the ETP reaction mixture.  Linear dose-response relations 
between MP numbers and the ETP-parameters ETP (area under the curve or total 
amount of thrombin) and lag-time (time from reaction start to start of thrombin 
generation), were observed when washed MP were added to MP-poor plasma 
(data not shown). ETP was determined in three di#erent MP dilutions in MP-poor 
pooled plasma and MP-speci!c ETP/1.000 MP was calculated after correction 
for background ETP of MP-poor plasma during each analytical session. 
Patient 1, a 28-year-old female, was diagnosed with AML FAB-subtype M2. On 
admission (day 0), her leukocyte count was 68.5 x 109/L (27% blasts), with a 
platelet count of 41 x 109/L and a hemoglobin concentration of 6.1 mmol/L. 
Treatment consisted of three cycles of chemotherapy with cytarabin and 
idarubicin, amsacrine and high dose cytarabin, and etoposide and mitoxantrone 
(HOVON 42 protocol; http://www.hovon.nl/trials).
Patient 2, a 56-year-old male was diagnosed with AML FAB-subtype M2. On 
admission his leukocyte count was 277.7 x 109/L (84% blasts), with a platelet 
count of 68 x 109/L and a hemoglobin concentration of 2.3 mmol/L. Induction 
therapy was as in patient 1. 
Patient 3, a 21-year-old male presented with a relapse after treatment for AML 
FAB-subtype M4. His leukocyte count was 1.4 x 109/L (1% peripheral and 26% 
bone marrow blasts), with a platelet count of 46 x 109/L and a hemoglobin 
concentration of 6.9 mmol/L. Reinduction therapy was initiated with high dose 
cytarabin combined with intrathecal methothrexate. 
Blast of patients expressed CD13, CD34, CD117 and HLA-DR. Late after 
chemotherapy, patient 1 and 2 were in complete remission (<5% bone marrow 
blasts, no peripheral blasts and a normal peripheral blood count). Patient 3 had 
a partial remission (8% bone marrow blasts). 
The numbers of MP per μL plasma determined at day 0 of chemotherapy were 
1206, 3980 and 2756 for patients 1,2 and 3, respectively. Number of MP in 
control pooled plasma was 3728 ±514 (SD). During chemotherapy (days 1-7), 
the numbers of MP declined in all three patients (nadir as sampled: 349, 2587 
and 2312 in patients 1, 2 and 3, respectively). In their (partial) remission samples, 
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increased numbers of MP were observed (3108, 10111 and 8163 in patients 1,2 
and 3, respectively).
 
In control plasma, 95-98% of all MP were platelet derived (CD41+) as described 
earlier [8]. Before treatment, this percentage was 60%, 43% and 99% in patients 
1,2 and 3, respectively, indicating that signi!cant subpopulations of MP of 
patients 1 and 2 but not patient 3 might derive from other, putatively AML 
blastoid, cellular sources. 
Indeed, MP from patients 1 and 2 before treatment expressed myeloblast 
markers (Fig. 1) that were not found on MP of control pooled plasma or MP 
of patient 3. MP from patient 1 were positive for CD13 (60%), CD34 (16%) and 
CD117 (9%). MFIs of these markers were, respectively, 40.9, 12.3 and 8.5 on 
patient MP, vs. 3.2, 5.0 and a 3.2 on control MP (all P < 0.001). MP of patient 2 
expressed CD117 (13%); MFI 10.2 (P < 0.001). In addition, MP of patients 1 and 2 
expressed HLA-DR at a considerable intensity at the start of treatment (44% and 
61% in patients 1 and 2, respectively, vs. 10% in control pooled plasma). MFIs 
were 47.6 and 109.8 on MP of patients 1 and 2, respectively, vs. 11.2 on control 
MP (P < 0.001). HLA-DR expression on MP appeared to be myeloblast derived 
and not related to an immune response, because in a control experiment 
it was not found on MP from three patients with sepsis and disseminated 
intravascular coagulation and three patients with metastasized breast cancer 
(data not shown). The various marker-positive MP population sizes indicated 
combined expression of platelet and leukocyte markers on single particles. 
Indeed, the myeloid markers were not only on CD41 negative MP, but also 
partly co-expressed with CD41 (Fig. 1). 
Thus, in patients 1 and 2 before chemotherapy high numbers of circulating 
leukemic cells correlated with relatively low percentages of platelet-derived MP 
and large proportions of MP that appeared to be myeloblast-derived. MP of 
patient 3, who presented without detectable peripheral circulating myeloblasts, 
did not express immature myeloid markers, indicating that at least in this case, 
the bone marrow blasts did not release MP into the blood stream.
During chemotherapy the absolute and relative numbers of such MP declined 
(Fig. 1). Late after chemotherapy 4% of MP of patient 1 remained positive for 
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CD13 but no other myeloid markers were found on MP of any of the patients 
in their remission samples. Also, aberrant HLA-DR expression was not found 
in the remission samples of any of the patients. In addition, in all remission 
samples >95% of MP expressed CD41. These data illustrate the disappearance 
of myeloblast-derived MP following chemotherapy.
The presence of myeloblast-derived MP was related to an elevated ETP (Fig. 1). 
In pre-treatment samples of patients 1 and 2 but not patient 3, MP-speci!c ETP 
(ETP per MP, or slope of the dose-response curve) was higher than in control 
MP. When these MP disappeared during chemotherapy, the MP-speci!c ETP 
declined and in remission samples values approximated those of control MP.
Taken together, normal or low numbers of MP were present in AML patients 
before chemotherapy but presence of MP expressing immature myeloid 
markers was related to MP-speci!c ETP, indicating that these MP were highly 
procoagulant.
We propose that procoagulant myeloblast-derived MP may play a role in 
the thrombosis risk of AML patients. Combined expression of platelet and 
leukocyte markers on single particles that may result from fusion of MP, may 
change catalytic processes by colocalizing molecular actors [9]. Of the actors 
possibly involved [2,3], interestingly, PSGL-1 expression corresponded with the 
myeloid marker expression (data not shown). Although a direct role for PSGL-
1 in the enzymatic processes leading to thrombin generation as measured 
here is unlikely, it is thought to play a role in thrombus formation in vivo and 
may thus contribute to a prothrombotic pro!le [2].  Prechemotherapy MP of 
patient 2 expressed TF (7%) and this was accompanied by reduced lag times 
(not shown) in addition to increased ETP, suggesting that TF on these MP 
may provide them with a procoagulant function, as has been described for 
other cancer-related MP [7,9]. However, TF was not found on MP of patient 
1 and therefore the high procoagulant properties of these MP remain to be 
explained.
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Fig 1.Presence of MP with aberrant expression of immature myeloid markers is related to an increased 
MP-speci!c ETP. (A/B) Histograms showing increased expression of myeloblast markers on MP of 
patients 1 (A; CD13) and 2 (B; CD117)  before treatment compared with remission samples. Inserts show 
scatter plots to illustrate CD13/CD45 expression on MP of patient 1 (A) and CD117 expression on MP of 
patient 2 (B). (C/D) Histograms showing increased expression of HLA-DR before treatment compared 
with remission samples on MP of patients 1 (C) and 2 (D). Inserts show scatter plots illustrative of CD41 
distribution on MP on day 0. HLA-DR was observed on CD41+ and CD41- MP of patient 1 (C) but mainly 
on CD41- MP of patient 2 (D). (E) Endogenous thrombin potential (ETP) of patient MP in normal MP-poor 
plasma. ETP per MP was much higher for MP of patients 1 and 2 before treatment, as compared with MP 
of control pooled plasma. ETP per MP declined during treatment and MP-speci!c ETP of remission 
samples was similar to that of MP of control pooled plasma.
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Despite cell death inducing chemotherapy, an early -treatment-associated 
decrease in MP was observed. Therefore, either chemotherapy-associated 
cell death does not lead to an overt MP production, or such MP have a very 
high clearance rate. The increased numbers of MP in all the remission samples 
may be explained as a postchemotherapy e#ect, possibly re"ecting sustained 
kinetic bone marrow proliferation abnormalities in early remission. Although 
the MP found in early remission did not have altered procoagulant properties 
compared with control MP, the high numbers in which they may circulate may 
contribute to a prothrombotic pro!le as well.
This is the !rst study describing increased MP-speci!c procoagulant activity in 
relation to a malignant myeloblast-derived population of MP. Further studies are 
necessary to identify the key players and any possible relation to the increased 
thrombotic risk of AML patients.
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In response to stress all circulating blood cells as well as endothelial cells release 
cellular microparticles (MP) [1]. MP are membranous fragments less than 1 
micrometer in diameter that express at least some of the antigenic markers 
distinctive of the parent cells. Cell activation by numerous agents stimulates 
their release, for example complement factors and cytokines, or cellular processes 
such as apoptosis, oxidative injury and shear stress [2]. MP are both cause and 
consequence of vascular changes, and play a role in thrombosis and haemostasis 
by providing a phosphatidylserine surface for procoagulant molecules including 
tissue factor [2]. However, the appearance of MP in response to stress is not well 
studied and an in vivo model is lacking. Ex vivo whole blood studies in which 
endotoxins are applied to establish MP release, showed an increase in MP count 
after 6-24 hours [3,4]. Aras et al. showed a 2-fold increase in MP levels three hours 
after intravenous endotoxin infusion in healthy volunteers and these MP levels 
returned to baseline after 8 hours [5].
We hypothesized that a bungee jump would be an adequate in vivo model to 
study the e#ects of acute stress on the generation of MP. Recently, this model 
was indeed used in a Dutch collaborative project focussing on immune- and 
haemostatic responses to stress. Twenty healthy male volunteers aged 18-35 
years made a bungee jump from a sixty meter high crane. In order to study the 
e#ect of beta adrenergic receptor blockade, an e#ective agent for attenuating 
most physiological responses to stress, propranolol was administered to half of 
the volunteers for three days prior to the jump (forty milligram three times a day).
We investigated the in"uence of the bungee jump on levels of circulating MP and 
their cellular origin. Results of the main study have been described previously 
[6,7]. In short, bungee jumps took place under supervision of an experienced 
commercial crew. The study was reviewed and approved by medical ethics 
committee of the Academic Medical Center in Amsterdam, The Netherlands and 
written informed consent was obtained from all subjects. On the morning of the 
study day an intravenous access catheter was placed in the cubital vein. Exactly 
two hours before the jump the !rst blood sample was drawn (20 ml), referred to 
as baseline sample. Subsequent samples were drawn directly before the jump 
(while elevated at jump level), immediately after the jump and two hours later.
For MP measurements, blood was collected into a 4 mL tube containing 3.2 % 
citrate (Becton-Dickinson, Breda, the Netherlands). MP isolation and phenotypic 
analysis of MP were performed as previously described [8]. To identify annexin 
V-positive events, a threshold was placed in a MP sample prepared without 
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calcium. In some samples (n=24) high numbers of erythrocyte-derived 
(glycophorin A-positive) MP were observed, and those samples appeared to 
have a high haemolysis index. As the numbers of erythrocyte-derived MP in 
these samples could not be corrected for haemolysis they are excluded from the 
present analysis. These samples were equally distributed between time points 
and between subjects.
To assess MP procoagulant properties as MP-dependent thrombin generation, 
we adapted the Siemens endogenous thrombin potential (ETP) assay on a 
BCS-XP analyser (Siemens Healthcare Diagnostics, Marburg, Germany) as 
previously described [9]. The reaction was initiated using 30 times diluted Actin 
FS (Siemens) instead of Innovin (Siemens), thus reducing the added amount 
of phospholipids and not providing reagent-derived TF in the ETP reaction 
mixture. The thrombin generation curves were analysed with Curves (v 1.0 spec. 
3.2, Dade Behring), and three parameters were calculated: ETP (endogenous 
thrombin potential, or area under the curve that represents the total amount 
of thrombin generation), lag time (time from onset of the reaction to start of 
thrombin generation) and peak height (represents the peak level of thrombin 
generation). Linear dose-response relations between MP numbers derived from 
normal pooled plasma and the ETP parameters were observed within certain 
limits of numbers of MP added (data not shown). ETP was determined in two 
di#erent MP dilutions (2.5x and 4x) in MP-poor pooled plasma for each subject, 
ascertaining that at least one data point would !t within the measuring range. 
Results are described as medians. We used the non-parametric Mann Whitney 
U test to compare groups and changes related to time to jump were analysed 
by one way analysis of variance (repeated measures). 
Hemodynamic e#ects (heart rate and blood pressure) were published previously 
[6,7]. In short, mean arterial blood pressure (MAP) increased directly prior to the 
jump compared with baseline in all subjects. Directly after the jump, MAP had 
decreased again, which was followed by a further decrease 2 hours after the 
jump. Heart rate increased in a similar fashion, but this change was absent in 
subjects pre-treated with propranolol.
Stress as provided by a bungee jump resulted in large changes in MP numbers. 
In all subjects MP levels increased right after the jump (Figure 1) and after two 
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hours these numbers had returned to baseline levels. Right after the jump an 
immediate and major increase in MP numbers was observed for platelet-derived 
MP (CD41-positive, 3230x106/L vs. 1850x106/L, p<0.001), leukocyte-derived 
MP (CD45-positive 43x106/L vs. 28x106/L, p<0.05) and monocyte-derived MP 
(CD14-positive 41x106/L vs. 9x106/L, p<0.001). No di#erences were observed for 
endothelial-derived MP (CD62E and CD144), MP expressing markers of platelet 
activation (CD62P and CD63) and tissue factor-positive MP. 
The increase of MP numbers was in"uenced by the pre-treatment with 
propranolol. Baseline MP levels did not di#er between the propranolol and 
control group. However, right after the jump the propranolol group had even 
higher levels of platelet-derived MP (propranolol 4025x106/L vs. controls 
1920x106/L; p<0.05). In contrast, monocyte-derived (CD14-positive) MP were 
lower in the propranolol group as compared to the controls (37x106/L vs. 
93x106/L; p<0.05). 
Right after the jump increased numbers of MP resulted in an increased 
thrombin generation peak height (41 vs. 35 mA/min, Figure 1F). Peak height 
correlated with the total numbers of MP (R=0.57, p<0.001). No di#erences in 
ETP and lag time were observed, neither were di#erences observed between 
the propranolol group and the control group.  
We studied whether an acute severe stress response as induced by a bungee 
jump in"uences MP numbers and subsets, and whether this was a#ected by 
beta-adrenergic blockade. Bungee jumping temporarily increased the numbers 
of circulating platelet-, leukocyte- and monocyte-derived MP. This increase was 
related to stress during the jump rather than to stress prior to the jump since 
the highest number of platelet-derived MP was observed right after the jump. 
Within 10 minutes an almost two-fold increase in leukocyte-derived MP was 
observed. This impressive increase of MP right after the jump could be due to 
cytokine release, oxidative injury or apoptosis [2]. Two hours after the jump MP 
levels had returned to baseline in all volunteers. Visual inspection of Figure 1A 
produced a crude estimate of the in vivo half-life of MP of 1 hour or less [5]. This 
is in line with previous studies that described a half-life of MP varying from 5 
minutes to 3 hours [5,10]. 
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The di#erence in MP levels in the propranolol and control group was observed 
right after the jump, and not at baseline, indicating that the e#ect of propranolol 
on MP levels is dependent on stress as induced by a bungee jump. Moreover, 
in this stress model propranolol has di#erential e#ects on MP-formation as 
platelet- and leukocyte-derived MP release was facilitated in the propranolol 
group, and monocyte- and endothelial-derived MP release was inhibited. As 
the beta receptor to which propranolol is targeted is present on the membrane 
of leukocytes [11], monocytes [12], endothelial cells [13] and platelets [14], they 
could all respond to propranolol. 
The increase of platelet-derived MP in the propranolol group was unexpected 
since propranolol is known to suppress platelet aggregation [15]. Sims et al. 
[16] described that shedding of MP induced by platelet activators may be 
uncoupled from other platelet responses necessary for platelet aggregation, as 
di#erent platelet agonists have di#erential e#ects on platelet MP composition 
and MP membrane components. The mechanisms by which platelets shed MP 
are largely unknown, but probably require an increase in intracellular calcium 
[17]. Cyclic adenosine monophosphate (cAMP) might also be involved as cAMP 
inhibited MP formation [18], probably by lowering intracellular calcium. There 
is a ß receptor-mediated cAMP increase in stress [18], which is inhibited by 
propranolol [14]. Thus, theoretically propranolol can lower cAMP in the cell 
by blocking the β receptor, thereby increasing MP shedding. Thus platelet 
aggregation and the shedding of platelet derived MP follow di#erent pathways. 
In conclusion, our results indicate that bungee jumping temporarily increased 
numbers of circulating platelet-, leukocyte- en monocyte- derived MP. 
Interestingly, pre treatment with propranolol resulted in an unexpected and 
marked additional increase in leukocyte- and platelet-derived MP as induced 
by acute stress. The beta receptor may therefore be involved in suppressing MP 
formation in leukocytes and platelets. The mechanisms by which propranolol 
in"uences the formation of MP remains to be elucidated. 
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Figure 1A-E: Numbers of Annexin V-positive, platelet-, leukocyte- and monocyte-derived microparticles 
relative to the jump are shown. All values changed signi! cantly during the jump (p<0.05). In platelet- 
and monocyte- derived MP a di# erence was observed between the propranolol and control group right 
after the jump. Figure 1F: Peak Height results relative to the jump are shown. Results are shown as 
medians and SEM .* p<0.05 propranolol vs. controls.
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Summary
The potential in"uence of MP in many di#erent thrombotic and bleeding 
diseases has been investigated. MP are procoagulant by nature as they express 
phosphatidylserine on their membrane, providing a surface for coagulation. 
Besides, expression of tissue factor, the initiator of coagulation, by MP 
contributes to clot formation as well. Moreover, expression of P-selectin and 
leukocyte activation markers like P-selectin glycoprotein ligand 1 (PSGL-1) by 
MP attributes to thrombosis [1,2]. 
In this thesis we investigated the contribution of MP to pre-thrombotic states 
in which patients have an increased risk of developing arterial and/or venous 
thrombosis. Both the number and phenotypic pro!le of MP was assessed as well 
as the procoagulant potential of MP. 
In Chapter 1 we describe the de!nition of MP, their formation and the technical 
di$culties involved in their analysis. In addition, we provide an overview of the 
literature on MP in thromboembolic disease.
In Chapter 2 MP in patients with Essential Thrombocythemia (ET) are studied. 
ET is a clonal disorder with a large increase in platelet numbers and patients 
with ET have a high risk of thrombosis. ET patients had an increased number of 
MP compared with controls and these MP expressed markers of platelets and 
endothelial cells: expressing both CD62E, an endothelial marker and CD41, a 
platelet marker. These MP of bilineal origin might result from physical interaction 
between activated platelets and endothelial cells, inducing MP formation and 
transfer of proteins from one to the other membrane. These CD62E+/CD41+ 
MP were only increased in patients who had one or more clinical risk factors for 
thrombosis.  Leukocyte-derived MP and MP expressing TF were increased as 
well. In a thrombin generation system, MP of patients with ET induced a shorter 
lag time and a higher peak height in thrombin formation, contributing to the 
clinical hypercoagulability of these patients. 
In Chapter 3 we described another study assessing MP in ET and Polycythemia 
Vera (PV). These are both myeloproliferative diseases in which patients have an 
increased risk of thrombosis, and patients with a JAK2V167 mutation and/or 
high leukocyte numbers are at an even higher thrombotic risk. ET is primarily 
associated with an increased platelet count, PV with an increased erythrocyte 
count. The only di#erence we observed between PV and ET was that patients 
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with PV had more leukocyte-derived MP, and this correlated with an increased 
leukocyte count and with JAK2 positivity. ET patients showed an impressive, and 
PV patients a moderate, increase in numbers of CD62E+/CD41+ MP, which was 
entirely absent in controls. When thrombin generation of MP was determined, 
patients with ET again had higher peak height and endogenous thrombin 
potential compared with controls, in line with the results described in Chapter 
2. Although patients with PV had higher numbers of MP carrying leukocyte 
activation markers, such as PSGL-1 and CD11b, their thrombin generation results 
did not di#er from controls. In this study we also assessed MP-speci!c thrombin 
generation, which we arbitrarily de!ned as the endogenous thrombin potential 
that could be generated by 1000 MP. This MP-speci!c thrombin generation 
did not di#er between patients and controls, indicating that the increased 
thrombogenicity in patients is a result of increased numbers of MP, rather than 
a di#erence in functional properties. 
In Chapter 4 we determined MP levels and their procoagulant potential in 
patients with chronic renal failure. These patients were divided in three groups, 
one group with patients with chronic kidney disease stage IV, one with patients 
on peritoneal dialyses and one with patients on haemodialysis. All patients 
showed endothelial activation, which was of a di#erent nature in peritoneal 
dialysis and chronic kidney disease stage IV compared with haemodialysis. All 
patient groups had a large increase in MP of platelet, leukocyte and endothelial 
ancestry. MP levels could not be used to di#erentiate patient groups from one 
another. Moreover, a haemodialysis session did not result in an increase of MP, 
showing that renal failure is a more important determinant of MP-pro!le in these 
patients than physical blood cell activation by the dialysis membrane or "ow 
through the arti!cial kidney. In peritoneal dialysis and chronic kidney stage IV a 
pattern compatible with chronic endothelial activation was observed. However, 
in haemodialysis acute endothelial activation was observed after a haemodialysis 
session. MP in patients with chronic renal failure had reduced thrombogenicity 
in the thrombin generation assay. We speculate that thrombopathic platelets in 
these patients, a well-known phenomenon in renal failure due to uremic toxins, 
result in platelet-derived MP with similarly reduced procoagulant potential.
MP in cancer and the e#ect of therapy
MP are increased in solid malignancies, especially when metastases are present. 
These studies include patients before therapy is started [3-5], but it is unknown 
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what happens to MP levels during therapy. In Chapter 5 we describe a cross-
sectional study in 40 breast cancer patients using endocrine therapy. These 
breast cancer patients were divided into two groups, 20 patients had had curative 
therapy and were considered disease free, and 20 patients had metastatic 
disease. All patients used either an aromatose inhibitor or an anti-estrogen. It is 
known that anti-estrogens, such as tamoxifen, increase the risk for thrombosis. 
We investigated whether patients who used anti-estrogens had another MP 
pro!le than those who used aromatase inhibitors, however no di#erences were 
observed. Moreover, no di#erences in MP numbers or thrombin generation 
results could be observed between the adjuvant group and the group with 
metastatic disease. The observation that patients with metastatic disease did 
not have higher MP levels was unexpected, and could re"ect the more or less 
‘stable disease’ of these patients while on endocrine therapy. On the other hand, 
patients with or without metastasis on any endocrine therapy had slightly higher 
numbers of MP and higher thrombin generation results compared with controls, 
indicating a hypercoagulable state, possibly resulting from endocrine therapy 
itself. To answer the question whether endocrine therapy itself in"uences MP 
subsets and their procoagulant potential more clearly, a prospective study in 
this patient group before, during and after therapy should be performed.
In Chapter 6 three patients with acute myeloid leukemia (AML) are described in 
which MP levels and their procoagulant potential was measured in subsequent 
samples obtained before and during chemotherapy and in remission. At 
diagnosis these AML patients had a high percentage (>30%) of myeloblast-
derived MP, and this percentage diminished during chemotherapy, showing that 
changes in MP subsets can be measured using "owcytometry. Upon remission 
myeloblast-derived MP could not be detected anymore. It has been suggested 
that apoptotic cell death during chemotherapy might result in a massive 
increase in MP, in this small study such an increase was not measured in the 
peripheral blood. The ETP/1000MP was higher at diagnosis than in remission, 
and diminished during therapy, indicating that the myeloblast-derived MP 
which were present at diagnosis are more procoagulant than control MP.
MP formation during stress
A bungee jump study that was designed to investigate the e#ect of stress 
on the immune system enabled us to investigate the e#ect of stress on the 
formation of MP as described in Chapter 7. Twenty healthy volunteers 
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performed a bungee jump from a 60 meter high crane, half of them were pre-
treated with propranolol three days prior to the jump. We determined the half-
life of MP, which was approximately one hour. We observed a large increase in 
MP numbers immediately after the jump that had returned to baseline two 
hours after the jump. Moreover, volunteers who had used propranolol had a 
larger increase in leukocyte- and platelet-derived MP. In contrast, numbers of 
monocyte-derived MP at the other hand were higher in the group who had 
not used propranolol. We hypothesized that the e#ect of propranolol is due 
to a decrease of intracellular cyclic AMP by blocking the beta-receptor. The 
beta-receptor therefore seems to be involved in the formation of MP. The use 
of propranolol did not alter MP-induced thrombin generation. 
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General discussion
The hypothesis of this thesis was that MP contribute to the pre-thrombotic 
state as observed in patients with thromboembolic disease. The number and 
phenotypic pro!le of MP was studied and their procoagulant potential assessed. 
The procoagulant properties of MP rely mainly on the expression of anionic 
phospholipids, especially phosphatidylserine, and of TF, the major cellular 
activator of the clotting system [6]. The presence of phosphatidylserine on MP 
is shown by their ability to bind Annexin V. In line with literature [7], we observed 
increased numbers of Annexin V-positive MP in our patient groups. Higher 
numbers of TF positive MP were observed in patients with chronic renal failure 
and ET. TF-positive MP are known to be signi!cantly higher in patients with 
cancer [3,8] and with cardiovascular disease [6]. However, the overall numbers 
of TF-positive MP in our studies were low, less than 1% of all MP. Tesselaar et al. 
found a percentage of TF+ MP in breast cancer patients of 6%, which is much 
higher than the percentages we observed; this di#erence might be explained 
by the fact that in this study metastasized patients were included before therapy 
was started [3]. The cellular origin of TF-positive MP might include platelets, 
cancer cells and monocytes [9]. We observed co-expression of TF and platelet 
markers, suggesting the platelet as source for TF-positive MP.
In concordance with previous observations [3,4,10], in almost all subjects studied 
the majority of MP was platelet –derived. These numbers varied from 43% in 
an AML patient with a large proportion of MP being myeloblast-derived to 93-
98% in patients with renal failure, breast cancer patients and ET/PV patients. 
MP from leukocytes, endothelial cells and erythrocytes were present at much 
lower levels. Changes in phenotypic pro!les of patients were observed, which 
could either be small or large. In ET and PV there was a large (27%) percentage 
of CD41+/CD62E+ MP, which were absent in controls. This might re"ect a novel 
mechanism involved in the increased risk on thrombosis in MPN patients, which 
needs further research. In AML patients before therapy was started a large 
percentage (30%) of myeloblast-derived MP were observed. Large percentages 
of tumor-derived MP have also been observed by Ghosh et al., who showed 
that patients with the earliest stage of CLL (Rai 0) had 84% platelet-derived MP 
and only small levels of MP derived from leukemic B-cells [11]. In patients with 
advanced stages of CLL (Rai III/IV) the percentage of platelet-derived MP had 
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dropped to 50% and the proportion of MP of leukemic B-cells had increased 
to around 40%. In breast cancer patients and in chronic renal failure only small 
di#ences in phenotypic pro!le were observed. These patients had more CD62P-
positive MP compared with controls; similar !ndings were obtained by Toth et 
al. and the signi!cance of this !nding is unknown [3]. P-selectin positive MP 
might attribute to the procoagulant potential of MP as they can bind PSGL-1, 
which promotes clot formation [1].
The e#ect of medical treatment on MP numbers and phenotypic pro!le was 
studied as well. We showed that therapy in cancer patients in"uenced MP levels. 
Despite cell death inducing chemotherapy, an early -treatment-associated 
decrease in MP was observed, especially in the number of myeloblast-derived 
MP. Therefore, either chemotherapy-associated cell death does not lead to an 
overt MP production, or such MP have a very high clearance rate. In breast 
cancer patients we did not observe the expected increase in MP in patients 
with metastatic disease, which was in contrast with previous studies [3-5]. We 
hypothesized this was due to the more or less ‘stable disease’ these patients had 
while using endocrine therapy, but prospective studies in which larger breast 
cancer patient groups need to be included are needed to study MP pro!les and 
the e#ects of therapy.
This thesis adds to other research on MP, improving our understanding 
of the pathogenesis of thrombosis. Experimental work provided a basis 
for understanding the signi!cance of MP in the onset and progression of 
thrombosis. During the initial phase of thrombus development in vivo TF derived 
from hematopoietic cells is delivered by MP [12]. Activated platelets at the site 
of injury express P-selectin. In P-selectin null mice MP failed to accumulate in 
the thrombus [1]. Therefore the accumulation of monocyte MP bearing TF in 
the thrombus is dependent on the interaction of platelet P-selectin and its 
counterreceptor P-selectin glycoprotein ligand 1 (PSGL-1) on the surface of 
MP [1]. Mice that overexpressed soluble P-selectin had increased numbers 
of leukocyte-derived MP bearing TF and had shortened clotting times [13]. 
When inhibitory PSGL-1 antibodies were infused into these mice the clotting 
time prolonged and thrombus size decreased [13,14]. In patients with PV we 
measured increased numbers of PSGL-1-positive MP. This did not, however, 
result in increased thrombin generation. Possibly, because PSGL-1-postive MP 
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were present at very low numbers minor e#ects escaped detection or that their 
main e#ects are mediated through interaction with the vessel wall.
The procoagulant potential of MP was investigated using a thrombin generation 
assay, in which three parameters were assessed; lag time is the time from onset 
of the reaction to start of thrombin generation, peak height represents the 
maximum speed of thrombin generation and endogenous thrombin potential 
(ETP) represents the total amount of thrombin generation. We have performed 
thrombin generation assays in three di#erent conditions; in MP rich plasma, in 
the MP pellet resuspended in human pooled plasma and in the supernatant. 
Using these di#erent conditions we were able to investigate the di#erent 
thrombogenic properties of MP in this test. Patients with renal failure, breast 
cancer and ET had increased MP-dependent thrombin generation compared 
with controls. Previous studies had shown that patients with recurrent venous 
thromboembolism and with myeloproliferative disease have increased MP-
associated thrombin generation [15,16]. Patients with thromboembolic 
disease have higher MP-dependent thrombin generation, this indicates that 
MP contribute to the prothrombotic pro!le in these patients.
We further investigated whether MP in some diseases were more procoagulant 
than in controls and whether MP had a qualitative or a quantitative e#ect in 
thrombin generation. Qualitative e#ects f.e. could be achieved by increased 
expression of TF, the main determinant of lag time, or by increased phospholipid 
content on MP. Quantitative e#ects could be achieved by increased numbers 
of MP. Based on our !ndings, we tend to conclude that both qualitative and 
quantitative aspects are involved. In AML we observed a qualitative e#ect, 
consisting of increased thrombin formation per MP at diagnosis as compared 
to remission. In ET and breast cancer a quantitative e#ect was found. Thrombin 
generation in these patients was higher, however ETP/1000MP was the same. 
In chronic renal failure both e#ects appeared to be operational. Due to a large 
increase in MP numbers in patients their MP-dependent thrombin generation 
was slightly higher, on the other hand ETP/1000MP was lower, leading to the 
conclusion that circulating MP possessed reduced ability to induce thrombin 
generation in patients. This suggests that MP contribute to thrombosis by 
di#erent functional mechanisms. 
Research in the functional properties of MP in thrombosis is comprommised 
as there are only few functional tests. Thrombin generation assays, speci!ed 
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to MP, could provide more information about the functional capacities of MP. 
Although of great interest, we were not able to investigate whether the ancestry 
of MP results in di#erences in procoagulant ability. For example, are monocyte-
derived MP more procoagulant than platelet-derived-MP? Monocyte-derived 
MP express TF, and shorten lag time and increase peak height in a TF-dependent 
manner [17,18]. Van der Meijden et al. observed that platelet-derived MP, as 
well as erythrocyte-derived MP not only propagate coagulation by exposing 
phosphatidylserine but also initiated thrombin generation indepedently of 
TF in a Factor XII-dependent manner [18]. Platelet-derived MP and monocyte-
derived MP di#erentially modulate thrombosis, the physiological relevance of 
this !nding, especially in various disease states, requires further investigation.
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Future perspectives
Although the initial studies on cellular MP considered these vesicles as  ‘platelet 
dust’, studies from the past decades have dramatically altered this view. MP 
are nowadays known to contribute to thrombosis, infection, angiogenesis, 
cell-cell interactions and can fuse with other cells delivering both proteins and 
mRNA. With all applications of MP detection, it remains of great importance 
that standardization of MP measurement and pre-analytical conditions is being 
accomplished. The characterization of MP remains di$cult because of their 
small size and heterogeneity in terms of phospholipid content and antigenic 
composition. In addition, there is no consensus on the best markers for de!ning 
MP subpopulations such as endothelium-, leukocyte-, or cancer-derived MP. 
Important e#orts in standardizing the pre-analytical and analytical variables 
have been developed on behalf of the International Society on Thrombosis 
and Haemostasis standardization subcommittee in vascular biology [19,20]. 
Hopefully, in the future, standardization of available methodologies can be 
achieved, this will be needed to advance the !eld. 
Although not all mechanisms by which MP contribute in the pathogenesis 
of thrombosis are revealed yet, and are still under investigation, they play an 
important role [21].  Recent studies report that MP not only are procoagulant, but 
also inhibit anticoagulant functions. Subpopulations of MP might express tissue 
factor pathway inhibitor and might convey !brinolytic properties. Therefore 
MP might act as a regulator in hemostasis. The possible clinical relevance of 
this !nding remains to be demonstrated [21]. Clinically, the relevance of MP 
for diagnostic strati!cation of patients in high and low risk for thrombosis is 
under investigation. For arterial thrombosis a few recent prospective studies 
demonstrated that the level of endothelial-derived MP is an independent 
predictor of major adverse cardiovascular events [22] and mortality [23]. The 
level of endothelial-derived MP might be used to monitor response to therapy 
in the future.
For venous thromboembolism (VTE) retrospective studies found increased 
levels of TF-positive MP in patients with VTE compared with those without 
risk strati!cation in venous thrombosis [3,24]. Recently the !rst randomised- 
controlled phase II trial with MP was performed, in which TF-bearing 
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microparticles (TFMP) were successfully used to predict the risk of VTE. In this 
study by Zwicker et al. [25] patients with cancer were divided in a group with 
high and a group with low numbers of TF-positive MP. After two months the 
cumulative incidence of VTE in the high TF- positive MP group was substantially 
higher than in the low TF-positive MP group (27.3 vs. 7.2%). The use of 
enoxoparin in the high TF-positve MP group reduced the incidence of VTE to a 
rate comparable to the low TF-positive MP group (5.6%). Hopefully more clinical 
prospective trials in which MP are used for diagnosis or to predict the risk of 
thrombosis will be performed in the future. 
It remains to be shown whether the addition of MP to existing diagnostic 
strategies including clinical risk pro!les (such as the Vienna risk score) and other 
laboratory markers like d-dimer, adds to better risk assessment.
It is not expected for MP to have a role in therapeutic regimens for thrombosis 
in the near future, but future therapeutic targets on MP might be P-selectin 
for the prevention of thrombosis in cancer [9], and phosphatidylserine for the 
prevention of metastases [26]. 
MP are now established contributors in the pathogenesis of thrombosis. Further 
research is needed before the full potential of MP can be realized. In the future, 
circulating MP may serve as a reservoir of prognostic and predictive biomarkers 
in thrombosis, therapeutic targets and may be used to monitor response to 
treatment.
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Micropartikels zijn kleine onregelmatig gevormde blaasjes, die kleiner zijn dan 
1 nanometer (ofwel 1x10-9 meter). Ze ontstaan wanneer cellen in het bloed 
in apoptose gaan, dit is geprogrammeerde celdood, of als cellen geactiveerd 
raken. Bloedplaatjes, witte bloedcellen, rode bloedcellen, endotheelcellen 
en ook kankercellen kunnen micropartikels afsnoeren als ze geactiveerd 
raken. Micropartikels hebben op hun membraan dezelfde eiwitten als de cel 
waarvan ze afkomstig zijn, en daarvan kan ook afgeleid worden van welke cel 
ze afkomstig zijn. 
Er zijn verschillende manieren om micropartikels te meten. Voor het 
onderzoek in dit proefschrift hebben we de "owcytometer gebruikt, en dit is 
over het algemeen ook de meest gebruikte methode voor het bepalen van 
micropartikels. Flowcytometrie is een techniek voor het tellen en bestuderen 
van in een stromende vloeistof voorkomende microscopisch kleine deeltjes. 
Laserlicht wordt gericht op de stromende vloeistof. Het type, de grootte en 
andere eigenschappen van het deeltje dat zich in de lichtstraal bevindt 
bepalen de mate van verstrooiing van het licht, en deze lichtweerkaatsing en 
"uorescentie wordt door meerdere detectoren waargenomen. Micropartikels 
in de "owcytometer hebben via toegevoegde antisto#en verschillende 
"uorescente markers (merksto#en) aan zich gebonden, en aan de hand van 
deze markers kan de cellulaire herkomst bepaald worden. 
Toen micropartikels voor het eerst beschreven werden in 1967 dacht men 
dat deze partikels helemaal geen rol hadden, maar de laatste 20 jaar heeft er 
zeer veel onderzoek naar de functies van micropartikels plaatsgevonden en 
heeft men ontdekt dat ze belangrijke zijn in verschillende processen. Ze zijn 
betrokken bij stolling, infecties, nieuwvorming van bloedvaten (angiogenese) 
en interacties tussen cellen. Daarnaast kunnen ze ook mRNA en eiwitten van de 
ene naar de andere cel overbrengen door te fuseren met een cel. 
Het beste bestudeerd is de rol van micropartikels in stolling. Micropartikels 
hebben het phospholipide phosphatidylserine in hun buitenmembraan, 
en daarmee vormen ze een oppervlak waarop stolling kan plaatsvinden. 
Daarnaast brengen sommige micropartikels ook tissue factor tot expressie 
op hun oppervlak. Tissue factor is de initiator van de stolling, en ook hierdoor 
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kunnen micropartikels bijdragen aan de vorming van een stolsel. Bovendien 
kunnen er ook andere eiwitten op micropartikels aanwezig zijn zoals 
P-selectine en P-selectin glycoprotein ligand 1 (PSGL-1) die van invloed zijn in 
de stolselvorming. 
Het doel van dit onderzoek was om bij patiëntengroepen van wie bekend is 
dat ze een verhoogd risico hebben op het krijgen van een arteriële of veneuze 
trombose te kijken wat de rol van micropartikels was. Dit hebben we gedaan 
door de aantallen micropartikels te meten, en te kijken naar de cellulaire 
herkomst van deze micropartikels; oftewel of ze van bloedplaatjes afkomstig 
zijn, of juist van witte bloedcellen enzovoort. Daarnaast werd er gekeken of 
ze ook maakten dat het bloed makkelijker stolde. Dit werd onderzocht door 
middel van een trombine generatie test.  In zo’n trombine generatie test wordt 
er gemeten hoeveel trombine er in een bepaalde tijd wordt gegenereerd. 
Trombine is een enzym dat van belang is in de bloedstolling. Het zorgt ervoor 
dat !brinogeen wordt omgezet in !brine. Fibrine is het basisbestanddeel van 
een stolsel. Er zijn verschillende parameters die men kan beoordelen als men 
een trombine generatie test gebruikt; de lag time, peak height en endogenous 
thrombin potential. Lag time is de tijd die het duurt van de start van de reactie 
tot het moment dat er trombine wordt gevormd. Peak height, of piekhoogte, 
staat voor de maximale snelheid waarmee trombine wordt gevormd, en 
endogenous trombine potential (endogene trombine potentiaal) staat voor 
de totale hoeveelheid trombine die gevormd wordt. Door onder verschillende 
condities te meten hebben we goed het e#ect van micropartikels in de 
trombine generatie kunnen testen. Samenvattend hebben we gekeken of er 
bij de onderzochte patiënten een toename van micropartikels was, of deze 
een andere herkomst hadden dan micropartikels bij gezonde proefpersonen 
en of micropartikels bijdroegen aan de verhoogde stollingsneiging van deze 
patiënten. 
Hoofdstuk 1 is de introductie. Hierin wordt beschreven op welke manieren 
micropartikels gemeten kunnen worden en wat de functies van micropartikels 
zijn. Daarnaast wordt er een literatuuroverzicht gegeven over de rol van 
micropartikels in trombo-embolische aandoeningen waarbij patiënten een 
verhoogd risico hebben op arteriële of veneuze trombose.
In Hoofdstuk 2 worden micropartikels beschreven bij patiënten met essentiële 
trombocytose. Dit is een beenmergziekte, zich voornamelijk uitend in een 
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toename van het aantal bloedplaatjes, waarbij patiënten een verhoogd risico 
hebben op trombose (bloedstolsel).  Bij patiënten met essentiële trombocytose 
werden verhoogde aantallen micropartikels gevonden. Deze micropartikels 
brachten eiwitten tot expressie die zowel van bloedplaatjes als endotheelcellen 
(vaatwand cellen) afkomstig waren, zo brachten ze CD62E tot expressie wat alleen 
gezien wordt op endotheelcellen, en CD41 wat van bloedplaatjes afkomstig is. 
Deze CD62E /CD41 positieve micopartikels hadden dus een bilineale herkomst, 
wat inhoudt dat ze van twee verschillende cellen afkomstig zijn. Dit kan zijn door 
interactie tussen bloedplaatjes en endotheelcellen waardoor micropartikels 
gevormd worden en transfer van oppervlakte-eiwitten plaatsvindt. Deze 
micropartikels waren alleen verhoogd bij patiënten die één of meer klinische 
risicofactoren hadden voor het ontstaan van trombose. Ook micropartikels 
afkomstig van witte bloedcellen en micropartikels die tissue factor tot expressie 
brachten waren verhoogd bij patiënten met essentiële trombocytose. Deze 
micropartikels zorgden er in de trombine generatietest voor dat de lag time 
korter was en de piekhoogte hoger bij patiënten, en lijken hierdoor bij te dragen 
aan de verhoogde hypercoagulabiliteit van deze patiënten. 
In hoofdstuk 3 worden micropartikels vergeleken tussen patiënten 
met essentiële trombocytose en polycythemia vera. Dit zijn allebei 
myeloproliferatieve aandoeningen; chronische ziekten waarbij het beenmerg 
te veel bloedplaatjes, witte bloedcellen of rode bloedcellen aanmaakt. Zoals 
eerder beschreven wordt in essentiële trombocytose een verhoogd aantal 
bloedplaatjes gevonden, en in polycythemia vera met name een verhoogd 
aantal rode bloedcellen. Beide aandoeningen worden gekenmerkt door een 
verhoogd risico op trombose. Dit risico kan verder worden verhoogd door 
de aanwezigheid van de JAK2V167 mutatie (een puntmutatie die de cel 
gevoeliger maakt voor groeifactoren) en de aanwezigheid van verhoogde 
aantallen witte bloedcellen in het bloed. Opvallend was dat bij onderzoek 
van de micropartikels in beide patiëntgroepen geen verschil werd gevonden 
in aantallen micropartikels afkomstig van bloedplaatjes en rode bloedcellen, 
terwijl de aantallen bloedplaatjes en rode bloedcellen wel verschillend waren 
tussen beide groepen. Het grootste verschil tussen beide patiëntgroepen 
was dat patiënten met polycythemia vera meer micropartikels hadden die 
afkomstig waren van witte bloedcellen, en dit correleerde met verhoogde 
aantallen witte bloedcellen en de aanwezigheid van de JAK2V167 mutatie. In 
de trombine generatietesten werden de resultaten uit hoofdstuk 2 bevestigd; 
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patiënten met essentiële trombocytose hadden een hogere piekhoogte, 
en een hogere totale hoeveelheid gevormd trombine (ETP). De trombine 
generatie resultaten van polycythemia vera patiënten waren niet verschillend 
van die van essentiële trombocytose patiënten en controles. Als we keken naar 
de speci!eke trombine generatie door micropartikels, die was gede!nieerd 
als de hoeveelheid trombine die gegenereerd kan worden door 1000 
micropartikels, was er geen verschil tussen patiënten en controles. Dit betekent 
dat de gevonden verschillen in trombine generatie verklaart worden door de 
toename in micropartikels, en daarbij de toename in phosphatidylserine op het 
oppervlak van micropartikels, en dat er geen verschil lijkt te zijn in functionele 
eigenschappen van de micropartikels bij deze patiënten. 
In Hoofdstuk 4 worden micropartikels en hun mate van procoagulantie 
(stollingsbevorderende eigenschappen) beschreven in patiënten met 
chronische nierinsu$ciëntie (verminderde werking van de nieren). Deze 
patiënten hadden verschillende stadia van nierinsu$ciëntie, er was een 
pre-dialyse groep, een groep die peritoneaal dialyse kreeg en een groep die 
hemodialyseerde. Alle patiënten met chronische nierinsu$ciëntie lieten 
verhoogde endotheelactivatie (activatie van de vaatwand) zien in vergelijking 
met controles, maar in de peritoneaal dialyse groep en de pre-dialyse groep 
had dit een ander patroon dan in de hemodialyse groep. Deze laatste groep 
had een patroon van acute endotheelactivatie na een dialyse, terwijl de andere 
twee groepen het beeld van chronische endotheelactivatie lieten zien. Alle 
patiënten lieten fors verhoogde aantallen micropartikels zien, die zowel van 
bloedplaatjes, witte bloedcellen en endotheelcellen afkomstig waren. Er was 
geen verschil tussen de patiëntengroepen onderling, en er was ook geen verschil 
voor en na dialyse. Hieruit kan geconcludeerd worden dat het verhoogde aantal 
micropartikels in hemodialyse patiënten komt door het nierfalen zelf, en niet 
door activatie door contact met de dialysemembraan of bloedstroom door 
het dialyse apparaat.  De micropartikels waren per 1000 micropartikels minder 
trombogeen dan de micropartikels van controles. Micropartikels in patiënten 
met chronisch nierinsu$ciëntie hadden ook een lagere mean "uorescence 
intensity, wat inhoudt dat ze minder phosphatidylserine tot expressie brengen 
in verhouding tot controles. Over de oorzaak kan alleen gespeculeerd worden, 
maar het zou kunnen dat de bloedplaatjes, die in chronische nierinsu$ciëntie 
minder goed plakken doordat er door de verminderde werking van de nier 
meer uremische toxines zijn, ook tot minder trombogene micropartikels leiden. 
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Micropartikels in patiënten met kanker en het e#ect van medicamenteuze 
behandeling
Het is bekend uit de literatuur dat micropartikels verhoogd zijn bij maligniteiten 
(kwaadaardige tumoren), met name wanneer er ook sprake is van metastasen 
(uitzaaiingen). Deze studies hebben micropartikels gemeten voordat er met 
behandeling werd gestart, derhalve is het niet bekend wat het e#ect van 
behandeling is op de aantallen micropartikels. 
In Hoofdstuk 5 wordt een cross-sectionele studie beschreven, ofwel 
dwarsdoorsnedeonderzoek; dit is een vorm van observationeel onderzoek 
waarbij op een bepaald tijdstip gegevens over risicofactoren en/of uitkomsten 
in een populatie worden verzameld. In deze studie betrof het 40 patiënten met 
borstkanker die behandeld worden met hormoontherapie. Deze patiënten 
zijn onderverdeeld in twee groepen, 20 patiënten zijn curatief behandeld 
en krijgen de hormoontherapie als adjuvante behandeling, en 20 patiënten 
hebben gemetastaseerde ziekte. Anti-oestrogenen en aromataseremmers zijn 
beiden hormoontherapeutica en worden bij patiënten die borstkanker hebben 
gehad gebruikt om de kans op een recidief te verlagen, en als er sprake is van 
uitzaaiingen bij borstkanker worden ze gebruikt om de groei van de tumor te 
remmen. Het is bekend dat anti-oestrogenen, zoals tamoxifen, een verhoogd 
risico op trombose geven, en er werd onderzocht of de patiënten die anti-
oestrogenen gebruikte een ander micropartikel pro!el hadden dan degenen 
die aromataseremmers gebruikten. Dit kon niet worden geobserveerd. 
Daarnaast werden er ook geen verschillen gevonden in aantallen micropartikels 
of resultaten van trombine generatie testen tussen de adjuvante groep en 
de groep met gemetastaseerde ziekte. Dit was een onverwachte bevinding, 
en kan een uiting zijn van de min of meer ‘stabiele ziekte’ die patiënten met 
gemetastaseerde ziekte hebben door het gebruik van hormoontherapie. Aan 
de andere kant hadden patiënten wel meer micropartikels in vergelijking met 
controles, en ook een hogere ETP (totale hoeveelheid gevormd trombine) bij 
trombine generatie testen, passend bij hypercoagulabiliteit, mogelijk door 
de hormoontherapie geïnduceerd.  Om dit goed te kunnen bekijken zou 
een prospectief onderzoek uitgevoerd moeten worden, dat wil zeggen een 
onderzoeksopzet waarbij een bij het begin van het onderzoek geïdenti!ceerde 
groep patiënten die gaat starten met hormoontherapie wordt opgevolgd met 
betrekking tot veranderingen in procoagulante micropartikels en e#ecten in 
trombine generatie.
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In hoofdstuk 6 beschrijven we drie patiënten met acute myeloide leukemie bij 
wie voor, tijdens en na chemotherapie de aantallen micropartikels en de mate 
van procoagulantie van deze micropartikels werden bepaald. Op het moment 
dat de diagnose werd gesteld hadden de twee patiënten die circulerende 
myeloblasten (voorlopercellen van witte bloedcellen) in het bloed hadden 
ook meer dan 30% micropartikels die van deze myeloblasten afkomstig 
waren. Dit percentage nam af tijdens therapie, en toen patiënten in remissie 
waren werden deze micropartikels in het geheel niet meer gevonden. De ETP 
per 1000 micropartikels was op het moment van diagnose hoger dan tijdens 
remissie, waaruit geconcludeerd kan worden dat micropartikels afkomstig van 
myeloblasten meer procoagulant zijn dan controle micropartikels.
De formatie van micropartikels tijdens stress
In een bungeejump studie die was opgezet om het e#ect van stress op het 
immuunsysteem te onderzoeken hebben we micropartikels bepaald om het 
e#ect van stress op de vorming van micropartikels te onderzoeken, zoals 
beschreven staat in Hoofdstuk 7. Twintig gezonde mannelijke proefpersonen 
deden een bungeejump vanaf 60 meter hoogte. De helft van hen was 
voorbehandeld met propranolol (een beta-blokker) de drie dagen voor de 
sprong. Er werd op 4 verschillende tijdstippen rondom de sprong micropartikel 
aantallen bepaald, en hieruit konden we de halfwaarde van micropartikels 
bepalen die een uur bedroeg. Er was een grote toename in aantal micropartikels 
vlak na de sprong. Proefpersonen die propranolol hadden gebruikt hadden 
signi!cant hogere aantallen micropartikels afkomstig van bloedplaatjes en witte 
bloedcellen. Micropartikels afkomstig van monocyten daarentegen waren juist 
hoger bij de proefpersonen die geen propranolol hadden gebruikt. Hieruit kan 
geconcludeerd worden dat de beta-receptor is betrokken bij de vorming van 
micropartikels. Er is verder onderzoek nodig om duidelijk te krijgen op welke 
manieren propranolol precies de vorming van micropartikels beïnvloedt. 
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Toekomstperspectieven
Hoewel de eerste studies naar micropartikels nog weinig waarde aan hun 
aanwezigheid hechtten, is door de vele onderzoeken van de laatste twintig jaar 
het belang van micropartikels duidelijk geworden. Het feit dat micropartikels 
klein zijn, en de groep micropartikels een grote diversiteit kent aan eiwitten die 
ze op hun oppervlak tot expressie brengen, maakt dat het karakteriseren van 
micropartikels lastig is. Ook is er nog geen consensus wat de beste markers zijn 
om micropartikels afkomstig van endotheel, witte bloedcellen of kankercellen 
te de!niëren. Daarnaast zijn er veel verschillende manieren om deze 
micropartikels te meten, en het zal de volgende jaren van groot belang zijn om 
tot een standaardisatie van deze metingen te komen, zodat resultaten beter met 
elkaar vergeleken kunnen worden. Een commissie van de ‘International Society 
on Thrombosis and Haemostasis’ spant zich in om tot deze standaardisatie van 
metingen te komen, om hiermee het veld van micropartikel onderzoek verder 
te ontwikkelen. 
Het is nog niet volledig duidelijk op welke manieren micropartikels bijdragen 
aan de pathogenese van trombose, dit zal de komende jaren zeker duidelijker 
worden. Het is de vraag of micropartikels ook een rol kunnen spelen in het 
voorspellen van trombose of in de behandeling hiervan. Er is een aantal 
studies geweest van patiënten met arteriële trombose waarbij hoge aantallen 
van micropartikels afkomstig van endotheelcellen een voorspeller waren 
voor morbiditeit en sterfte. Het aantal micropartikels afkomstig van deze 
endotheelcellen zou dan in de toekomst mogelijk ook gebruikt kunnen worden 
om de therapie te monitoren. Voor veneuze trombose zijn er studies geweest 
waarin de aanwezigheid van micropartikels die tissue factor tot expressie 
brengen bijdraagt aan het voorspellen wie er een veneuze trombose krijgt. 
Wat de toegevoegde waarde van micropartikels is bovenop al bestaande risico-
scores moet de toekomst uitwijzen. Op lange termijn zouden micropartikels 
wellicht zelfs een rol kunnen spelen in behandeling van trombose.
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In 2007 begon ik met onderzoek naar micropartikels in het Onze Lieve Vrouwe 
Gasthuis (OLVG). Het is zeker niet als promotie-onderzoek begonnen, maar ik 
ben blij dat het wel als zodanig geëindigd is. Het onderzoek heb ik al die jaren 
met heel veel plezier heb gedaan, en er zijn veel mensen die ik hierbij graag 
voor hun bijdrage zou willen bedanken. 
Allereerst professor ten Cate, beste Hugo, jij raakte betrokken bij het onderzoek 
door de trombine generatie testen en ik ben blij dat jij mijn promotor bent 
geworden. Hoewel op afstand, voelde je dichtbij door je immer snelle 
antwoorden. Je hebt altijd heldere commentaren op mijn stukken, en gaf me het 
vertrouwen dat ik nodig had. Dank ook voor je geduld. Ik moet de laatste tijd vaak 
uitleggen waarom ik helemaal in Maastricht ga promoveren, maar jij bent een 
hele goede reden. Wim Terpstra en Anja Leyte, mijn co-promotoren. Wim, toen 
ik jouw praatje zag over micropartikels werd ik gegrepen door je enthousiasme, 
en besloot dat ik graag met jou en met Anja onderzoek wilde doen in het OLVG. 
Je bent een zeer toegewijde hematoloog, en vanwege je grote betrokkenheid 
bij je patiënten en je kennis ben je voor mij een groot voorbeeld als dokter. 
Je bent daarnaast een echte onderzoeker, altijd geïnteresseerd in nieuwe 
resultaten. Ik wil je bedanken voor je enthousiaste begeleiding en je heldere 
analyses.  Anja, in onze samenwerking heb ik je toegewijde begeleiding altijd 
zeer gewaardeerd. Ik kan altijd bij je terecht, en je bent ongeloo!ijk zorgvuldig 
in de dingen die je doet. Ik zou graag willen dat ik ooit mijn bevindingen net zo 
duidelijk en to-the point zou kunnen verwoorden als jij. Daarnaast was het ook 
buiten het werk gezellig. Ongeveer gelijktijdig met mijn vertrek uit het OLVG 
werd jij hoofd van het HKCL en ik heb veel bewondering voor hoe je dat doet.
Ik wil de leden van de promotiecommissie hartelijk danken voor het zitting 
nemen in deze commissie; professor Reutelingsperger, professor Kees Brinkman, 
professor Biessen, doctor Anna Falanga en professor Kooman. Anna Falanga, I 
greatly appreciate you are in my assessment committee. I’m grateful for our nice 
cooperation on our work on microparticles in essential thrombocythemia. Kees 
(Brinkman), jij bent degene die mij op het spoor van het onderzoek heeft gezet 
omdat je tijdens een beoordelingsgesprek van mij als AIOS aangaf dat ik toch 
ook echt onderzoekservaring moest opdoen. Dank daarvoor!
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Veel dank voor mijn mede-onderzoekers. Muriel, jij bent degene geweest die 
mij de praktijk van het onderzoeken heeft geleerd in alle facetten; van hoe ik 
een pipet moest vasthouden, tot hoe ik een excel-sheet maakte, of resultaten 
op moest schrijven. Ik heb heel, heel veel van je geleerd en een supergezellige 
tijd met je gehad. We hebben zoveel uren naast de FACS gestaan dat we zelfs 
tegen haar praatten als ze het zwaar had met al onze metingen;-) Ik ben er 
heel blij mee dat je straks als paranimf naast me zal staan. Henri, jij bent voor 
mij de man van de trombine generatie, die met veel geduld mijn vele vragen 
beantwoordde. Ook heb ik genoten van je grappige mailtjes en verhalen, en we 
moeten eigenlijk nog een keer een echte Limburgse vlaai gaan eten. Michiel, jij 
was een goede versterking op het onderzoek. Jij hebt geweldig werk gedaan 
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heel veel kennis van een onderwerp had. Daarnaast heb je een heel aanstekelijk 
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het AMC. Pascal, jij was absoluut een vrolijke noot op het lab, en ook altijd heel 
relaxt. De man van de BCS, en ik was niet jaloers op je, want wat een kuren had 
dat apparaat. Ik hoop dat je het goed naar je zin hebt in je nieuwe baan. Lea, 
jij bent mijn steun en toeverlaat in de statistiek. Als ik met mijn handen in het 
haar zat omdat ik een power berekening nodig had, of moest corrigeren voor 
multiple testing, dan wist jij gelukkig altijd de oplossing. Ook was het gezellig 
om samen te lunchen, of met de kinderen af te spreken. Jij nog heel veel succes 
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Jacomien !jn dat je zoveel hebt onderzocht over het e#ect van propranolol op 
de vorming micropartikels, en Bob wat zou ik graag zulke mooie !guren kunnen 
maken als jij.
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door de bibliotheek. Joep Maeijer, sorry voor alle keren dat we (net te laat) onze 
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te maken. Dank daarvoor. 
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Jessica, Josephine, Edwin, Femke en Christine, we zijn samen begonnen in het 
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altijd gezellig om bij te kletsen, laten we snel weer eens gaan eten. Edwin en 
Fenneke, jullie zijn me voorgegaan op het onderzoekspad in het OLVG, en ik heb 
veel te danken aan jullie inspanningen. David, thanx dat we mee konden doen 
met je bungee jump studie. Collega’s van het AMC, Mentrum en Slotervaart 
ziekenhuis, dank voor de !jne samenwerking. 
Lieve vrienden, jullie zorgen voor veel gezelligheid en a"eiding. Kjell en Judith, 
!jn dat we zo dicht bij elkaar wonen dat we makkelijk bij elkaar langs kunnen, 
Nieke en Rogier, onze stranduitjes waren een welkome a"eiding, en ik heb nu al 
zin in de skivakantie, Matthijs en Margo, we verheugen ons op een weekendje 
samen in Duitsland! Hannah, Anouk en Haike, Lisette en Rogier, Andrieke en 
Egle-Jan, Astrid en Andy, wat !jn dat jullie er zijn om leuke dingen mee te 
doen. Lieve vriendinnen, Lily, Liedewij, Miriam, Mirjam en Sanne, jullie zijn heel 
belangrijk voor mij, jullie zorgen voor veel lol, maar ook voor steun, en ik ben 
trots op alle stoere dingen die jullie doen. Lily, als jij iets bedenkt gebeurt het 
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26739 Trappenburg, Marijke.indd   153 08-10-13   14:32
154
zo ver terug, het is !jn te weten dat je er altijd bent als ik je nodig heb, en je 
maakt de beste grappen. Ik geloof in Nieuwerzijds! Miriam, ik geniet ervan je 
verhalen te horen, en ik vind het zo stoer dat je altijd bezig bent je dromen waar 
te maken, heel veel succes nu met Inkt!sk. Sanne mede-dokter, heel !jn om met 
jou het leven en werk te bespreken, wie weet komen we ooit ook wel in Noord 
wonen, en Mirjam, ik ken niemand die zo sterk en dapper is als jij. Hoe jij door 
moeilijke tijden heen gaat bewonder ik enorm, ik vind het !jn dat jij naast me 
staat als mijn paranimf.  
Lieve schoonfamilie wat ben ik blij met jullie, Ludo, jij bent alweer vier jaar één 
dag per week vast onderdeel van ons gezin, onwijs bedankt daarvoor en voor 
je wijze lessen en de lekkere maaltijden. Barbara en Jan, geweldig dat jullie 
altijd voor ons klaar staan om ons te helpen, en voor alle keren dat jullie door 
op te passen ons enorm hebben geholpen. Zo kunnen we hard werken, maar 
ook leuke dingen doen. Rob en Nancy dank voor jullie gezelligheid, en Rob, 
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dat jullie er zijn, en dat ik van al jullie levenservaring kan leren. Lieve broer en 
zus; Nelleke en Sergi, wat !jn om mijn zusje Amsterdam te hebben, ik ben heel 
blij met onze goede band, broer Kees, schoonzus Else met nichtje Sara, altijd 
gezellig om jullie te zien, !jn dat jullie voor leuke a"eiding zorgen tijdens mijn 
drukke onderzoekstijd. Lieve papa en mama, dank dat jullie me altijd gesteund 
hebben in alles wat ik heb gedaan, en voor een hele !jne thuisbasis hebben 
gezorgd. Fantastisch ook dat jullie de afgelopen jaren altijd klaar staan om voor 
de meisjes te zorgen. 
Allerliefste Janna en Lena, jullie maken mijn leven zo veel mooier en iedere dag 
tot een feestje. Het is heerlijk om jullie te zien opgroeien, en ik zie er naar uit dat 
ik straks weer extra veel tijd heb om met jullie te spelen. Tom, je bent mijn liefste, 
en je bent een fantastische steun geweest tijdens het schrijven van dit boekje. 
Dank voor je vertrouwen en liefde, je bent de allerbeste die ik me kan wensen!
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